[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8,"_9":10},"actionData","errors","root",{"_3599":3600,"_3601":3598},"routes/en-gate",{"_3597":3598},"en-conference",{"_11":12},"data",{"_13":14,"_15":16,"_17":-5,"_18":-5,"_19":-5,"_20":21,"_22":-5,"_23":24,"_25":-5,"_26":27,"_28":29,"_30":31,"_32":-5,"_33":34,"_35":36,"_37":38,"_39":40,"_41":40,"_42":-5,"_43":44},"conference",{"_3585":3586,"_3587":3588,"_3589":3561,"_3590":3565,"_3591":3592,"_3593":3594,"_3595":3596},"tracks",[3566,3567,3568,3569],"final","daySummary","track","days",[3561,3562,3563,3564,3565],"q","view","topics","day","topic","tag:#cctg","topicProbe",{"_242":3556,"_244":27,"_246":290,"_248":3557,"_250":3558,"_252":3559,"_253":3559,"_254":3558,"_256":3558,"_257":3560,"_259":-5,"_260":-5,"_261":-5,"_263":40},"directions",[],"hot","probes",[45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241],"posts",[],"items",[],"page",1,"pageCount","nextCursor","generatedAt","2026-10-25T14:01:33.345Z",{"_242":3537,"_244":3538,"_246":247,"_248":3539,"_250":3540,"_252":3541,"_253":3542,"_254":3543,"_256":3544,"_257":3545,"_259":379,"_260":3546,"_261":3547,"_263":413},{"_242":3515,"_244":3516,"_246":247,"_248":3517,"_250":3518,"_252":3519,"_253":3520,"_254":3521,"_256":3522,"_257":3523,"_259":379,"_260":3524,"_261":3525,"_263":413},{"_242":3494,"_244":3495,"_246":247,"_248":3496,"_250":3497,"_252":3474,"_253":3498,"_254":3499,"_256":3500,"_257":3501,"_259":379,"_260":3502,"_261":3503,"_263":413},{"_242":3469,"_244":3470,"_246":629,"_248":3471,"_250":3472,"_252":3473,"_253":3474,"_254":3475,"_256":3476,"_257":3477,"_259":-5,"_260":-5,"_261":3478,"_263":413},{"_242":3444,"_244":3445,"_246":603,"_248":3446,"_250":3447,"_252":3428,"_253":3448,"_254":3449,"_256":3450,"_257":3451,"_259":-5,"_260":-5,"_261":3452,"_263":413},{"_242":3424,"_244":3425,"_246":247,"_248":3426,"_250":3427,"_252":3428,"_253":3429,"_254":3430,"_256":3431,"_257":3432,"_259":379,"_260":3433,"_261":3434,"_263":413},{"_242":3407,"_244":3408,"_246":247,"_248":3409,"_250":3410,"_252":3411,"_253":3412,"_254":2324,"_256":3413,"_257":3414,"_259":379,"_260":-5,"_261":3415,"_263":413},{"_242":3384,"_244":3385,"_246":629,"_248":3386,"_250":3387,"_252":3372,"_253":3388,"_254":3389,"_256":3390,"_257":3391,"_259":379,"_260":-5,"_261":3392,"_263":413},{"_242":3368,"_244":3369,"_246":629,"_248":3370,"_250":3371,"_252":3372,"_253":3373,"_254":2182,"_256":3374,"_257":3375,"_259":379,"_260":-5,"_261":3376,"_263":413},{"_242":3352,"_244":3353,"_246":247,"_248":3354,"_250":3355,"_252":2595,"_253":3050,"_254":3356,"_256":3357,"_257":3358,"_259":-5,"_260":-5,"_261":3359,"_263":413},{"_242":3334,"_244":3335,"_246":247,"_248":3336,"_250":3337,"_252":2595,"_253":2596,"_254":3338,"_256":3339,"_257":3340,"_259":-5,"_260":-5,"_261":3341,"_263":413},{"_242":3308,"_244":3309,"_246":629,"_248":3310,"_250":3311,"_252":3264,"_253":3312,"_254":1474,"_256":3313,"_257":3314,"_259":379,"_260":-5,"_261":3315,"_263":413},{"_242":3294,"_244":3295,"_246":247,"_248":3296,"_250":3297,"_252":3264,"_253":2595,"_254":3298,"_256":3299,"_257":3300,"_259":-5,"_260":-5,"_261":3301,"_263":413},{"_242":3276,"_244":3277,"_246":247,"_248":3278,"_250":3279,"_252":3264,"_253":2595,"_254":3280,"_256":3281,"_257":3282,"_259":379,"_260":3283,"_261":3284,"_263":413},{"_242":3260,"_244":3261,"_246":247,"_248":3262,"_250":3263,"_252":2528,"_253":3264,"_254":3265,"_256":3266,"_257":3267,"_259":-5,"_260":3268,"_261":3269,"_263":413},{"_242":3241,"_244":3242,"_246":247,"_248":3243,"_250":3244,"_252":3229,"_253":2563,"_254":3245,"_256":3246,"_257":3247,"_259":-5,"_260":-5,"_261":3248,"_263":413},{"_242":3225,"_244":3226,"_246":247,"_248":3227,"_250":3228,"_252":3229,"_253":2528,"_254":3230,"_256":3231,"_257":3232,"_259":379,"_260":-5,"_261":3233,"_263":413},{"_242":3204,"_244":3205,"_246":629,"_248":3206,"_250":3207,"_252":2489,"_253":2528,"_254":3208,"_256":3209,"_257":3210,"_259":379,"_260":-5,"_261":3211,"_263":413},{"_242":3187,"_244":3188,"_246":247,"_248":3189,"_250":3190,"_252":2514,"_253":3191,"_254":3192,"_256":3193,"_257":3194,"_259":379,"_260":-5,"_261":3195,"_263":413},{"_242":3172,"_244":3173,"_246":247,"_248":3174,"_250":3175,"_252":2514,"_253":2514,"_254":3176,"_256":3177,"_257":3178,"_259":379,"_260":-5,"_261":3179,"_263":413},{"_242":3159,"_244":3160,"_246":290,"_248":3161,"_250":3162,"_252":2427,"_253":2528,"_254":3163,"_256":3164,"_257":3165,"_259":-5,"_260":-5,"_261":3166,"_263":413},{"_242":3138,"_244":3139,"_246":603,"_248":3140,"_250":3141,"_252":2427,"_253":2514,"_254":3142,"_256":3143,"_257":3144,"_259":-5,"_260":-5,"_261":3145,"_263":413},{"_242":3115,"_244":3116,"_246":603,"_248":3117,"_250":3118,"_252":3065,"_253":2489,"_254":3119,"_256":3120,"_257":3121,"_259":-5,"_260":-5,"_261":3122,"_263":413},{"_242":3095,"_244":3096,"_246":603,"_248":3097,"_250":3098,"_252":3065,"_253":2514,"_254":3099,"_256":3100,"_257":3101,"_259":-5,"_260":-5,"_261":3102,"_263":413},{"_242":3081,"_244":3082,"_246":247,"_248":3083,"_250":3084,"_252":3065,"_253":2450,"_254":3085,"_256":282,"_257":3086,"_259":379,"_260":-5,"_261":3087,"_263":413},{"_242":3061,"_244":3062,"_246":247,"_248":3063,"_250":3064,"_252":3065,"_253":3065,"_254":3066,"_256":3067,"_257":3068,"_259":-5,"_260":3069,"_261":3070,"_263":413},{"_242":3046,"_244":3047,"_246":290,"_248":3048,"_250":3049,"_252":2231,"_253":3050,"_254":3051,"_256":3052,"_257":3053,"_259":-5,"_260":-5,"_261":3054,"_263":413},{"_242":3027,"_244":3028,"_246":247,"_248":3029,"_250":3030,"_252":2231,"_253":2427,"_254":3031,"_256":3032,"_257":3033,"_259":-5,"_260":-5,"_261":3034,"_263":413},{"_242":3004,"_244":3005,"_246":247,"_248":3006,"_250":3007,"_252":2374,"_253":2450,"_254":3008,"_256":3009,"_257":3010,"_259":-5,"_260":3011,"_261":3012,"_263":413},{"_242":2990,"_244":2991,"_246":629,"_248":2992,"_250":2993,"_252":2323,"_253":2231,"_254":1652,"_256":2994,"_257":2995,"_259":-5,"_260":-5,"_261":2996,"_263":413},{"_242":2975,"_244":2976,"_246":247,"_248":2977,"_250":2978,"_252":2067,"_253":2067,"_254":2979,"_256":2980,"_257":2981,"_259":-5,"_260":-5,"_261":2982,"_263":413},{"_242":2960,"_244":2961,"_246":629,"_248":2962,"_250":2963,"_252":2067,"_253":2067,"_254":2964,"_256":2965,"_257":2966,"_259":379,"_260":-5,"_261":2967,"_263":413},{"_242":2946,"_244":2947,"_246":247,"_248":2948,"_250":2949,"_252":484,"_253":2067,"_254":2950,"_256":2951,"_257":2952,"_259":-5,"_260":-5,"_261":2953,"_263":413},{"_242":2931,"_244":2932,"_246":247,"_248":2933,"_250":2934,"_252":484,"_253":2067,"_254":2935,"_256":2936,"_257":2937,"_259":-5,"_260":-5,"_261":2938,"_263":413},{"_242":2918,"_244":2919,"_246":247,"_248":2920,"_250":2921,"_252":1808,"_253":1808,"_254":2922,"_256":2923,"_257":2924,"_259":-5,"_260":-5,"_261":2925,"_263":413},{"_242":2904,"_244":2905,"_246":629,"_248":2906,"_250":2907,"_252":1808,"_253":1808,"_254":2908,"_256":2909,"_257":2910,"_259":-5,"_260":-5,"_261":2911,"_263":413},{"_242":2887,"_244":2888,"_246":247,"_248":2889,"_250":2890,"_252":1808,"_253":1808,"_254":2891,"_256":2892,"_257":2893,"_259":-5,"_260":-5,"_261":2894,"_263":413},{"_242":2873,"_244":2874,"_246":629,"_248":2875,"_250":2876,"_252":456,"_253":1808,"_254":2877,"_256":2878,"_257":2879,"_259":-5,"_260":-5,"_261":2880,"_263":413},{"_242":2859,"_244":2860,"_246":247,"_248":2861,"_250":2862,"_252":456,"_253":456,"_254":2863,"_256":2864,"_257":2865,"_259":-5,"_260":-5,"_261":2866,"_263":413},{"_242":2843,"_244":2844,"_246":247,"_248":2845,"_250":2846,"_252":456,"_253":456,"_254":2847,"_256":2848,"_257":2849,"_259":-5,"_260":2850,"_261":2851,"_263":413},{"_242":2817,"_244":2818,"_246":247,"_248":2819,"_250":2820,"_252":456,"_253":456,"_254":2821,"_256":2822,"_257":2823,"_259":-5,"_260":2824,"_261":2825,"_263":413},{"_242":2803,"_244":2804,"_246":247,"_248":2805,"_250":2806,"_252":413,"_253":413,"_254":2807,"_256":2808,"_257":2809,"_259":-5,"_260":-5,"_261":2810,"_263":413},{"_242":2789,"_244":2790,"_246":247,"_248":2791,"_250":2792,"_252":413,"_253":413,"_254":2793,"_256":2794,"_257":2795,"_259":-5,"_260":-5,"_261":2796,"_263":413},{"_242":2775,"_244":2776,"_246":247,"_248":2777,"_250":2778,"_252":413,"_253":413,"_254":2779,"_256":2780,"_257":2781,"_259":-5,"_260":-5,"_261":2782,"_263":413},{"_242":2762,"_244":2763,"_246":247,"_248":2764,"_250":2765,"_252":413,"_253":413,"_254":2766,"_256":2767,"_257":2768,"_259":-5,"_260":-5,"_261":2769,"_263":413},{"_242":2747,"_244":2748,"_246":247,"_248":2749,"_250":2750,"_252":413,"_253":413,"_254":2751,"_256":2752,"_257":2753,"_259":-5,"_260":-5,"_261":2754,"_263":413},{"_242":2735,"_244":2736,"_246":290,"_248":2737,"_250":2738,"_252":293,"_253":413,"_254":2739,"_256":2740,"_257":2741,"_259":-5,"_260":-5,"_261":2742,"_263":413},{"_242":2722,"_244":2723,"_246":247,"_248":2724,"_250":2725,"_252":293,"_253":413,"_254":2726,"_256":2727,"_257":2728,"_259":-5,"_260":-5,"_261":2729,"_263":413},{"_242":2698,"_244":2699,"_246":247,"_248":2700,"_250":2701,"_252":293,"_253":293,"_254":2702,"_256":2703,"_257":2704,"_259":379,"_260":-5,"_261":2705,"_263":413},{"_242":2678,"_244":2679,"_246":290,"_248":2680,"_250":2681,"_252":293,"_253":293,"_254":2682,"_256":2683,"_257":2684,"_259":379,"_260":-5,"_261":2685,"_263":413},{"_242":2664,"_244":2665,"_246":290,"_248":2666,"_250":2667,"_252":40,"_253":484,"_254":2668,"_256":2669,"_257":2670,"_259":-5,"_260":-5,"_261":2671,"_263":413},{"_242":2652,"_244":2653,"_246":394,"_248":2654,"_250":2655,"_252":40,"_253":293,"_254":890,"_256":2656,"_257":2657,"_259":-5,"_260":-5,"_261":2658,"_263":413},{"_242":2640,"_244":2641,"_246":290,"_248":2642,"_250":2643,"_252":40,"_253":293,"_254":2644,"_256":2645,"_257":2646,"_259":-5,"_260":-5,"_261":2647,"_263":413},{"_242":2618,"_244":2619,"_246":629,"_248":2620,"_250":2621,"_252":2595,"_253":2547,"_254":2622,"_256":2623,"_257":2624,"_259":379,"_260":-5,"_261":2625,"_263":293},{"_242":2591,"_244":2592,"_246":629,"_248":2593,"_250":2594,"_252":2595,"_253":2596,"_254":2597,"_256":2598,"_257":2599,"_259":379,"_260":-5,"_261":2600,"_263":293},{"_242":2574,"_244":2575,"_246":629,"_248":2576,"_250":2577,"_252":2578,"_253":2578,"_254":2579,"_256":2580,"_257":2581,"_259":-5,"_260":-5,"_261":2582,"_263":293},{"_242":2559,"_244":2560,"_246":290,"_248":2561,"_250":2562,"_252":2563,"_253":2564,"_254":2565,"_256":2566,"_257":2567,"_259":-5,"_260":-5,"_261":2568,"_263":293},{"_242":2543,"_244":2544,"_246":247,"_248":2545,"_250":2546,"_252":2528,"_253":2547,"_254":2548,"_256":2549,"_257":2550,"_259":379,"_260":-5,"_261":2551,"_263":293},{"_242":2524,"_244":2525,"_246":629,"_248":2526,"_250":2527,"_252":2528,"_253":2528,"_254":2529,"_256":2530,"_257":2531,"_259":379,"_260":-5,"_261":2532,"_263":293},{"_242":2510,"_244":2511,"_246":247,"_248":2512,"_250":2513,"_252":2514,"_253":2514,"_254":2515,"_256":2516,"_257":2517,"_259":-5,"_260":-5,"_261":2518,"_263":293},{"_242":2485,"_244":2486,"_246":629,"_248":2487,"_250":2488,"_252":2450,"_253":2489,"_254":2490,"_256":2491,"_257":2492,"_259":-5,"_260":-5,"_261":2493,"_263":293},{"_242":2466,"_244":2467,"_246":629,"_248":2468,"_250":2469,"_252":2450,"_253":2427,"_254":2470,"_256":2471,"_257":2472,"_259":379,"_260":-5,"_261":2473,"_263":293},{"_242":2446,"_244":2447,"_246":629,"_248":2448,"_250":2449,"_252":2450,"_253":2450,"_254":2451,"_256":2452,"_257":2453,"_259":379,"_260":-5,"_261":2454,"_263":293},{"_242":2423,"_244":2424,"_246":603,"_248":2425,"_250":2426,"_252":2231,"_253":2427,"_254":2428,"_256":2429,"_257":2430,"_259":-5,"_260":-5,"_261":2431,"_263":293},{"_242":2400,"_244":2401,"_246":629,"_248":2402,"_250":2403,"_252":2231,"_253":2231,"_254":2039,"_256":2404,"_257":2405,"_259":379,"_260":-5,"_261":2406,"_263":293},{"_242":2386,"_244":2387,"_246":290,"_248":2388,"_250":2389,"_252":2374,"_253":2374,"_254":2390,"_256":2391,"_257":2392,"_259":-5,"_260":-5,"_261":2393,"_263":293},{"_242":2370,"_244":2371,"_246":629,"_248":2372,"_250":2373,"_252":2323,"_253":2374,"_254":2375,"_256":2376,"_257":2377,"_259":379,"_260":-5,"_261":2378,"_263":293},{"_242":2353,"_244":2354,"_246":629,"_248":2355,"_250":2356,"_252":2323,"_253":2323,"_254":2357,"_256":2358,"_257":2359,"_259":-5,"_260":-5,"_261":2360,"_263":293},{"_242":2336,"_244":2337,"_246":247,"_248":2338,"_250":2339,"_252":2323,"_253":2323,"_254":2340,"_256":2341,"_257":2342,"_259":379,"_260":-5,"_261":2343,"_263":293},{"_242":2319,"_244":2320,"_246":629,"_248":2321,"_250":2322,"_252":2067,"_253":2323,"_254":2324,"_256":2325,"_257":2326,"_259":379,"_260":-5,"_261":2327,"_263":293},{"_242":2305,"_244":2306,"_246":629,"_248":2307,"_250":2308,"_252":2067,"_253":2067,"_254":2309,"_256":2310,"_257":2311,"_259":-5,"_260":-5,"_261":2312,"_263":293},{"_242":2267,"_244":2268,"_246":290,"_248":2269,"_250":2270,"_252":2067,"_253":2067,"_254":2271,"_256":2272,"_257":2273,"_259":379,"_260":-5,"_261":2274,"_263":293},{"_242":2254,"_244":2255,"_246":629,"_248":2256,"_250":2257,"_252":2067,"_253":2067,"_254":1652,"_256":2258,"_257":2259,"_259":379,"_260":-5,"_261":2260,"_263":293},{"_242":2241,"_244":2242,"_246":629,"_248":2243,"_250":2244,"_252":2067,"_253":2067,"_254":2245,"_256":2246,"_257":2247,"_259":-5,"_260":-5,"_261":2248,"_263":293},{"_242":2227,"_244":2228,"_246":290,"_248":2229,"_250":2230,"_252":484,"_253":2231,"_254":2232,"_256":2233,"_257":2234,"_259":-5,"_260":-5,"_261":2235,"_263":293},{"_242":2213,"_244":2214,"_246":247,"_248":2215,"_250":2216,"_252":484,"_253":2067,"_254":2217,"_256":2218,"_257":2219,"_259":-5,"_260":-5,"_261":2220,"_263":293},{"_242":2196,"_244":2197,"_246":629,"_248":2198,"_250":2199,"_252":484,"_253":484,"_254":2200,"_256":2201,"_257":2202,"_259":-5,"_260":-5,"_261":2203,"_263":293},{"_242":2178,"_244":2179,"_246":629,"_248":2180,"_250":2181,"_252":484,"_253":484,"_254":2182,"_256":2183,"_257":2184,"_259":-5,"_260":-5,"_261":2185,"_263":293},{"_242":2165,"_244":2166,"_246":247,"_248":2167,"_250":2168,"_252":484,"_253":484,"_254":2169,"_256":2170,"_257":2171,"_259":-5,"_260":-5,"_261":2172,"_263":293},{"_242":2141,"_244":2142,"_246":290,"_248":2143,"_250":2144,"_252":484,"_253":484,"_254":2145,"_256":2146,"_257":2147,"_259":-5,"_260":-5,"_261":2148,"_263":293},{"_242":2128,"_244":2129,"_246":629,"_248":2130,"_250":2131,"_252":484,"_253":484,"_254":2132,"_256":2133,"_257":2134,"_259":-5,"_260":-5,"_261":2135,"_263":293},{"_242":2095,"_244":2096,"_246":290,"_248":2097,"_250":2098,"_252":484,"_253":484,"_254":2099,"_256":2100,"_257":2101,"_259":-5,"_260":-5,"_261":2102,"_263":293},{"_242":2063,"_244":2064,"_246":629,"_248":2065,"_250":2066,"_252":1808,"_253":2067,"_254":2068,"_256":2069,"_257":2070,"_259":-5,"_260":-5,"_261":2071,"_263":293},{"_242":2050,"_244":2051,"_246":603,"_248":2052,"_250":2053,"_252":1808,"_253":1808,"_254":2054,"_256":2055,"_257":2056,"_259":-5,"_260":-5,"_261":2057,"_263":293},{"_242":2035,"_244":2036,"_246":247,"_248":2037,"_250":2038,"_252":1808,"_253":1808,"_254":2039,"_256":2040,"_257":2041,"_259":-5,"_260":-5,"_261":2042,"_263":293},{"_242":2021,"_244":2022,"_246":603,"_248":2023,"_250":2024,"_252":1808,"_253":1808,"_254":2025,"_256":2026,"_257":2027,"_259":-5,"_260":-5,"_261":2028,"_263":293},{"_242":2004,"_244":2005,"_246":603,"_248":2006,"_250":2007,"_252":1808,"_253":1808,"_254":2008,"_256":2009,"_257":2010,"_259":-5,"_260":-5,"_261":2011,"_263":293},{"_242":1989,"_244":1990,"_246":603,"_248":1991,"_250":1992,"_252":1808,"_253":1808,"_254":1993,"_256":1994,"_257":1995,"_259":-5,"_260":-5,"_261":1996,"_263":293},{"_242":1975,"_244":1976,"_246":290,"_248":1977,"_250":1978,"_252":456,"_253":1808,"_254":1979,"_256":1980,"_257":1981,"_259":-5,"_260":-5,"_261":1982,"_263":293},{"_242":1963,"_244":1964,"_246":290,"_248":1965,"_250":1966,"_252":456,"_253":1808,"_254":1967,"_256":1968,"_257":1969,"_259":-5,"_260":-5,"_261":1970,"_263":293},{"_242":1942,"_244":1943,"_246":629,"_248":1944,"_250":1945,"_252":456,"_253":456,"_254":1946,"_256":1947,"_257":1948,"_259":-5,"_260":-5,"_261":1949,"_263":293},{"_242":1928,"_244":1929,"_246":603,"_248":1930,"_250":1931,"_252":456,"_253":456,"_254":1932,"_256":1933,"_257":1934,"_259":-5,"_260":-5,"_261":1935,"_263":293},{"_242":1915,"_244":1916,"_246":247,"_248":1917,"_250":1918,"_252":456,"_253":456,"_254":1919,"_256":1920,"_257":1921,"_259":-5,"_260":-5,"_261":1922,"_263":293},{"_242":1891,"_244":1892,"_246":629,"_248":1893,"_250":1894,"_252":456,"_253":456,"_254":1895,"_256":1896,"_257":1897,"_259":-5,"_260":-5,"_261":1898,"_263":293},{"_242":1874,"_244":1875,"_246":629,"_248":1876,"_250":1877,"_252":456,"_253":456,"_254":1878,"_256":1879,"_257":1880,"_259":-5,"_260":-5,"_261":1881,"_263":293},{"_242":1861,"_244":1862,"_246":603,"_248":1863,"_250":1864,"_252":456,"_253":456,"_254":1865,"_256":1866,"_257":1867,"_259":-5,"_260":-5,"_261":1868,"_263":293},{"_242":1845,"_244":1846,"_246":629,"_248":1847,"_250":1848,"_252":456,"_253":456,"_254":1849,"_256":1850,"_257":1851,"_259":-5,"_260":-5,"_261":1852,"_263":293},{"_242":1832,"_244":1833,"_246":629,"_248":1834,"_250":1835,"_252":456,"_253":456,"_254":1836,"_256":1837,"_257":1838,"_259":-5,"_260":-5,"_261":1839,"_263":293},{"_242":1819,"_244":1820,"_246":290,"_248":1821,"_250":1822,"_252":413,"_253":484,"_254":1823,"_256":1824,"_257":1825,"_259":-5,"_260":-5,"_261":1826,"_263":293},{"_242":1804,"_244":1805,"_246":290,"_248":1806,"_250":1807,"_252":413,"_253":1808,"_254":1809,"_256":1810,"_257":1811,"_259":-5,"_260":-5,"_261":1812,"_263":293},{"_242":1785,"_244":1786,"_246":290,"_248":1787,"_250":1788,"_252":413,"_253":456,"_254":1789,"_256":1790,"_257":1791,"_259":-5,"_260":-5,"_261":1792,"_263":293},{"_242":1764,"_244":1765,"_246":629,"_248":1766,"_250":1767,"_252":413,"_253":456,"_254":1768,"_256":1769,"_257":1770,"_259":-5,"_260":-5,"_261":1771,"_263":293},{"_242":1751,"_244":1752,"_246":290,"_248":1753,"_250":1754,"_252":413,"_253":413,"_254":1755,"_256":1756,"_257":1757,"_259":-5,"_260":-5,"_261":1758,"_263":293},{"_242":1739,"_244":1740,"_246":247,"_248":1741,"_250":1742,"_252":413,"_253":413,"_254":1743,"_256":1744,"_257":1745,"_259":-5,"_260":-5,"_261":1746,"_263":293},{"_242":1726,"_244":1727,"_246":247,"_248":1728,"_250":1729,"_252":413,"_253":413,"_254":1730,"_256":1731,"_257":1732,"_259":-5,"_260":-5,"_261":1733,"_263":293},{"_242":1712,"_244":1713,"_246":629,"_248":1714,"_250":1715,"_252":413,"_253":413,"_254":1716,"_256":1717,"_257":1718,"_259":-5,"_260":-5,"_261":1719,"_263":293},{"_242":1698,"_244":1699,"_246":629,"_248":1700,"_250":1701,"_252":413,"_253":413,"_254":1702,"_256":1703,"_257":1704,"_259":-5,"_260":-5,"_261":1705,"_263":293},{"_242":1685,"_244":1686,"_246":629,"_248":1687,"_250":1688,"_252":413,"_253":413,"_254":1689,"_256":1690,"_257":1691,"_259":-5,"_260":-5,"_261":1692,"_263":293},{"_242":1648,"_244":1649,"_246":629,"_248":1650,"_250":1651,"_252":413,"_253":413,"_254":1652,"_256":1653,"_257":1654,"_259":379,"_260":-5,"_261":1655,"_263":293},{"_242":1631,"_244":1632,"_246":629,"_248":1633,"_250":1634,"_252":413,"_253":413,"_254":1635,"_256":1636,"_257":1637,"_259":-5,"_260":-5,"_261":1638,"_263":293},{"_242":1615,"_244":1616,"_246":629,"_248":1617,"_250":1618,"_252":413,"_253":413,"_254":1619,"_256":1620,"_257":1621,"_259":379,"_260":-5,"_261":1622,"_263":293},{"_242":1599,"_244":1600,"_246":629,"_248":1601,"_250":1602,"_252":413,"_253":413,"_254":1603,"_256":1604,"_257":1605,"_259":-5,"_260":-5,"_261":1606,"_263":293},{"_242":1585,"_244":1586,"_246":290,"_248":1587,"_250":1588,"_252":413,"_253":413,"_254":1589,"_256":1590,"_257":1591,"_259":-5,"_260":-5,"_261":1592,"_263":293},{"_242":1571,"_244":1572,"_246":290,"_248":1573,"_250":1574,"_252":413,"_253":413,"_254":1575,"_256":1576,"_257":1577,"_259":-5,"_260":-5,"_261":1578,"_263":293},{"_242":1559,"_244":1560,"_246":290,"_248":1561,"_250":1562,"_252":413,"_253":413,"_254":1563,"_256":1564,"_257":1565,"_259":-5,"_260":-5,"_261":1566,"_263":293},{"_242":1539,"_244":1540,"_246":290,"_248":1541,"_250":1542,"_252":293,"_253":456,"_254":1543,"_256":1544,"_257":1545,"_259":-5,"_260":-5,"_261":1546,"_263":293},{"_242":1526,"_244":1527,"_246":290,"_248":1528,"_250":1529,"_252":293,"_253":413,"_254":1530,"_256":1531,"_257":1532,"_259":-5,"_260":-5,"_261":1533,"_263":293},{"_242":1511,"_244":1512,"_246":629,"_248":1513,"_250":1514,"_252":293,"_253":413,"_254":1515,"_256":1516,"_257":1517,"_259":-5,"_260":-5,"_261":1518,"_263":293},{"_242":1498,"_244":1499,"_246":290,"_248":1500,"_250":1501,"_252":293,"_253":413,"_254":1502,"_256":1503,"_257":1504,"_259":-5,"_260":-5,"_261":1505,"_263":293},{"_242":1483,"_244":1484,"_246":247,"_248":1485,"_250":1486,"_252":293,"_253":413,"_254":1487,"_256":415,"_257":1488,"_259":-5,"_260":-5,"_261":1489,"_263":293},{"_242":1470,"_244":1471,"_246":394,"_248":1472,"_250":1473,"_252":293,"_253":413,"_254":1474,"_256":1475,"_257":1476,"_259":-5,"_260":-5,"_261":1477,"_263":293},{"_242":1457,"_244":1458,"_246":290,"_248":1459,"_250":1460,"_252":293,"_253":413,"_254":1461,"_256":1462,"_257":1463,"_259":-5,"_260":-5,"_261":1464,"_263":293},{"_242":1443,"_244":1444,"_246":247,"_248":1445,"_250":1446,"_252":293,"_253":413,"_254":1447,"_256":1448,"_257":1449,"_259":-5,"_260":-5,"_261":1450,"_263":293},{"_242":1429,"_244":1430,"_246":290,"_248":1431,"_250":1432,"_252":293,"_253":293,"_254":1433,"_256":1434,"_257":1435,"_259":-5,"_260":-5,"_261":1436,"_263":293},{"_242":1416,"_244":1417,"_246":247,"_248":1292,"_250":1418,"_252":293,"_253":293,"_254":1419,"_256":1420,"_257":1421,"_259":-5,"_260":-5,"_261":1422,"_263":293},{"_242":1403,"_244":1404,"_246":247,"_248":1405,"_250":1406,"_252":293,"_253":293,"_254":1407,"_256":1408,"_257":1409,"_259":-5,"_260":-5,"_261":1410,"_263":293},{"_242":1389,"_244":1390,"_246":247,"_248":1391,"_250":1392,"_252":293,"_253":293,"_254":1393,"_256":1394,"_257":1395,"_259":-5,"_260":-5,"_261":1396,"_263":293},{"_242":1373,"_244":1374,"_246":629,"_248":1375,"_250":1376,"_252":293,"_253":293,"_254":1377,"_256":1378,"_257":1379,"_259":-5,"_260":-5,"_261":1380,"_263":293},{"_242":1356,"_244":1357,"_246":629,"_248":1358,"_250":1359,"_252":293,"_253":293,"_254":1360,"_256":1361,"_257":1362,"_259":-5,"_260":-5,"_261":1363,"_263":293},{"_242":1337,"_244":1338,"_246":629,"_248":1339,"_250":1340,"_252":293,"_253":293,"_254":1341,"_256":1342,"_257":1343,"_259":-5,"_260":-5,"_261":1344,"_263":293},{"_242":1324,"_244":1325,"_246":629,"_248":1326,"_250":1327,"_252":293,"_253":293,"_254":1328,"_256":1329,"_257":1330,"_259":-5,"_260":-5,"_261":1331,"_263":293},{"_242":1310,"_244":1311,"_246":247,"_248":1312,"_250":1313,"_252":293,"_253":293,"_254":1314,"_256":1315,"_257":1316,"_259":-5,"_260":-5,"_261":1317,"_263":293},{"_242":1265,"_244":1266,"_246":290,"_248":1267,"_250":1268,"_252":293,"_253":293,"_254":1269,"_256":1270,"_257":1271,"_259":379,"_260":-5,"_261":1272,"_263":293},{"_242":1251,"_244":1252,"_246":290,"_248":1253,"_250":1254,"_252":293,"_253":293,"_254":1255,"_256":1256,"_257":1257,"_259":-5,"_260":-5,"_261":1258,"_263":293},{"_242":1226,"_244":1227,"_246":629,"_248":1228,"_250":1229,"_252":293,"_253":293,"_254":1230,"_256":1231,"_257":1232,"_259":-5,"_260":-5,"_261":1233,"_263":293},{"_242":1213,"_244":1214,"_246":629,"_248":1215,"_250":1216,"_252":293,"_253":293,"_254":1217,"_256":1218,"_257":1219,"_259":-5,"_260":-5,"_261":1220,"_263":293},{"_242":1160,"_244":1161,"_246":290,"_248":1162,"_250":1163,"_252":293,"_253":293,"_254":1164,"_256":1165,"_257":1166,"_259":-5,"_260":-5,"_261":1167,"_263":293},{"_242":1146,"_244":1147,"_246":290,"_248":1148,"_250":1149,"_252":293,"_253":293,"_254":1150,"_256":1151,"_257":1152,"_259":-5,"_260":-5,"_261":1153,"_263":293},{"_242":1133,"_244":1134,"_246":290,"_248":1135,"_250":1136,"_252":293,"_253":293,"_254":1137,"_256":1138,"_257":1139,"_259":-5,"_260":-5,"_261":1140,"_263":293},{"_242":1119,"_244":1120,"_246":290,"_248":1121,"_250":1122,"_252":293,"_253":293,"_254":1123,"_256":1124,"_257":1125,"_259":-5,"_260":-5,"_261":1126,"_263":293},{"_242":1106,"_244":1107,"_246":290,"_248":1108,"_250":1109,"_252":293,"_253":293,"_254":1110,"_256":1111,"_257":1112,"_259":-5,"_260":-5,"_261":1113,"_263":293},{"_242":1084,"_244":1085,"_246":290,"_248":1086,"_250":1087,"_252":293,"_253":293,"_254":1088,"_256":1089,"_257":1090,"_259":379,"_260":-5,"_261":1091,"_263":293},{"_242":1070,"_244":1071,"_246":247,"_248":1072,"_250":1073,"_252":293,"_253":293,"_254":1074,"_256":1075,"_257":1076,"_259":-5,"_260":-5,"_261":1077,"_263":293},{"_242":1057,"_244":1058,"_246":290,"_248":1059,"_250":1060,"_252":293,"_253":293,"_254":1061,"_256":1062,"_257":1063,"_259":-5,"_260":-5,"_261":1064,"_263":293},{"_242":1043,"_244":1044,"_246":247,"_248":1045,"_250":1046,"_252":293,"_253":293,"_254":1047,"_256":1048,"_257":1049,"_259":-5,"_260":-5,"_261":1050,"_263":293},{"_242":1029,"_244":1030,"_246":290,"_248":1031,"_250":1032,"_252":293,"_253":293,"_254":1033,"_256":1034,"_257":1035,"_259":-5,"_260":-5,"_261":1036,"_263":293},{"_242":1015,"_244":1016,"_246":247,"_248":1017,"_250":1018,"_252":293,"_253":293,"_254":1019,"_256":1020,"_257":1021,"_259":-5,"_260":-5,"_261":1022,"_263":293},{"_242":1002,"_244":1003,"_246":290,"_248":1004,"_250":1005,"_252":293,"_253":293,"_254":1006,"_256":1007,"_257":1008,"_259":-5,"_260":-5,"_261":1009,"_263":293},{"_242":983,"_244":984,"_246":247,"_248":985,"_250":986,"_252":293,"_253":293,"_254":987,"_256":988,"_257":989,"_259":-5,"_260":-5,"_261":990,"_263":293},{"_242":969,"_244":970,"_246":247,"_248":971,"_250":972,"_252":40,"_253":293,"_254":973,"_256":974,"_257":975,"_259":-5,"_260":-5,"_261":976,"_263":293},{"_242":957,"_244":958,"_246":394,"_248":959,"_250":960,"_252":40,"_253":293,"_254":934,"_256":961,"_257":962,"_259":-5,"_260":-5,"_261":963,"_263":293},{"_242":943,"_244":944,"_246":290,"_248":945,"_250":946,"_252":40,"_253":293,"_254":947,"_256":948,"_257":949,"_259":-5,"_260":-5,"_261":950,"_263":293},{"_242":930,"_244":931,"_246":394,"_248":932,"_250":933,"_252":40,"_253":293,"_254":934,"_256":935,"_257":936,"_259":-5,"_260":-5,"_261":937,"_263":293},{"_242":916,"_244":917,"_246":290,"_248":918,"_250":919,"_252":40,"_253":293,"_254":920,"_256":921,"_257":922,"_259":-5,"_260":-5,"_261":923,"_263":293},{"_242":903,"_244":904,"_246":290,"_248":905,"_250":906,"_252":40,"_253":293,"_254":907,"_256":908,"_257":909,"_259":-5,"_260":-5,"_261":910,"_263":293},{"_242":886,"_244":887,"_246":394,"_248":888,"_250":889,"_252":40,"_253":293,"_254":890,"_256":891,"_257":892,"_259":-5,"_260":-5,"_261":893,"_263":293},{"_242":872,"_244":873,"_246":290,"_248":874,"_250":875,"_252":40,"_253":293,"_254":876,"_256":877,"_257":878,"_259":-5,"_260":-5,"_261":879,"_263":293},{"_242":859,"_244":860,"_246":394,"_248":861,"_250":862,"_252":40,"_253":293,"_254":863,"_256":864,"_257":865,"_259":-5,"_260":-5,"_261":866,"_263":293},{"_242":845,"_244":846,"_246":290,"_248":847,"_250":848,"_252":40,"_253":293,"_254":849,"_256":850,"_257":851,"_259":-5,"_260":-5,"_261":852,"_263":293},{"_242":832,"_244":833,"_246":394,"_248":834,"_250":835,"_252":40,"_253":293,"_254":836,"_256":837,"_257":838,"_259":-5,"_260":-5,"_261":839,"_263":293},{"_242":818,"_244":819,"_246":629,"_248":820,"_250":821,"_252":40,"_253":293,"_254":822,"_256":823,"_257":824,"_259":-5,"_260":-5,"_261":825,"_263":293},{"_242":804,"_244":805,"_246":290,"_248":806,"_250":807,"_252":40,"_253":293,"_254":808,"_256":809,"_257":810,"_259":-5,"_260":-5,"_261":811,"_263":293},{"_242":787,"_244":788,"_246":394,"_248":789,"_250":790,"_252":40,"_253":293,"_254":791,"_256":792,"_257":793,"_259":-5,"_260":-5,"_261":794,"_263":293},{"_242":773,"_244":774,"_246":247,"_248":775,"_250":776,"_252":40,"_253":293,"_254":777,"_256":778,"_257":779,"_259":-5,"_260":-5,"_261":780,"_263":293},{"_242":759,"_244":760,"_246":247,"_248":761,"_250":762,"_252":40,"_253":293,"_254":763,"_256":764,"_257":765,"_259":-5,"_260":-5,"_261":766,"_263":293},{"_242":746,"_244":747,"_246":290,"_248":748,"_250":749,"_252":40,"_253":293,"_254":750,"_256":751,"_257":752,"_259":-5,"_260":-5,"_261":753,"_263":293},{"_242":732,"_244":733,"_246":290,"_248":734,"_250":735,"_252":40,"_253":293,"_254":736,"_256":737,"_257":738,"_259":-5,"_260":-5,"_261":739,"_263":293},{"_242":718,"_244":719,"_246":394,"_248":720,"_250":721,"_252":40,"_253":293,"_254":722,"_256":723,"_257":724,"_259":-5,"_260":-5,"_261":725,"_263":293},{"_242":706,"_244":707,"_246":247,"_248":493,"_250":708,"_252":40,"_253":293,"_254":709,"_256":710,"_257":711,"_259":-5,"_260":-5,"_261":712,"_263":293},{"_242":687,"_244":688,"_246":290,"_248":689,"_250":690,"_252":484,"_253":484,"_254":691,"_256":692,"_257":693,"_259":379,"_260":-5,"_261":694,"_263":40},{"_242":674,"_244":675,"_246":290,"_248":676,"_250":677,"_252":413,"_253":413,"_254":678,"_256":472,"_257":679,"_259":-5,"_260":-5,"_261":680,"_263":40},{"_242":660,"_244":661,"_246":290,"_248":662,"_250":663,"_252":413,"_253":413,"_254":664,"_256":665,"_257":666,"_259":-5,"_260":-5,"_261":667,"_263":40},{"_242":646,"_244":647,"_246":290,"_248":648,"_250":649,"_252":293,"_253":413,"_254":650,"_256":651,"_257":652,"_259":-5,"_260":-5,"_261":653,"_263":40},{"_242":627,"_244":628,"_246":629,"_248":630,"_250":631,"_252":293,"_253":293,"_254":632,"_256":633,"_257":634,"_259":-5,"_260":-5,"_261":635,"_263":40},{"_242":601,"_244":602,"_246":603,"_248":604,"_250":605,"_252":293,"_253":293,"_254":606,"_256":607,"_257":608,"_259":-5,"_260":-5,"_261":609,"_263":40},{"_242":588,"_244":589,"_246":290,"_248":590,"_250":591,"_252":293,"_253":293,"_254":592,"_256":593,"_257":594,"_259":-5,"_260":-5,"_261":595,"_263":40},{"_242":574,"_244":575,"_246":290,"_248":576,"_250":577,"_252":293,"_253":293,"_254":578,"_256":579,"_257":580,"_259":-5,"_260":-5,"_261":581,"_263":40},{"_242":560,"_244":561,"_246":290,"_248":562,"_250":563,"_252":293,"_253":293,"_254":564,"_256":565,"_257":566,"_259":-5,"_260":-5,"_261":567,"_263":40},{"_242":546,"_244":547,"_246":290,"_248":548,"_250":549,"_252":293,"_253":293,"_254":550,"_256":551,"_257":552,"_259":-5,"_260":-5,"_261":553,"_263":40},{"_242":533,"_244":534,"_246":290,"_248":535,"_250":536,"_252":293,"_253":293,"_254":537,"_256":538,"_257":539,"_259":-5,"_260":-5,"_261":540,"_263":40},{"_242":514,"_244":515,"_246":290,"_248":516,"_250":517,"_252":293,"_253":293,"_254":518,"_256":519,"_257":520,"_259":379,"_260":-5,"_261":521,"_263":40},{"_242":500,"_244":501,"_246":290,"_248":502,"_250":503,"_252":293,"_253":293,"_254":504,"_256":505,"_257":506,"_259":-5,"_260":-5,"_261":507,"_263":40},{"_242":480,"_244":481,"_246":290,"_248":482,"_250":483,"_252":40,"_253":484,"_254":485,"_256":486,"_257":487,"_259":-5,"_260":-5,"_261":488,"_263":40},{"_242":467,"_244":468,"_246":290,"_248":469,"_250":470,"_252":40,"_253":456,"_254":471,"_256":472,"_257":473,"_259":-5,"_260":-5,"_261":474,"_263":40},{"_242":452,"_244":453,"_246":290,"_248":454,"_250":455,"_252":40,"_253":456,"_254":457,"_256":458,"_257":459,"_259":-5,"_260":-5,"_261":460,"_263":40},{"_242":438,"_244":439,"_246":290,"_248":440,"_250":441,"_252":40,"_253":413,"_254":442,"_256":443,"_257":444,"_259":-5,"_260":-5,"_261":445,"_263":40},{"_242":424,"_244":425,"_246":290,"_248":426,"_250":427,"_252":40,"_253":413,"_254":428,"_256":429,"_257":430,"_259":-5,"_260":-5,"_261":431,"_263":40},{"_242":409,"_244":410,"_246":290,"_248":411,"_250":412,"_252":40,"_253":413,"_254":414,"_256":415,"_257":416,"_259":-5,"_260":-5,"_261":417,"_263":40},{"_242":372,"_244":373,"_246":290,"_248":374,"_250":375,"_252":40,"_253":293,"_254":376,"_256":377,"_257":378,"_259":379,"_260":-5,"_261":380,"_263":40},{"_242":358,"_244":359,"_246":247,"_248":360,"_250":361,"_252":40,"_253":293,"_254":362,"_256":363,"_257":364,"_259":-5,"_260":-5,"_261":365,"_263":40},{"_242":344,"_244":345,"_246":290,"_248":346,"_250":347,"_252":40,"_253":293,"_254":348,"_256":349,"_257":350,"_259":-5,"_260":-5,"_261":351,"_263":40},{"_242":330,"_244":331,"_246":290,"_248":332,"_250":333,"_252":40,"_253":293,"_254":334,"_256":335,"_257":336,"_259":-5,"_260":-5,"_261":337,"_263":40},{"_242":317,"_244":318,"_246":290,"_248":319,"_250":320,"_252":40,"_253":293,"_254":321,"_256":322,"_257":323,"_259":-5,"_260":-5,"_261":324,"_263":40},{"_242":303,"_244":304,"_246":290,"_248":305,"_250":306,"_252":40,"_253":293,"_254":307,"_256":308,"_257":309,"_259":-5,"_260":-5,"_261":310,"_263":40},{"_242":288,"_244":289,"_246":290,"_248":291,"_250":292,"_252":40,"_253":293,"_254":294,"_256":295,"_257":296,"_259":-5,"_260":-5,"_261":297,"_263":40},{"_242":275,"_244":276,"_246":277,"_248":278,"_250":279,"_252":280,"_253":280,"_254":281,"_256":282,"_257":283,"_259":-5,"_260":-5,"_261":284,"_263":40},{"_242":243,"_244":245,"_246":247,"_248":249,"_250":251,"_252":40,"_253":40,"_254":255,"_256":255,"_257":258,"_259":-5,"_260":-5,"_261":262,"_263":40},"story",{"_272":273,"_248":274},"subject","code:LBA77","kind","code","title","LBA77","summary","坦康阿妥塔单抗在ESMO 2026 LBA77公布G-HOPE-001Ⅲ期后线CLDN18.2阳性胃癌期中结果，达到PFS和OS双主要终点。IA2中位PFS为7.1个月对3.1个月，HR=0.45（95% CI 0.35–0.58）；中位OS为10.2个月对6.9个月，HR=0.57（95% CI 0.45–0.73），确认ORR为37.4%对7.7%。","participantCount","reportCount","firstAt","2026-10-23T12:40:00.000Z","latestAt","abstracts",[],"program","reading","representative",{"_264":265,"_266":251,"_267":268,"_269":270,"_271":-5},"stars","id","cpbp06lxk14d5r2x0pthc3xdi","text","translated",false,"originalUrl","https://mp.weixin.qq.com/s?__biz=MjM5Nzc4MDk2MA==&mid=2651291419&idx=1&sn=6ed99edebee579dfd282d435afa31362","handle","publicId","252673b3-dada-453a-b488-048892ace17c","ESMO 2026：Arcotatug tavatecan 胃癌三期达双终点",{"_272":287,"_248":278},"meeting:esmo-2026","meeting","ESMO 2026","JNM 在线发表 TheraPb Ⅰb 期全文，首次完整披露 ²¹²Pb-ADVC001 的 RP2D、剂量学与疗效数据，α 核素从“概念验证”走向“剂量-窗口刻画”的转折点正在形成。Perspective Therapeutics 发布 ²¹²Pb-VMT-α-NET Ⅰ/Ⅱa 期中期数据，Ⅲ 期拟 2027 年启动。",38,"2026-10-11T11:41:36.000Z","2026-10-24T12:00:00.000Z",[],{"_264":285,"_266":279,"_267":268,"_269":286,"_271":-5},"dvq5gr5n27lmkdwk818e6hqsa","https://mp.weixin.qq.com/s?__biz=MzIwNTY5NzM5NA==&mid=2247492238&idx=1&sn=e74e3ca228ef2f6a5c8b5d399853c79d","f7aeb790-ad0b-4d4f-882d-908bb349078d",{"_272":301,"_248":302},"tag:#day2","tag","#DAY2","Rapid oral session #GU starting in 15 min 🕐 10:15am 📍Bilbao Auditorium - Hall 3 #ESMO26 #Day2 @myESMO @OncoAlert",2,"2026-10-24T06:59:52.000Z","2026-10-24T08:01:22.000Z",[],{"_264":298,"_266":292,"_267":268,"_269":299,"_271":300},"lf9hhe716ugs5rkfcjqp10y3j","https://x.com/DrChoueiri/status/2113903664070832366","DrChoueiri","1b067cfc-7d08-4dfc-afa3-385650326ede","Rapid oral session #GU starting in 15 min Rapid oral session #GU starting in 15 min 🕐 10:15am 📍Bilbao Auditorium - Hall 3 #ESMO26 #Day2 @m",{"_272":315,"_248":316},"tag:#vhio","#VHIO","🏆 Congratulations to @pablo_cresta, researcher in #VHIO’s Prostate Cancer Translational Research Group, on winning the Best Poster Award at #ESMO2026! His poster highlights BioChiP, an academic trial investigating carbo","2026-10-23T15:08:03.000Z","2026-10-23T15:56:29.000Z",[],{"_264":311,"_266":312,"_267":268,"_269":313,"_271":314},"zv22qzy3yqy5ltjntqdzl3kvt","🏆 Congratulations to @pablo_cresta, researcher in #VHIO’s Prostate Cancer Translational Research Group, on winning the Best Poster Award at #ESMO2026! His poster highlights BioChiP, an academic trial investigating carboplatin in metastatic castration-resistant #prostatecancer. 👏 Well deserved, Pablo!","https://x.com/VHIO/status/2113648655785689541","VHIO","3ee6a090-5477-47a6-9b31-3ba66cca25e0","🏆 Congratulations to @pablo_cresta, researcher in #VHIO’s Prostate Cancer Translational Research Group, on winning the Best Poster Award at",{"_272":328,"_248":329},"tag:#oncosteps","#ONCOSTEPS","#ESMO26 | Dato-DXd nelle pazienti triplo negative con metastasi cerebrali non candidabili all’immunoterapia. Armando Orlandi da Madrid👇 #OncoSTEPS #mTNBC #ADCs","2026-10-24T18:19:47.000Z","2026-10-24T18:21:30.000Z",[],{"_264":325,"_266":320,"_267":268,"_269":326,"_271":327},"zq8vrcn2z0mv4ggek6zwamx1m","https://x.com/Oncoinfo_it/status/2114059291456151651","Oncoinfo_it","bdb340e0-740c-4191-8c59-3462e0d33748","#ESMO26 | Dato-DXd nelle pazienti triplo negative con metastasi cerebrali non candidabili all’immunoterapia",{"_272":342,"_248":343},"tag:#pcsm","#PCSM","WATCH 👀: Johanna Enke, MD, of @UCLAHealth discusses safety findings from a phase 2 study of lutetium Lu 177 vipivotide tetraxetan rechallenge in mCRPC at #ESMO26 See here ➡️: https://www.onclive.com/view/dr-enke-on-inte","2026-10-23T12:26:37.000Z","2026-10-24T15:33:38.000Z",[],{"_264":338,"_266":339,"_267":268,"_269":340,"_271":341},"qdijeb9izh29nto6e6j5wycyu","WATCH 👀: Johanna Enke, MD, of @UCLAHealth discusses safety findings from a phase 2 study of lutetium Lu 177 vipivotide tetraxetan rechallenge in mCRPC at #ESMO26 See here ➡️: https://www.onclive.com/view/dr-enke-on-interim-safety-data-for-lutetium-lu-177-vipivotide-tetraxetan-retreatment-in-mcrpc #pcsm #oncology","https://x.com/OncLive/status/2114017481031352400","OncLive","9dc7d2b9-32f1-4b40-b203-ee3d405f717a","🗣️ Kicking things off with Johanna S",{"_272":356,"_248":357},"tag:#personalisedmedicine","#PERSONALISEDMEDICINE","🔬 From early detection to treatment monitoring, personalised oncology depends on decisions across the entire patient pathway. Explore these challenges with IAPM on 23 October. Register: https://shorturl.at/afPsg #ESMO26","2026-10-21T09:52:28.000Z","2026-10-23T07:50:13.000Z",[],{"_264":352,"_266":353,"_267":268,"_269":354,"_271":355},"tewss3xbub3boe3u4jx7xyfx4","🔬 From early detection to treatment monitoring, personalised oncology depends on decisions across the entire patient pathway. Explore these challenges with IAPM on 23 October. Register: https://shorturl.at/afPsg #ESMO26 #PersonalisedMedicine","https://x.com/united4cancer/status/2112844459063021825","united4cancer","370399ee-d0c8-4aa1-8cec-cd9eda106edb","🔬 From early detection to treatment monitoring, personalised oncology depends on decisions across the entire patient pathway",{"_272":370,"_248":371},"code:1095EP","1095EP","Tomorrow, @myESMO Congress 2026 opens its doors in Madrid. And the first-in-human Phase I clinical trial of RS-0139 is part of the scientific programme (1095eP). A poster tells part of the story. The rest happens in conv","2026-10-22T11:58:56.000Z","2026-10-24T09:57:39.000Z",[],{"_264":366,"_266":367,"_267":268,"_269":368,"_271":369},"k2lcpjnzcn85oh1ytnzm69xsz","Tomorrow, @myESMO Congress 2026 opens its doors in Madrid. And the first-in-human Phase I clinical trial of RS-0139 is part of the scientific programme (1095eP). A poster tells part of the story. The rest happens in conversation. See you at #ESMO2026 w/ @gulsahnomak11","https://x.com/RS_Research_TR/status/2113238675077149165","RS_Research_TR","cc3a11f3-df24-4a92-9d4a-b19cd2c55601","Tomorrow, @myESMO Congress 2026 opens its doors in Madrid",{"_272":407,"_248":408},"tag:#data","#DATA",".@myESMO conference has started today in Madrid. #ESMO2026 Top Companies Source: @Larvol CLIN database #cancer #oncology #data","2026-10-23T17:11:04.000Z","2026-10-23T17:12:13.000Z",[384,385,386],"LB",{"_264":381,"_266":375,"_267":268,"_269":382,"_271":383},"gjhx9zr4yjgaj7ap900fsfcxv","https://x.com/robertfsiegmund/status/2113679901572141486","robertfsiegmund",{"_387":402,"_19":398,"_248":403,"_391":400,"_393":-5,"_394":404,"_395":405},{"_387":397,"_19":398,"_248":399,"_391":400,"_393":-5,"_394":-5,"_395":401},{"_387":388,"_19":389,"_248":390,"_391":392,"_393":-5,"_394":-5,"_395":396},"no","LBA79","late-breaking","Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01","url","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/249","authors","nct","clue","Rapid oral 1: Gastrointestinal tumour, upper digestive","3609P","regular","Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: A reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials","https://www.esmo.org/meeting-calendar/esmo-congress-2026","Renal cancer","132P","Reasoning LLMs with structured EHR data and for scalable, cross-national clinical trial eligibility screening",[406,406,406],"AI for clinical research and drug development","NCT06216301","80428e52-cb37-41ac-ae33-7fa42bb50bc2",".@myESMO conference has started today in Madrid. .@myESMO conference has started today in Madrid. #ESMO2026 Top Companies Source: @Larvol CL",{"_272":422,"_248":423},"tag:#cnrealtimereport","#CNREALTIMEREPORT","Tune in tomorrow as @DrArturoAI takes over @cancernetwrk live from #ESMO26! He will be breaking down cutting-edge AI breakthroughs in oncology, from digital pathology and foundation models to LLM-assisted clinical decisi",3,"2026-10-23T21:00:01.000Z","2026-10-24T14:00:00.000Z",[],{"_264":418,"_266":419,"_267":268,"_269":420,"_271":421},"uzf83c13f6jz8htt97rseceg6","Tune in tomorrow as @DrArturoAI takes over @cancernetwrk live from #ESMO26! He will be breaking down cutting-edge AI breakthroughs in oncology, from digital pathology and foundation models to LLM-assisted clinical decision support. Catch the coverage from 1 PM to 4 PM CEST (7 AM to 10 AM EST)! #CNRealtimeReport","https://x.com/CancerNetwrk/status/2113737227926733016","CancerNetwrk","f05cb763-9216-4d10-b4da-21b8e4838a52","Tune in tomorrow as @DrArturoAI takes over @cancernetwrk live from #ESMO26",{"_272":436,"_248":437},"tag:#ttdenesmo26","#TTDENESMO26","El Dr. Valentino Martelli, del @hospitaldelmar, @SanMartino_Ge y @GrupoTTD , presenta en el Congreso ESMO 2026 los resultados del estudio TTD-15-01 PLATFORM-B META-ANÁLISIS HIPERSELECCIÓN NEGATIVA 🏅 ESMO Merit Award ¡Ag","2026-10-23T10:20:10.000Z","2026-10-23T11:35:11.000Z",[],{"_264":432,"_266":433,"_267":268,"_269":434,"_271":435},"pvkj9t55eqnb4rmsugx1xhtpl","El Dr. Valentino Martelli, del @hospitaldelmar, @SanMartino_Ge y @GrupoTTD , presenta en el Congreso ESMO 2026 los resultados del estudio TTD-15-01 PLATFORM-B META-ANÁLISIS HIPERSELECCIÓN NEGATIVA 🏅 ESMO Merit Award ¡Agende esta presentación en #ESMO26! #TTDenESMO26","https://x.com/GrupoTTD/status/2113576204435595379","GrupoTTD","12c92dfd-e32b-494d-87f1-f94bc4d30cf0","El Dr",{"_272":450,"_248":451},"tag:#rocheenesmo","#ROCHEENESMO","¡Hoy comienza #ESMO2026! 🔬 Madrid reúne del 23 al 27 de octubre a la comunidad oncológica internacional para compartir avances y explorar nuevas perspectivas en el tratamiento del cáncer. Desde Roche, seguimos de cerca ","2026-10-21T14:16:19.000Z","2026-10-23T08:48:57.000Z",[],{"_264":446,"_266":447,"_267":268,"_269":448,"_271":449},"kz88rn0boc9ggonh8amg5prnl","¡Hoy comienza #ESMO2026! 🔬 Madrid reúne del 23 al 27 de octubre a la comunidad oncológica internacional para compartir avances y explorar nuevas perspectivas en el tratamiento del cáncer. Desde Roche, seguimos de cerca esta cita clave para la innovación en oncología. 📅 23-27 de octubre 📍 Madrid, España https://www.rocheplus.es/campaigns/roche-en-esmo-2026.html #RocheEnESMO #Oncología #InnovaciónMédica #Salud","https://x.com/Roche_Plus/status/2113553249106059350","Roche_Plus","7a824628-8807-498e-926e-bb850b2fc8d9","¿Hacia dónde se dirige el futuro del tratamiento del cáncer de pulmón",{"_272":465,"_248":466},"tag:#uromigos","#UROMIGOS","Could a new mechanism change how we target prostate cancer? Live from #ESMO2026, Dr. Ben Garmezy joins Brian and Tom to discuss Phase 1 data on RIPTAC, a novel approach that uses the androgen receptor (AR) to target BRD4",4,"2026-10-23T15:49:16.000Z","2026-10-24T19:30:04.000Z",[],{"_264":461,"_266":462,"_267":268,"_269":463,"_271":464},"b5osv54gqpu8kaucsn5ejvda5","Could a new mechanism change how we target prostate cancer? Live from #ESMO2026, Dr. Ben Garmezy joins Brian and Tom to discuss Phase 1 data on RIPTAC, a novel approach that uses the androgen receptor (AR) to target BRD4 and disrupt cancer cell transcription. 🎙️ Episode 524 of The Uromigos Podcast is now live: https://bit.ly/4z6zWaG #Uromigos #ProstateCancer #GUOncology","https://x.com/Uromigos/status/2114046327030006193","Uromigos","82de2358-1f69-44c2-ab25-7447bc931273","Could a new mechanism change how we target prostate cancer",{"_272":478,"_248":479},"tag:#oncologyai","#ONCOLOGYAI","🎙️ Reporting in from the Bilbao room at #ESMO26! @DrArturoAI is settling in for the proffered paper session on AI and digital health, where 3 talks are up next: 🤖 A large language model for detecting adverse events in ","2026-10-24T13:00:01.000Z","2026-10-24T21:00:01.000Z",[],{"_264":475,"_266":476,"_267":268,"_269":477,"_271":421},"nr4lvt3yhvwbz8d50hmuzm6uv","🎙️ Reporting in from the Bilbao room at #ESMO26! @DrArturoAI is settling in for the proffered paper session on AI and digital health, where 3 talks are up next: 🤖 A large language model for detecting adverse events in an Alliance randomized clinical trial ☢️ How AI foundation models are transforming treatment and outcome prediction in radiation oncology 🔬 AI-driven pathology in breast cancer Stay tuned for takeaways! 👀 #OncologyAI #DigitalHealth #CNRealtimeReport","https://x.com/CancerNetwrk/status/2114009023406301370","313a7546-6230-40df-8353-426bbe5e0dbf","Live from #ESMO26: @DrArturoAI recaps a session on AI and real-world data in oncology, covering guardrails for LLMs in the clinic, why verif",{"_272":498,"_248":499},"tag:#lacog","#LACOG","The ESMO Congress 2026 brings together researchers and healthcare professionals worldwide to share scientific advances and discuss the future of oncology. LACOG is in Madrid. Follow our coverage! #LACOG #ESMO2026",6,"2026-10-23T19:15:23.000Z","2026-10-24T19:04:44.000Z",[492],{"_264":489,"_266":483,"_267":268,"_269":490,"_271":491},"aq31jgx90owzdqo37lukethjn","https://x.com/LACOG_group/status/2114025898504601713","LACOG_group",{"_387":493,"_19":398,"_248":494,"_391":400,"_393":-5,"_394":495,"_395":496},"2259P","Genomic biomarkers of response to extreme bipolar androgen therapy (BAT) alternating darolutamide in metastatic castration-resistant prostate cancer: An ancillary biomarker analysis of the ExBAT/LACOG 0620 trial",[497,497,497],"Metastatic prostate cancer","NCT04558866","ecdb83d2-9f1f-4764-a9a9-a0f5b0c30d87","The ESMO Congress 2026 brings together researchers and healthcare professionals worldwide to share scientific advances and discuss the futur",{"_272":512,"_248":513},"tag:#ovariancancer","#OVARIANCANCER","Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer. The results reinforce our confide","2026-10-22T19:12:34.000Z","2026-10-24T06:47:56.000Z",[],{"_264":508,"_266":509,"_267":268,"_269":510,"_271":511},"jveigfjyozcaf6e77vgtqq3gs","Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer. The results reinforce our confidence in the potential of this approach to help expand treatment options for patients with ovarian cancer. Read the key data highlights here: https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-presents-new-phase-1-data-folate-receptor-alpha-0 #OvarianCancer #ADC","https://x.com/ZymeworksInc/status/2113885183263006744","ZymeworksInc","3a21845b-08f3-469c-9f96-9d160a463ba3","Heading to #ESMO26",{"_272":531,"_248":532},"tag:#mrna","#MRNA","#ESMO26: With long-awaited positive survival outcomes for a personalised #mRNA #NeoantigenVaccine, a key question discussed by John Haanen in his Editorial is how to make #CellularTherapies practical, scalable and sustai","2026-10-23T13:42:36.000Z","2026-10-24T17:00:21.000Z",[526],{"_264":522,"_266":523,"_267":268,"_269":524,"_271":525},"kcc5vhvv3zulb5s4av4k0c7vs","#ESMO26: With long-awaited positive survival outcomes for a personalised #mRNA #NeoantigenVaccine, a key question discussed by John Haanen in his Editorial is how to make #CellularTherapies practical, scalable and sustainable #InsightsbyESMO ➡️ https://ow.ly/8wqg5100Kzp","https://x.com/myESMO/status/2114039305194664150","myESMO",{"_387":527,"_19":389,"_248":528,"_391":529,"_393":-5,"_394":-5,"_395":530},"LBA1","INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346","Presidential Symposium I","867cecd5-b99c-4cf7-9628-939c67d102a1","#ESMO26: With long-awaited positive survival outcomes for a personalised #mRNA #NeoantigenVaccine, a key question discussed by John Haanen i",{"_272":544,"_248":545},"tag:#melsm","#MELSM","Size does matter (for intralesional injections/TIL) in #melsm #ESMO26 Really informative talk @amandakirane @StanfordMed","2026-10-23T17:34:37.000Z","2026-10-24T13:56:35.000Z",[],{"_264":541,"_266":536,"_267":268,"_269":542,"_271":543},"ybkz8ywo6hvrrmm6eyo87hgqf","https://x.com/anmwongNZ/status/2113993057117061233","anmwongNZ","ad349c89-5934-4b49-b681-4fe7b4ecf893","#melsm #ESMO26 #melsm #ESMO26 #melsm #ESMO26",{"_272":558,"_248":559},"tag:#echobox","#ECHOBOX","#ESMO26 | Los oncólogos europeos se fijan como prioridad reducir la carga del 💉tratamiento del cáncer. 👉@myESMO comenzará a financiar ensayos con el objetivo de reducir toxicidades y favorecer el acceso a la innovación","2026-10-23T12:54:07.000Z","2026-10-23T21:53:49.000Z",[],{"_264":554,"_266":555,"_267":268,"_269":556,"_271":557},"ypef24nm5fg9s39qa1odaxnhc","#ESMO26 | Los oncólogos europeos se fijan como prioridad reducir la carga del 💉tratamiento del cáncer. 👉@myESMO comenzará a financiar ensayos con el objetivo de reducir toxicidades y favorecer el acceso a la innovación. https://www.diariomedico.com/medicina/oncologia/oncologia-europea-fija-objetivo-reducir-carga-tratamiento-cancer.html?utm_medium=Social&utm_source=Twitter#Echobox=1792756005","https://x.com/diariomedico/status/2113614947145892142","diariomedico","47167004-380d-4fa8-8a3a-3b710c839f37","#ESMO26 | Los oncólogos europeos se fijan como prioridad reducir la carga del 💉tratamiento del cáncer",{"_272":572,"_248":573},"tag:#cancerdemama","#CANCERDEMAMA","¡La investigación avanza y la esperanza también! 💜. Así lo evidencia ESMO 2026, el mayor congreso de oncología de Europa. Objetivo: “Reconectar la ciencia con el hecho de que hablamos de seres humanos\" 👏. #ESMO2026 #Ca","2026-10-24T08:10:17.000Z","2026-10-24T10:51:05.000Z",[],{"_264":568,"_266":569,"_267":268,"_269":570,"_271":571},"pz2wz8r44e9xhg2jrdlajurc5","¡La investigación avanza y la esperanza también! 💜. Así lo evidencia ESMO 2026, el mayor congreso de oncología de Europa. Objetivo: “Reconectar la ciencia con el hecho de que hablamos de seres humanos\" 👏. #ESMO2026 #CancerDeMama #ASAMMA","https://x.com/asammavitoria/status/2113946376081916174","asammavitoria","6c167851-dfd5-4afb-894e-1f64ba27977b","#Cancerdemama en #ESMO26 #Cancerdemama en #ESMO26 #Cancerdemama en #ESMO26",{"_272":586,"_248":587},"tag:#cancercare","#CANCERCARE","Strong collaborations drive new possibilities in #CancerCare. At #ESMO26, we, along with our research collaborators, will present 25 abstracts, including 5 rapid oral presentations, exploring advances in liquid biopsy ac","2026-10-20T15:04:25.000Z","2026-10-24T05:00:00.000Z",[],{"_264":582,"_266":583,"_267":268,"_269":584,"_271":585},"bsvennyf8iw7og66t4djz01dx","Strong collaborations drive new possibilities in #CancerCare. At #ESMO26, we, along with our research collaborators, will present 25 abstracts, including 5 rapid oral presentations, exploring advances in liquid biopsy across lung, colorectal, & gastric cancers. Reflecting the strength of our biopharma, academic, & public-private partnerships, these findings expand the evidence across MRD surveillance, treatment response, and resistance research, advancing our understanding of how genomic and epigenomic insights can inform cancer care. Details: https://t.co/CmI0I7iVco","https://x.com/GuardantHealth/status/2112560577964847121","GuardantHealth","05935242-6b4c-4c23-9e32-5c569e63235e","Strong collaborations drive new possibilities in #CancerCare",{"_272":599,"_248":600},"tag:#biotech","#BIOTECH","What to watch in cancer medicine at the European Society for Medical Oncology #ESMO26: four themes, plus a plain-language guide to reading a survival curve. https://bit.ly/4dYHfZM #ESMO2026 #Oncology #Biotech","2026-10-21T12:38:52.000Z","2026-10-23T16:28:09.000Z",[],{"_264":596,"_266":591,"_267":268,"_269":597,"_271":598},"sg7j7fck92n697yip0tmpmpx9","https://x.com/RtwLp/status/2113668812457284058","RtwLp","46a10d15-5d1b-4a1f-b487-2b9e4edeba27","What to watch in cancer medicine at the European Society for Medical Oncology #ESMO26: four themes, plus a plain-language guide to reading a",{"_272":625,"_248":626},"gene:VEGF","gene","VEGF","‼️ Hey #ESMO26 family! Great discussion by Funda Meric-Bernstam on the rationale behind ADC + IO combinations!! @UTMDAnderson ▪️ADCs may induce immunogenic cell death, release DAMPs and prime the TME ▪️They may also incr","2026-10-24T13:40:13.000Z","2026-10-24T13:45:11.000Z",[614,615,616],{"_264":610,"_266":611,"_267":268,"_269":612,"_271":613},"jeakg3nms47myvf7hyn13yky9","‼️ Hey #ESMO26 family! Great discussion by Funda Meric-Bernstam on the rationale behind ADC + IO combinations!! @UTMDAnderson ▪️ADCs may induce immunogenic cell death, release DAMPs and prime the TME ▪️They may also increase PD-L1 expression and help overcome antigen heterogeneity ▪️VEGF–PD-(L)1 bispecifics aim to reverse vascular immunosuppression and improve tumour immune access @OncoAlert @OncoReporte @myESMO @_SEOM","https://x.com/MarioBalsaMD/status/2113988939140735355","MarioBalsaMD",{"_387":622,"_19":398,"_248":623,"_391":400,"_393":-5,"_394":-5,"_395":624},{"_387":619,"_19":398,"_248":620,"_391":400,"_393":-5,"_394":-5,"_395":621},{"_387":617,"_19":398,"_248":618,"_391":400,"_393":-5,"_394":-5,"_395":401},"3636TIP","LITESPARK-034: Phase 3 study of belzutifan plus zanzalintinib versus belzutifan in participants with advanced renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy and VEGF-TKI","2660P","Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results","NSCLC, metastatic","1963P","First-in-human phase I study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF in advanced solid tumours","Investigational immunotherapy","a7c8d46e-a428-4fce-b751-5c30fb2ec3b3","‼️ Hey #ESMO26 family",{"_272":644,"_248":645},"drug:mipitecan","drug","mipitecan","Learn more about FRAmework-01, a Phase 3 study of sofetabart mipitecan (Sofe-M) in PROC and Sofe-M + Bevacizumab (Bev) in platinum sensitive ovarian cancer. ePoster 1448eTiP at #ESMO2026. See congress program details: ht","2026-10-22T15:00:01.000Z","2026-10-24T06:15:01.000Z",[640],{"_264":636,"_266":637,"_267":268,"_269":638,"_271":639},"av88fh565340damj7pp1w5gvy","Learn more about FRAmework-01, a Phase 3 study of sofetabart mipitecan (Sofe-M) in PROC and Sofe-M + Bevacizumab (Bev) in platinum sensitive ovarian cancer. ePoster 1448eTiP at #ESMO2026. See congress program details: https://e.lilly/4yuiYms #GynOnc","https://x.com/LillyOncMed/status/2113284242964725922","LillyOncMed",{"_387":641,"_19":398,"_248":642,"_391":400,"_393":-5,"_394":-5,"_395":643},"1288P","Sofetabart mipitecan (Sofe-M) in patients (pts) ≥65 y with platinum-resistant and -sensitive ovarian cancer","Gynaecological cancers","ca928eaf-b4f0-4a89-89b3-8a5b976993d9","Learn more about FRAmework-01, a Phase 3 study of sofetabart mipitecan (Sofe-M) in PROC and Sofe-M + Bevacizumab (Bev) in platinum sensitive",{"_272":658,"_248":659},"tag:#communicationcommittee","#COMMUNICATIONCOMMITTEE","So proud to have the opportunity to help shape the communication strategy of @myESMO. Brainstorming ways to maximize the reach of good science — alongside a group of remarkable individuals — has been, and continues to be","2026-10-24T18:15:03.000Z","2026-10-24T23:51:53.000Z",[],{"_264":654,"_266":655,"_267":268,"_269":656,"_271":657},"uk1mpbuiwbrv0ocmobr38imsg","So proud to have the opportunity to help shape the communication strategy of @myESMO. Brainstorming ways to maximize the reach of good science — alongside a group of remarkable individuals — has been, and continues to be, tremendously inspiring! #ESMO26 #CommunicationCommittee","https://x.com/PTarantinoMD/status/2114142869661667805","PTarantinoMD","7c358855-2387-4bc0-9925-57a8d31a8bda","On behalf of @myESMO and the #CommunicationCommittee huge thanks to our #ESMOAmbassadors for all the effort On behalf of @myESMO and the #Co",{"_272":672,"_248":673},"tag:#medicaloncology","#MEDICALONCOLOGY","Next stop: Madrid for #ESMO26! We’d love to connect with anyone curious about Mednet and how we support the oncology community. Come find @DocLHenry (Senior Medical Director, Oncology), Varsha Hotchandani (Head of Commer","2026-10-21T12:10:36.000Z","2026-10-23T15:15:09.000Z",[],{"_264":668,"_266":669,"_267":268,"_269":670,"_271":671},"xgkxww34zxizhzo6u4aje5fqb","Next stop: Madrid for #ESMO26! We’d love to connect with anyone curious about Mednet and how we support the oncology community. Come find @DocLHenry (Senior Medical Director, Oncology), Varsha Hotchandani (Head of Commercialization), and Travis Sullivan (Director, Business Development) at @ESMO - European Society for Medical Oncology Congress, October 23–27. Have questions about @Mednet? Send us a message here on X and we’ll find a time to connect. #ESMO26 #Oncology #MedicalOncology #CancerResearch #MedicalEducation","https://x.com/themednet/status/2113641900569747799","themednet","3995b9d1-d08b-4521-921d-116841a8c7cf","Next stop: Madrid for #ESMO26",{"_272":685,"_248":686},"tag:#kidneycancer","#KIDNEYCANCER","At #ESMO26, Rahul Winayak, MD (@cityofhope) explains new metastatic #RCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome #immunotherapy resistance. 🎥 WATCH: https://www.targetedonc.com/view/rahul-winayak-emerging-","2026-10-24T16:00:00.000Z",[],{"_264":681,"_266":682,"_267":268,"_269":683,"_271":684},"fxnwtimsie23ny0b9h63zrxdf","At #ESMO26, Rahul Winayak, MD (@cityofhope) explains new metastatic #RCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome #immunotherapy resistance. 🎥 WATCH: https://www.targetedonc.com/view/rahul-winayak-emerging-therapeutic-targets-metastatic-renal-cell-carcinoma #KidneyCancer #Oncology | @RWinayak @CityofHope_GU","https://x.com/TargetedOnc/status/2114099618883731596","TargetedOnc","3e4f1743-ea95-4bc8-83f6-1a8166cbf9b1","Sharing our commitment to the #kidneycancer community at #ESMO26 Sharing our commitment to the #kidneycancer community at #ESMO26 Sharing ou",{"_272":704,"_248":705},"tag:#oncolog","#ONCOLOG","📍🟣 ¡Ya estamos aquí, #ESMO26 🙌! Arranca una nueva edición del congreso de la European Society for Medical Oncology (@myESMO), que nos trae unos días para compartir ciencia, debate e intercambio en torno a los principa","2026-10-22T09:24:29.000Z","2026-10-24T08:00:00.000Z",[699],{"_264":695,"_266":696,"_267":268,"_269":697,"_271":698},"hx0mr57xwg4n2dmvzjpn76h86","📍🟣 ¡Ya estamos aquí, #ESMO26 🙌! Arranca una nueva edición del congreso de la European Society for Medical Oncology (@myESMO), que nos trae unos días para compartir ciencia, debate e intercambio en torno a los principales retos de la #oncología médica 🔬🧬 🙌 Nosotros, llegamos con muchas ganas de compartir los resultados de nuestro trabajo. ¡Vamos allá! 🚀","https://x.com/GEICAM/status/2113582637210014035","GEICAM",{"_387":700,"_19":389,"_248":701,"_391":702,"_393":-5,"_394":-5,"_395":703},"LBA24","Final analysis of NRG oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant therapy with a","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/240","Proffered paper 1: Breast cancer, early and advanced stage","d040fe58-47c0-422a-80fc-f2163d244de3","📍🟣 ¡Ya estamos aquí, #ESMO26 🙌",{"_272":716,"_248":717},"code:2259P","At ESMO 2026, Dr. Diogo Assed Bastos presented poster 2259P from the ExBAT study (LACOG 0620), evaluating genomic biomarkers of response to alternating darolutamide and testosterone cypionate in patients with mCRPC. #LAC","2026-10-24T13:47:01.000Z","2026-10-24T15:18:22.000Z",[],{"_264":713,"_266":714,"_267":268,"_269":715,"_271":491},"t9rs690a3clu2zkrk2lqkkgkk","At ESMO 2026, Dr. Diogo Assed Bastos presented poster 2259P from the ExBAT study (LACOG 0620), evaluating genomic biomarkers of response to alternating darolutamide and testosterone cypionate in patients with mCRPC. #LACOG #ESMO2026","https://x.com/LACOG_group/status/2113990650563895611","a03474f3-d884-4d6c-8b72-ba8491a1bf40","At ESMO 2026, Dr",{"_272":730,"_248":731},"nct:NCT05281406","NCT05281406","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥PACE-LUNG (AIO-TRK-0422/ass): A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients With EGFRm NSCLC With the Continued Pr","2026-10-24T05:10:48.000Z","2026-10-24T06:36:52.000Z",[],{"_264":726,"_266":727,"_267":268,"_269":728,"_271":729},"dkyqrbi2tgwdf9k5ah78zixun","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥PACE-LUNG (AIO-TRK-0422/ass): A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients With EGFRm NSCLC With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment 🎙️Dr. Martin Sebastian 🔢LBA73 🎯ctDNA-Guided Treatment Intensification Feasible 🎯mPFS 16.3mo From Start of Chemo ( 29% of Screened Pts Had Persistent ctDNA) 🎯mOS 29.2mo, 24-Mo OS 65.4% ☑️NCT05281406 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters","https://x.com/HHorinouchi/status/2113860739425542648","HHorinouchi","0819cca0-a895-40f1-8465-c0c0b5baf6a8","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥PACE-LUNG (AIO-TRK-0422/ass): A Multicenter, Single-Arm, Phase II Cl",{"_272":744,"_248":745},"tag:#mcbs","#MCBS","@bishalgyawali RN at #ESMO26 delivering his expertise on 'how to read a trial report' but truly how to critical appraise and put in context the wave of new data injecting the field! @OncologyBGLab #BGLab #ESMOAmbassadors","2026-10-23T11:38:31.000Z","2026-10-23T12:42:35.000Z",[],{"_264":740,"_266":741,"_267":268,"_269":742,"_271":743},"ez6da5q0t5iu1b4avfwjdbupk","@bishalgyawali RN at #ESMO26 delivering his expertise on 'how to read a trial report' but truly how to critical appraise and put in context the wave of new data injecting the field! @OncologyBGLab #BGLab #ESMOAmbassadors @myESMO #MCBS","https://x.com/darioT_/status/2113595921728430248","darioT_","46b8e7f5-c7a7-4ddc-a036-33e23b64fdd4","@bishalgyawali RN at #ESMO26 delivering his expertise on 'how to read a trial report' but truly how to critical appraise and put in context ",{"_272":757,"_248":758},"tag:#mattfreedman","#MATTFREEDMAN","Presenting rising star @RashadNawfal post-doc MD in our group working on novel liquid biopsy methods for non-invasive profiling of cancers! Come on down! #ESMO26 @DanaFarber_GU @DanaFarber Also applying for IM match! Don","2026-10-23T14:48:54.000Z","2026-10-24T12:28:58.000Z",[],{"_264":754,"_266":755,"_267":268,"_269":756,"_271":300},"qmq2bj3shb3a40892xolj1vtu","Presenting rising star @RashadNawfal post-doc MD in our group working on novel liquid biopsy methods for non-invasive profiling of cancers! Come on down! #ESMO26 @DanaFarber_GU @DanaFarber Also applying for IM match! Don’t miss on him ! @OncoAlert @SylvanBacaLab #MattFreedman","https://x.com/DrChoueiri/status/2113643836610347376","e0e67182-cbc3-43cd-998b-d9b84e8b233f","Presenting rising star @RashadNawfal post-doc MD in our group working on novel liquid biopsy methods for non-invasive profiling of cancers",{"_272":771,"_248":772},"code:3975P","3975P","Lung Cancer Europe is in Madrid for #ESMO26. 🇪🇸 It's a big year for #lungcancer, with new trial results that could change treatment. On Saturday, our President, Debra Montague presents our research on the cost of lung ","2026-10-22T14:52:15.000Z","2026-10-24T10:35:34.000Z",[],{"_264":767,"_266":768,"_267":268,"_269":769,"_271":770},"xjoqboo6yxtgpzk8c6pxujapw","Lung Cancer Europe is in Madrid for #ESMO26. 🇪🇸 It's a big year for #lungcancer, with new trial results that could change treatment. On Saturday, our President, Debra Montague presents our research on the cost of lung cancer: two in three people we surveyed were struggling financially. 📍 3975P, Sat 24 Oct, 12:00 #LCSM","https://x.com/LungCancerEu/status/2113282288419008985","LungCancerEu","9acfee0c-518d-4925-ad9e-39fc096fdd99","Lung Cancer Europe is in Madrid for #ESMO26",{"_272":785,"_248":786},"code:HS-20122","HS-20122","#ESMO26 💉 Developmental therapeutics 📌 HS-20122: novel EGFR/c-MET 46% =>2L ✔️ ORR ✔️ ORR for #EGFRm NSCLC 61.3% at 6mg/kg 💊 Seems to work better in L858R > Del19 ☣️ 44% >G3, mostly hematologic @OncoAlert @myE","2026-10-24T13:05:19.000Z","2026-10-24T13:25:30.000Z",[],{"_264":781,"_266":782,"_267":268,"_269":783,"_271":784},"cxvmvfswsyo1nhg9u4br4s7ms","#ESMO26 💉 Developmental therapeutics 📌 HS-20122: novel EGFR/c-MET 46% =>2L ✔️ ORR ✔️ ORR for #EGFRm NSCLC 61.3% at 6mg/kg 💊 Seems to work better in L858R > Del19 ☣️ 44% >G3, mostly hematologic @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson 👇🏽👇🏽","https://x.com/DrMirallas/status/2113980153898442933","DrMirallas","c273542f-7448-4d0f-8667-f361c0fb66d2","#ESMO26 #ESMO26 💉 Developmental therapeutics 📌 HS-20122: novel EGFR/c-MET 46% =>2L ✔️ ORR ✔️ ORR for #EGFRm NSCLC 61",{"_272":802,"_248":803},"nct:NCT05933577","NCT05933577","🆙#ESMO26 Presidential Symposium I 🔥INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoantigen Therapy (INT) Intismeran Autogene (Intismeran) Plus Pembrolizumab (Pembro) vs Pembro Alone for Adjuvant Treatm","2026-10-24T05:04:07.000Z","2026-10-24T14:57:16.000Z",[798],{"_264":795,"_266":796,"_267":268,"_269":797,"_271":729},"rsav4vos9kd5b8u342c68mkkr","🆙#ESMO26 Presidential Symposium I 🔥INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoantigen Therapy (INT) Intismeran Autogene (Intismeran) Plus Pembrolizumab (Pembro) vs Pembro Alone for Adjuvant Treatment of Resected Stage IIB-IV Melanoma (MEL) 🎙️ @ProfGLongMIA 🔢LBA1 🎯Met Primary Endpoint: Significantly Improved RFS 🎯24-Mo 82.2% vs 70.0%, HR 0.58 🎯DMFS HR 0.62 🎯Grade≥3 AEs 23.6% vs 20.3% ☑️NCT05933577 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346 @OncoAlert @Larvol @myESMO","https://x.com/HHorinouchi/status/2114008329064460757",{"_387":789,"_19":398,"_248":799,"_391":800,"_393":-5,"_394":801,"_395":799},"INTerpath-001","https://clinicaltrials.gov/study/NCT05933577",[789],"a379f5dc-4b21-47b7-8cf1-d86a70863884","🆙#ESMO26 Presidential Symposium I 🆙#ESMO26 Presidential Symposium I 🔥INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoant",{"_272":816,"_248":817},"tag:#livercancer","#LIVERCANCER","🧬 #ESMO26 EMERALD-3:can STRIDE-based therapy preserve liver function in intermediate-stage HCC? 📊 Exploratory analyses suggest: 👉 Liver function (ALBI & Child-Pugh scores) remained broadly stable during treatment.","2026-10-24T12:49:17.000Z","2026-10-24T13:06:40.000Z",[],{"_264":812,"_266":813,"_267":268,"_269":814,"_271":815},"pr9qmuqanqhttjs28kcwzme4s","🧬 #ESMO26 EMERALD-3:can STRIDE-based therapy preserve liver function in intermediate-stage HCC? 📊 Exploratory analyses suggest: 👉 Liver function (ALBI & Child-Pugh scores) remained broadly stable during treatment. 👉 No clear signal of deterioration with combination therapy","https://x.com/lucykflanders/status/2113980496514355447","lucykflanders","258c5cf7-6128-459f-a074-3485ff4df480","🧬 #ESMO26: BGB-B2033, a GPC3 × 4-1BB bispecific antibody, shows promising activity in advanced HCC",{"_272":830,"_248":831},"drug:disitamab","disitamab","#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC.81% HER2-positive Promising antitumor activity Higher HER2 expression may predict response. @SCUC","2026-10-24T08:35:29.000Z","2026-10-24T09:06:27.000Z",[],{"_264":826,"_266":827,"_267":268,"_269":828,"_271":829},"wvmk5sx49mz4aywllgjprmm2j","#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC.81% HER2-positive Promising antitumor activity Higher HER2 expression may predict response. @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily","https://x.com/zapatalaguadomd/status/2113920041242472896","zapatalaguadomd","ef80c2fe-53d5-4a69-84db-478c5f44b34a","#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC",{"_272":843,"_248":844},"nct:NCT06211036","NCT06211036","🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Durva as 1L Maintenance (1LM) Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-","2026-10-24T05:07:43.000Z","2026-10-24T15:40:30.000Z",[],{"_264":840,"_266":841,"_267":268,"_269":842,"_271":729},"ddgsutj3fmgk3xhvwy4f7gbbm","🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Durva as 1L Maintenance (1LM) Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 Trial 🎙️ @sands_jacob 🔢LBA3 🎯Met Primary Endpoint: Significantly Improved OS 🎯mOS 21.1 vs 12.7m, HR 0.42 🎯mPFS 7.4 vs 1.9m, HR 0.34 🎯ORR 26.4% vs 4.1% 🎯CRS 49.6% (Mostly Low Grade), No Fatal Events ☑️NCT06211036 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346 @OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2114019208766095425","5a7bcf4f-dc51-4ffb-88e2-9d41bf3f366d","🆙#ESMO26 Presidential Symposium I: #LCSM 🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Dur",{"_272":857,"_248":858},"tag:#neurooncology","#NEUROONCOLOGY","Fantastic to see CNS oncology take centre stage with a keynote lecture at @myESMO meeting in Madrid! Anna Berghoff introducing Wolfgang Wick on glioblastoma, brain metastases and LMD disease: the next frontier in oncolog","2026-10-23T13:33:07.000Z","2026-10-23T14:56:35.000Z",[],{"_264":853,"_266":854,"_267":268,"_269":855,"_271":856},"n6holq2pr89lk3y1h7xb8lz4d","Fantastic to see CNS oncology take centre stage with a keynote lecture at @myESMO meeting in Madrid! Anna Berghoff introducing Wolfgang Wick on glioblastoma, brain metastases and LMD disease: the next frontier in oncology care. #ESMO2026 #NeuroOncology @EANOassociation","https://x.com/gminniti2012/status/2113624762496987434","gminniti2012","5cafafc1-c19d-4085-9868-50801fb9a9f8","Fantastic to see CNS oncology take centre stage with a keynote lecture at @myESMO meeting in Madrid",{"_272":870,"_248":871},"nct:NCT05048797","NCT05048797","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥DESTINY-Lung04 (DL-04): First-Line (1L) Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutant (HER2m) NSCLC: Patient-Reported Outcomes (PROs) 🎙️Dr. Silvia Novello 🔢LBA74","2026-10-24T05:12:28.000Z","2026-10-24T07:11:42.000Z",[],{"_264":867,"_266":868,"_267":268,"_269":869,"_271":729},"q5brs8guvhtj3dy6wp5e57ism","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥DESTINY-Lung04 (DL-04): First-Line (1L) Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutant (HER2m) NSCLC: Patient-Reported Outcomes (PROs) 🎙️Dr. Silvia Novello 🔢LBA74 🎯T-DXd Delayed Time to Deterioration in Cough vs Pembro+Chemo (26.2 vs 11.0mo, HR 0.66 ☑️NCT05048797 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2113861160042889431","d817a90f-ec84-4d97-aa05-a1e0a0705ee3","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥DESTINY-Lung04 (DL-04): First-Line (1L) Trastuzumab Deruxtecan (T-DX",{"_272":884,"_248":885},"tag:#metastaticbreastcancer","#METASTATICBREASTCANCER","BriaCell will present new clinical biomarker findings at the #ESMO26 Congress highlighting CAML PD-L1 as a potential biomarker of clinical outcomes in #metastaticbreastcancer. “We are encouraged by these findings showing","2026-10-23T11:55:18.000Z","2026-10-23T17:15:09.000Z",[],{"_264":880,"_266":881,"_267":268,"_269":882,"_271":883},"zzngmx2nhxrbfqu8go21w946d","BriaCell will present new clinical biomarker findings at the #ESMO26 Congress highlighting CAML PD-L1 as a potential biomarker of clinical outcomes in #metastaticbreastcancer. “We are encouraged by these findings showing that dynamic changes in a circulating immune biomarker were associated with progression-free and overall survival in patients with metastatic breast cancer treated with immunotherapies,” stated Dr. William V. Williams, BriaCell’s President and CEO. For more: https://bit.ly/4yGWuOd $BCTX $BCTXL","https://x.com/BriaCell/status/2113680638070944002","BriaCell","3462cb23-1f38-4c23-b7dd-c31a830b82d5","BriaCell announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with #metastaticbreastcanc",{"_272":901,"_248":902},"nct:NCT06341114","NCT06341114","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced NSCLC: Results From a Multicenter Phase 2 Study 🎙️Dr. Shaodong Hong 🔢2631RO 🎯Overall: ORR 57.9%, DCR 89.5%, 6-M","2026-10-21T13:00:02.000Z","2026-10-24T07:39:04.000Z",[897],{"_264":894,"_266":895,"_267":268,"_269":896,"_271":729},"uxmad99z1obdb3ximfr0tq3c0","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced NSCLC: Results From a Multicenter Phase 2 Study 🎙️Dr. Shaodong Hong 🔢2631RO 🎯Overall: ORR 57.9%, DCR 89.5%, 6-Mo PFS 64.8% 🎯ORR 83% in PD-L1 TPS≥50% 🎯Grade≥3 Stomatitis Only 7.2%, Grade≥3 TRAEs 38.1% ☑️NCT06341114 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2113898053040267773",{"_387":888,"_19":398,"_248":898,"_391":899,"_393":-5,"_394":900,"_395":898},"- **标题 / Title：** A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","https://clinicaltrials.gov/study/NCT06341114",[888],"21881840-7fdd-45cb-b6e6-1729c80181d9","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced",{"_272":914,"_248":915},"tag:#idweek","#IDWEEK","@PeterHotez @celinegounder @IDWeekmtg An illustrious group! Sorry I didn't attend #IDWeek in person this year, but since I also need to cover overlapping #ESMO2026 on another continent, doing it front home works best.","2026-10-24T04:58:45.000Z","2026-10-24T05:00:56.000Z",[],{"_264":911,"_266":906,"_267":268,"_269":912,"_271":913},"ng5tjwx4kapqmekvam4frpqdi","https://x.com/LizHighleyman/status/2113858256477307299","LizHighleyman","c26e3c64-5106-483b-ad15-3db1c38b724c","An illustrious group",{"_272":928,"_248":929},"tag:#sciencelink","#SCIENCELINK","#ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia En ACTICCA-1 (fase III; 591 pacientes analizados), el análisis preespecificado de SLE media restringida favoreció a gemcitabina + cisplatino frente a capecitabina","2026-10-24T17:49:23.000Z","2026-10-24T18:11:50.000Z",[],{"_264":924,"_266":925,"_267":268,"_269":926,"_271":927},"itbxi8bbi9qkx7ygerl8x379y","#ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia En ACTICCA-1 (fase III; 591 pacientes analizados), el análisis preespecificado de SLE media restringida favoreció a gemcitabina + cisplatino frente a capecitabina como adyuvancia en cáncer de vía biliar resecado. ⏰ Mediana de seguimiento: 4.8 años ⏳ Mediana de SLE: 25.7 vs 17.9 meses La comparación por log-rank no alcanzó significancia estadística (p=0.097). 📈 SLE media restringida a los primeros 3 años Ganancia promedio de 2.6 meses (p=0.011). Este análisis estaba preespecificado ante un efecto del tratamiento variable en el tiempo. 📊 SG: 58.1 vs 48.2 meses HR 0.82; p=0.103. Sin diferencia estadísticamente significativa. ⚠️ Mayor toxicidad con gemcitabina + cisplatino, predominantemente hematológica. Estos resultados no establecen a gemcitabina + cisplatino como nuevo estándar adyuvante. 🔗 Leer/escuchar noticia completa: https://buff.ly/8CxPRn0","https://x.com/sciencelinkonco/status/2114057290638581926","sciencelinkonco","e3193f3b-1406-4df9-af9d-5a3a28d77759","#ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia #ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia En ACTICCA-1 (fase III; ",{"_272":941,"_248":942},"nct:NCT03052608","NCT03052608","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥CROWN: Characterizing Resistance Mechanisms and Predictors of Early Progression and Long-Term Response to Lorlatinib: Circulating Tumor DNA (ctDNA) Analyses From the CROWN Study 🎙️ @","2026-10-21T13:00:01.000Z","2026-10-24T07:18:34.000Z",[],{"_264":938,"_266":939,"_267":268,"_269":940,"_271":729},"eswk2efskxzvmvm48hi5a4f9r","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥CROWN: Characterizing Resistance Mechanisms and Predictors of Early Progression and Long-Term Response to Lorlatinib: Circulating Tumor DNA (ctDNA) Analyses From the CROWN Study 🎙️ @bensolomon1 🔢2636RO 🎯No New On-Target ALK Resistance Mutations 🎯Bypass (RTK/RAS/MAPK) Pathways Drive Resistance; Baseline Genomic Complexity Higher in Early Progressors 🎯On-Treatment TF Drop Predicts Longer PFS ☑️NCT03052608 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC @ALKpositiveINT","https://x.com/HHorinouchi/status/2113892891042922538","6bce8a7e-f3bc-4d21-88bd-547a725cc75b","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥CROWN: Characterizing Resistance Mechanisms and Predictors of Early ",{"_272":955,"_248":956},"tag:#practicechanging","#PRACTICECHANGING","🚀 ESMO Congress 2026 ,Here we go! The wait is over! #ESMO26 officially kicks off today! I’m delighted and honoured to be one of the #ESMOAmbassadors for one of the most exciting and influential events in oncology worldw","2026-10-23T04:42:01.000Z","2026-10-24T14:34:35.000Z",[],{"_264":951,"_266":952,"_267":268,"_269":953,"_271":954},"tubxc7azxxzgm4906h367e42z","🚀 ESMO Congress 2026 ,Here we go! The wait is over! #ESMO26 officially kicks off today! I’m delighted and honoured to be one of the #ESMOAmbassadors for one of the most exciting and influential events in oncology worldwide. Over the next few days, science will take centre stage, bringing together the global oncology community to share groundbreaking research, challenge current standards, and shape the future of cancer care. 🔬 Will we see practice-changing data? I suspect we will ,and I can’t wait to discover, discuss, and critically appraise the results! 📢 Stay tuned! I’ll be sharing highlights, key findings, and my perspectives on the most exciting developments throughout the congress. Let’s follow the science, challenge the evidence, and keep pushing the boundaries of cancer care. Let the science begin! 🔬🌍 #ESMO26 #Oncology #CancerResearch #ClinicalTrials #PracticeChanging","https://x.com/Alfdoc2/status/2113491107975688701","Alfdoc2","79c068e2-755d-470e-8d03-ad94d7c3eb23","🚀 ESMO Congress 2026 ,Here we go",{"_272":967,"_248":968},"nct:NCT04035486","NCT04035486","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associated Clinical Outcomes in Patients (Pts) With EGFRm Advanced NSCLC Treated With First-Line (1L) Osimertinib (Osi) ± P","2026-10-24T06:42:39.000Z",[],{"_264":964,"_266":965,"_267":268,"_269":966,"_271":729},"ggr7bx8g4wsnmw4uhx9jy73fk","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associated Clinical Outcomes in Patients (Pts) With EGFRm Advanced NSCLC Treated With First-Line (1L) Osimertinib (Osi) ± Platinum–Pemetrexed (Plat–Pem) 🎙️ @dplanchard 🔢2719RO 🎯EGFRm Clearance Prognostic but Not Predictive 🎯Osi+Plat–Pem Benefit Over Osi Alone Consistent Regardless of Clearance Status at Wk 1, 2, 3, 6; Clearance Rates Comparable Between Arms ☑️NCT04035486 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters","https://x.com/HHorinouchi/status/2112891655754076171","b23d84e6-2604-4103-a145-ae0c84211227","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associat",{"_272":981,"_248":982},"code:LBA68","LBA68","Sigvotatug vedotin vs docetaxel in pretreated nonsquamous NSCLC: Pfizer said in June the phase 3 missed its OS endpoint. Our faculty member Solange Peters (@peters_solange) presents the data at #ESMO26, LBA68, Sun 25 Oct","2026-10-18T11:01:45.000Z","2026-10-24T11:02:14.000Z",[],{"_264":977,"_266":978,"_267":268,"_269":979,"_271":980},"j8f0t5m218qhrcpme3x76jmq3","Sigvotatug vedotin vs docetaxel in pretreated nonsquamous NSCLC: Pfizer said in June the phase 3 missed its OS endpoint. Our faculty member Solange Peters (@peters_solange) presents the data at #ESMO26, LBA68, Sun 25 Oct, 11:13, Hall 6. Calendar file: https://t.co/T7PqGHFhac Is it on your list? @myESMO","https://x.com/LungSummit/status/2111774732383048134","LungSummit","c34edc43-21b1-474d-9753-b64f0cf68f03","Sigvotatug vedotin vs docetaxel in pretreated nonsquamous NSCLC: Pfizer said in June the phase 3 missed its OS endpoint",{"_272":1000,"_248":1001},"code:EV-103","EV-103","#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years The next step is identifying long-term responders through biomarkers (Nectin4?) and opti","2026-10-24T09:20:27.000Z","2026-10-24T09:25:33.000Z",[995],{"_264":991,"_266":992,"_267":268,"_269":993,"_271":994},"s04n6alwi1qozdl3e4hrynfjl","#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years The next step is identifying long-term responders through biomarkers (Nectin4?) and optimising treatment duration (ctDNA?) @OncoAlert","https://x.com/scocmem/status/2113924850758603027","scocmem",{"_387":996,"_19":398,"_248":997,"_391":998,"_393":-5,"_394":-5,"_395":999},"4740RO","Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/261","Rapid oral 1: Genitourinary tumours, renal and urothelial","77760006-8973-4b2c-8016-6d3752b7e5ad","#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years #ESMO26 ",{"_272":1013,"_248":1014},"tag:#oaonthego","#OAONTHEGO","🎬New #OAOnTheGo from #ESMO26 🇪🇸 Our #OncoAlertAF collegue Dr @MarioBalsaMD 🇪🇸 on treating #melanoma patients who don’t fit the trials 👇 @OncoAlert","2026-10-24T10:34:56.000Z","2026-10-24T10:35:23.000Z",[],{"_264":1010,"_266":1005,"_267":268,"_269":1011,"_271":1012},"so54qoja2241tz1w2wb42ivby","https://x.com/JankovicK/status/2113942308450136298","JankovicK","ea321ca2-8682-4cef-936a-c135765fd167","🎬New #OAOnTheGo from #ESMO26 🇪🇸 🎬New #OAOnTheGo from #ESMO26 🇪🇸 Our #OncoAlertAF collegue Dr @MarioBalsaMD 🇪🇸 on treating #melanoma ",{"_272":1027,"_248":1028},"code:KEYNOTE-091","KEYNOTE-091","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Final Analysis of Adjuvant Pembrolizumab in Resected Early-Stage Non–Small-Cell Lung Cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 Study @LuisPaz_Ares @AlxMtzMarti @Benj","2026-10-23T08:00:05.000Z","2026-10-23T08:59:19.000Z",[],{"_264":1023,"_266":1024,"_267":268,"_269":1025,"_271":1026},"c3ywl19zsrkf40kwfv1fab2by","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Final Analysis of Adjuvant Pembrolizumab in Resected Early-Stage Non–Small-Cell Lung Cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 Study @LuisPaz_Ares @AlxMtzMarti @BenjaminBesseMD @peters_solange 🫁 Phase 3 (n=1177): adjuvant pembrolizumab vs placebo in resected stage IB–IIIA NSCLC. Final analysis; median follow-up 87.7 mo. ➡️ DFS HR 0.85 (0.73–0.98); median 58.7 vs 43.3 mo ➡️ OS HR 0.98 (0.81–1.18); 6-y OS 68.5% vs 66.4% ➡️ LCSS HR 0.81 (0.63–1.03); grade ≥3 AEs 34.0% vs 25.6% ✅ Consistent DFS benefit with a favorable trend in LCSS and manageable safety; OS was not significantly improved, and the study was not powered for OS. 🎙️ Mary O’Brien 👥 Luis Paz-Ares · Sandrine Marreaud · Urania Dafni · Kersti Oselin · Libor Havel · Emilio Esteban · Dolores Isla · Alex Martinez-Marti · Martin Faehling · Masahiro Tsuboi · Jong-Seok Lee · Kazuhiko Nakagawa · Jing Yang · Ayman Samkari · Steven Keller · Murielle Mauer · Nitish Jha · Rolf Stahel · Benjamin Besse · Solange Peters (4Sight Made from Abstracts publicly available at the ESMO website) Pinging our faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers","https://x.com/OncoAlert/status/2113540950865608795","OncoAlert","7d1a3fb0-fec4-4d18-9adf-0ed65942757d","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Final Analysis of Adjuvant Pembr",{"_272":1041,"_248":1042},"tag:#medicaleducation","#MEDICALEDUCATION","🚨 #ESMO26 is here — and so is the @OncoAlert PULSE Faculty. 🇪🇸 Proud to be part of this international team reporting live from Madrid and helping translate an overwhelming amount of congress data into what colleagues ","2026-10-22T17:30:14.000Z","2026-10-23T08:57:31.000Z",[],{"_264":1037,"_266":1038,"_267":268,"_269":1039,"_271":1040},"uld8kpx7niyb5vgtruo3mk4tv","🚨 #ESMO26 is here — and so is the @OncoAlert PULSE Faculty. 🇪🇸 Proud to be part of this international team reporting live from Madrid and helping translate an overwhelming amount of congress data into what colleagues actually need: 📊 the trials that may change practice 🧬 the biology that changes how we think 🎯 the clinical questions behind the headlines 💬 expert perspective from across tumor types Whether you are in Madrid or following from home, the goal is simple: Less noise. More context. More useful science. And, as always with @OncoAlert: By colleagues, for colleagues. Looking forward to sharing the most relevant #ESMO26 updates with this incredible faculty: @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists #OncoAlert #ESMO26 #Oncology #MedicalEducation #CancerResearch","https://x.com/nataliagandur/status/2113555406261793040","nataliagandur","aad71156-584e-4c91-a8e1-3a26411b32e7","🚨 #ESMO26 is here — and so is the @OncoAlert PULSE Faculty",{"_272":1055,"_248":1056},"code:LBA21","LBA21","⚡ Phase III ACTICCA-1: Adjuvant Gemcitabine Plus Cisplatin Versus Capecitabine in Biliary Tract Cancer At #ESMO26, Henning Wege presented results from the Phase III ACTICCA-1 trial (LBA21), evaluating adjuvant gemcitabin","2026-10-24T10:41:52.000Z","2026-10-24T14:26:21.000Z",[],{"_264":1051,"_266":1052,"_267":268,"_269":1053,"_271":1054},"fha9hca60uwoaedmo35unbmme","⚡ Phase III ACTICCA-1: Adjuvant Gemcitabine Plus Cisplatin Versus Capecitabine in Biliary Tract Cancer At #ESMO26, Henning Wege presented results from the Phase III ACTICCA-1 trial (LBA21), evaluating adjuvant gemcitabine plus cisplatin versus capecitabine following curative-intent resection of biliary tract cancer. Key findings: 👉 Median DFS: 25.7 vs 17.9 months (HR 0.82; 95% CI 0.67–1.01; log-rank p=0.097). 👉Prespecified RMST analysis: An additional 2.6 months of DFS over three years with gemcitabine plus cisplatin (95% CI 0.6–4.68; p=0.011). 👉Median OS: 58.1 vs 48.2 months (HR 0.82; p=0.103). 👉Safety: Gemcitabine plus cisplatin was associated with increased toxicity, predominantly haematological. Takeaway: The prespecified RMST analysis favoured gemcitabine plus cisplatin, although the log-rank DFS comparison and overall survival analysis did not demonstrate statistically significant improvements. @oncodaily @myESMO https://oncodaily.com/gastrointestinal-oncology/acticca-1 #ESMO26 #ESMO2026 #ACTICCA1 #OncoDaily","https://x.com/OncoDailyGI/status/2113944056074043455","OncoDailyGI","d45c11dc-c013-49a4-bbcc-9b1302e79c84","⚡ Phase III ACTICCA-1: Adjuvant Gemcitabine Plus Cisplatin Versus Capecitabine in Biliary Tract Cancer ⚡ Phase III ACTICCA-1: Adjuvant Gemci",{"_272":1068,"_248":1069},"tag:#vacuna","#VACUNA","#ESMO26 | 📌 Primer éxito de con una #vacuna personalizada de #ARNm para #cáncer. 👉Los datos para #melanoma de alto riesgo indican una reducción del 42% en recaída o muerte, según los datos en @myESMO https://www.diario","2026-10-23T10:52:16.000Z","2026-10-23T19:50:50.000Z",[],{"_264":1065,"_266":1066,"_267":268,"_269":1067,"_271":557},"r0jt789ctl33j0esrdyvrgqrq","#ESMO26 | 📌 Primer éxito de con una #vacuna personalizada de #ARNm para #cáncer. 👉Los datos para #melanoma de alto riesgo indican una reducción del 42% en recaída o muerte, según los datos en @myESMO https://www.diariomedico.com/medicina/oncologia/primer-exito-fase-iii-vacuna-personalizada-arnm-cancer.html?utm_medium=Social&utm_source=Twitter#Echobox=1792749241","https://x.com/diariomedico/status/2113584282669105437","06e4fa3c-2b6d-4f85-9031-be488a2da7ee","#ESMO26 | 📌 Primer éxito de con una #vacuna personalizada de #ARNm para #cáncer",{"_272":1082,"_248":1083},"code:LBA31","LBA31","#ESMO26 | LBA31 PRABITAS: Pragmatic Ph3 biweekly FTD/TPI + bev vs conventional FTD/TPI + bev in mCRC (non-inferiority) ▪️OS: 11.3 vs 10.3 mo, HR 0.93, 95% CI 0.80-1.08 (<1.25) ▪️PFS: 3.9 vs 3.9 mo, HR 0.93, 95% CI 0.81-1","2026-10-24T05:04:20.000Z","2026-10-24T14:03:01.000Z",[],{"_264":1078,"_266":1079,"_267":268,"_269":1080,"_271":1081},"yrocd9a268xq2uh0cg60zzhon","#ESMO26 | LBA31 PRABITAS: Pragmatic Ph3 biweekly FTD/TPI + bev vs conventional FTD/TPI + bev in mCRC (non-inferiority) ▪️OS: 11.3 vs 10.3 mo, HR 0.93, 95% CI 0.80-1.08 (<1.25) ▪️PFS: 3.9 vs 3.9 mo, HR 0.93, 95% CI 0.81-1.06 ▪️Safety - ≥G3 neutropenia: 13% vs 39% - FN: 1% vs 5% - ≥G2 anorexia: 15% vs 26% 👉Biweekly FTD/TPI + bev showed non-inferior OS with less toxicities! @myESMO @OncoAlert","https://x.com/DaisukeKotani/status/2113859113499169206","DaisukeKotani","67152a8c-4cf9-47bb-821a-470f78f87de7","#ESMO26 | LBA31 #ESMO26 | LBA31 PRABITAS: Pragmatic Ph3 biweekly FTD/TPI + bev vs conventional FTD/TPI + bev in mCRC (non-inferiority) ▪️OS:",{"_272":1104,"_248":1105},"tag:#tnbc","#TNBC","Impressive ctDNA dynamics in B-STRONGER-I! 95.1% baseline detection in stage I–III TNBC. By C3D1: 80.8% clearance and a 99.8% median reduction in ctDNA levels. A striking window into early treatment response—before surge","2026-10-23T20:05:09.000Z","2026-10-24T13:03:04.000Z",[1096,1097],{"_264":1092,"_266":1093,"_267":268,"_269":1094,"_271":1095},"wv5r79gfl2qo2vrn9h82t7zi6","Impressive ctDNA dynamics in B-STRONGER-I! 95.1% baseline detection in stage I–III TNBC. By C3D1: 80.8% clearance and a 99.8% median reduction in ctDNA levels. A striking window into early treatment response—before surgery. #ESMO26 #TNBC #ctDNA @Larvol @OncoAlert","https://x.com/Dr_ElvinaA/status/2113723420001149266","Dr_ElvinaA",{"_387":1102,"_19":389,"_248":1103,"_391":1100,"_393":-5,"_394":-5,"_395":1101},{"_387":1098,"_19":389,"_248":1099,"_391":1100,"_393":-5,"_394":-5,"_395":1101},"LBA96","First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts ","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/254","Proffered paper 2: Breast cancer, early and advanced stage","LBA26","Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial","6f9c97b5-b309-4e8b-888b-0bfaef07235e","Impressive ctDNA dynamics in B-STRONGER-I",{"_272":1117,"_248":1118},"tag:#insightsbyesmo","#INSIGHTSBYESMO","The #ESMO26 Award for Translational Research recognises @landau_lab pioneering contributions to advancing our understanding of #cancer evolution through innovative genomic and computational #research. Find out more:https","2026-10-23T12:30:14.000Z","2026-10-24T06:50:04.000Z",[],{"_264":1114,"_266":1115,"_267":268,"_269":1116,"_271":525},"i543zo3tq9yuigk47ihc4w9s8","The #ESMO26 Award for Translational Research recognises @landau_lab pioneering contributions to advancing our understanding of #cancer evolution through innovative genomic and computational #research. Find out more:https://ow.ly/OEiq50ZZjCI #InsightsbyESMO","https://x.com/myESMO/status/2113608938377687074","e03dc6d5-c14e-4cb1-9893-21619d8264f3","The #ESMO26 Award for Translational Research recognises @landau_lab pioneering contributions to advancing our understanding of #cancer evolu",{"_272":1131,"_248":1132},"tag:#escatv2","#ESCATV2","Excellent timing for the launch of @myESMO #ESCATv2 ahead of #ESMO26 in Madrid 🇪🇸. Thanks @AyaHelali @BenWestphalen for your leadership and other co-authors (too many to name! 😁) in putting this important document tog","2026-10-22T08:45:51.000Z","2026-10-24T13:04:22.000Z",[],{"_264":1127,"_266":1128,"_267":268,"_269":1129,"_271":1130},"cr0k7tp9wfeqcveswqeqd1c9e","Excellent timing for the launch of @myESMO #ESCATv2 ahead of #ESMO26 in Madrid 🇪🇸. Thanks @AyaHelali @BenWestphalen for your leadership and other co-authors (too many to name! 😁) in putting this important document together to move the field of #precisiononcology forward! @apoddc @APCLC_2023 @CUHKMedicine @hkumed #ESMOAmbassadors","https://x.com/herbloong/status/2113190082240725243","herbloong","ce91cea0-7a8d-4864-b38c-b8b89b6c1a58","Excellent timing for the launch of @myESMO #ESCATv2 ahead of #ESMO26 in Madrid 🇪🇸",{"_272":1144,"_248":1145},"tag:#tropionbreast02","#TROPIONBREAST02","Promising CNS activity with Dato-DXd! #TROPIONBreast02: In 61 patients with mTNBC & asymptomatic brain metastases, median CNS PFS was 9.5 vs 2.6 months with chemo (HR 0.27). Included patients without prior CNS-direct","2026-10-24T07:42:36.000Z","2026-10-24T09:24:06.000Z",[],{"_264":1141,"_266":1142,"_267":268,"_269":1143,"_271":1095},"wstz23xcpcvcsrzij7pq5mm3x","Promising CNS activity with Dato-DXd! #TROPIONBreast02: In 61 patients with mTNBC & asymptomatic brain metastases, median CNS PFS was 9.5 vs 2.6 months with chemo (HR 0.27). Included patients without prior CNS-directed therapy—a key strength. #ESMO26 #BCSM @Larvol @OncoAlert","https://x.com/Dr_ElvinaA/status/2113898941406122355","5e674de3-61e3-4752-979b-401a6b1628fa","Promising CNS activity with Dato-DXd",{"_272":1158,"_248":1159},"tag:#tumoredellaprostata","#TUMOREDELLAPROSTATA","#Tumoredellaprostata ad alto rischio di recidiva: darolutamide più ADT e radioterapia riduce il rischio di metastasi o di morte del 58%. I dati da #ESMO26: https://www.medinews.it/comunicati/tumore-della-prostata-ad-alto","2026-10-24T07:32:10.000Z","2026-10-24T07:33:20.000Z",[],{"_264":1154,"_266":1155,"_267":268,"_269":1156,"_271":1157},"rx2r84tut6b2ujvcd8pv4rqji","#Tumoredellaprostata ad alto rischio di recidiva: darolutamide più ADT e radioterapia riduce il rischio di metastasi o di morte del 58%. I dati da #ESMO26: https://www.medinews.it/comunicati/tumore-della-prostata-ad-alto-rischio-di-recidiva-darolutamide-piu-adt-e-radioterapia-riduce-il-rischio-di-metastasi-o-di-morte-del-58/ @myESMO","https://x.com/Medinews_/status/2113896314387972230","Medinews_","901861f7-558f-4053-9fb9-4a5c401ae0dd","#Tumoredellaprostata, ad #ESMO26 presentati i nuovi dati late-breaking dello studio di Fase III DASL-HiCa",{"_272":1211,"_248":1212},"tag:#ctdna","#CTDNA","ctDNA tumor fraction in TALAPRO-3 from @AzadOncology at #ESMO26 🧬 In HRR-deficient mCSPC, baseline ctDNA+ (TF ≥1%) was prognostic for rPFS in both arms. Week 5 matters too: 82% of ctDNA+ patients cleared on TALA + ENZA ","2026-10-22T14:30:12.000Z","2026-10-23T12:21:37.000Z",[1172,1173,1174,1175,1176,1177,1178,1179],{"_264":1168,"_266":1169,"_267":268,"_269":1170,"_271":1171},"etyn2bpul91ne1zykpzc24lvy","ctDNA tumor fraction in TALAPRO-3 from @AzadOncology at #ESMO26 🧬 In HRR-deficient mCSPC, baseline ctDNA+ (TF ≥1%) was prognostic for rPFS in both arms. Week 5 matters too: 82% of ctDNA+ patients cleared on TALA + ENZA vs 68% on PBO + ENZA, and clearance tracked with longer rPFS (HR 0.36 vs persistent ctDNA+). Early on-treatment ctDNA could become a real tool for risk stratification and monitoring. Next up is whether it adds value beyond PSA. #MRD #ctDNA #ProstateCancer","https://x.com/alantanmd/status/2113606769515626599","alantanmd",{"_387":1208,"_19":398,"_248":1209,"_391":1204,"_393":-5,"_394":1210,"_395":1206},{"_387":1202,"_19":398,"_248":1203,"_391":1204,"_393":-5,"_394":1205,"_395":1206},{"_387":1198,"_19":398,"_248":1199,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1195,"_19":398,"_248":1196,"_391":400,"_393":-5,"_394":-5,"_395":1197},{"_387":1191,"_19":398,"_248":1192,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":1189,"_19":398,"_248":1190,"_391":1187,"_393":-5,"_394":-5,"_395":1188},{"_387":1185,"_19":398,"_248":1186,"_391":1187,"_393":-5,"_394":-5,"_395":1188},{"_387":1180,"_19":398,"_248":1181,"_391":400,"_393":-5,"_394":1182,"_395":1183},"806P","Extended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer",[1184,1184,1184],"Colon cancer","NCT04787341","542RO","Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/248","Rapid oral: Breast cancer, early stage","540RO","Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study","4734O","ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/242","Proffered paper 1: Genitourinary tumour, renal and urothelial","4260P","Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors","Translational research and biomarkers","2636RO","Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255","Rapid oral 1: NSCLC, metastatic","2220RO","Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/243",[1207],"Rapid oral: Genitourinary tumours, prostate, penile and testis","NCT04746300","2219RO","Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta",[1207],"b6b5c4e3-3305-4d45-886f-703068bb9ed5","ctDNA tumor fraction in TALAPRO-3 from @AzadOncology at #ESMO26 🧬 In HRR-deficient mCSPC, baseline ctDNA+ (TF ≥1%) was prognostic for rPFS ",{"_272":1224,"_248":1225},"drug:zidesamtinib","zidesamtinib","🎥 NEW for #ESMO26 🚨#Podium2Screen | Dr. @alexdrilon 🇺🇸 from @MSKCancerCenter walks us through ARROS-1, presented at the #WCLC26 Presidential Symposium in Seoul 🇰🇷 Zidesamtinib in TKI-naive ROS1+ #NSCLC 🎯 ORR 94% (","2026-10-23T10:59:48.000Z","2026-10-23T14:13:11.000Z",[],{"_264":1221,"_266":1222,"_267":268,"_269":1223,"_271":1026},"rzqmcfsdxv2fhjfz3gu0vuyeb","🎥 NEW for #ESMO26 🚨#Podium2Screen | Dr. @alexdrilon 🇺🇸 from @MSKCancerCenter walks us through ARROS-1, presented at the #WCLC26 Presidential Symposium in Seoul 🇰🇷 Zidesamtinib in TKI-naive ROS1+ #NSCLC 🎯 ORR 94% (88/94), CR 15% ⏳ 86% of responses durable at 12 mo 🧠 Intracranial ORR 100% (10/10), iCR 70% ✅ Low rates of dose reduction and discontinuation Is a new frontline option coming for ROS1+ lung cancer? 👇 Watch the full breakdown #LCSM #ROS1 #LungCancer @bensolomon1, @DrSanjayPopat, @EnriquetaFelip, @alexdrilon, @BenjaminBesseMD, @dwightowenmd, @ramon_yarza, @AkamatsuHiroaki, @marinagarassino @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @JordiRemon @JulienMazieres @TerriConneran @HenningWillers","https://x.com/OncoAlert/status/2113586180746858745","0f9d53b8-56c6-486a-af53-9d5dd5221067","🎥 NEW for #ESMO26 🚨#Podium2Screen 🎥 NEW for #ESMO26 🚨#Podium2Screen | Dr",{"_272":1249,"_248":1250},"drug:pertuzumab","pertuzumab","DB09では、T-DXd+pertuzumabに内分泌療法の維持療法をした方が13%程度いました。一部は、T-DXd+pertuzumab+内分泌療法だったのかもしれません。でも、この内分泌療法の上乗せ効果は、前向き試験では示されていません。今のところは患者さんにお勧めはし難い気持ち。 #ESMO26","2026-10-23T13:34:08.000Z","2026-10-24T11:53:46.000Z",[1237,1238,1239],{"_264":1234,"_266":1229,"_267":268,"_269":1235,"_271":1236},"y6krf1d5mwa3y274jswm1kw9y","https://x.com/shimoi_oncology/status/2113625017154187390","shimoi_oncology",{"_387":1245,"_19":398,"_248":1246,"_391":1247,"_393":-5,"_394":-5,"_395":1248},{"_387":1242,"_19":398,"_248":1243,"_391":400,"_393":-5,"_394":-5,"_395":1244},{"_387":1240,"_19":398,"_248":1241,"_391":1187,"_393":-5,"_394":-5,"_395":1188},"543RO","DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (","1780P","Safety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study","HER2+ breast cancer","1766RO","Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/259","Rapid oral 1: Breast cancer, advanced stage","a3b3a3b4-b85a-4b09-86ff-fca5b0a09852","DB09では、T-DXd+pertuzumabに内分泌療法の維持療法をした方が13%程度いました。一部は、T-DXd+pertuzumab+内分泌療法だったのかもしれません。 DB09では、T-DXd+pertuzumabに内分泌療法の維持療法をした方が13%程度いました。一部は",{"_272":1263,"_248":1264},"tag:#cancervaccines","#CANCERVACCINES","As the oncology community gathers in Madrid for #ESMO26, new results from a phase 3 melanoma trial are putting personalized mRNA cancer vaccines in the spotlight. Merck and Moderna reported that adding an experimental mR","2026-10-23T13:42:08.000Z","2026-10-24T20:53:04.000Z",[],{"_264":1259,"_266":1260,"_267":268,"_269":1261,"_271":1262},"s8i5xfz4qzq80jek7yaedwln9","As the oncology community gathers in Madrid for #ESMO26, new results from a phase 3 melanoma trial are putting personalized mRNA cancer vaccines in the spotlight. Merck and Moderna reported that adding an experimental mRNA vaccine to immunotherapy reduced the risk of melanoma recurrence or death by 42% compared with immunotherapy alone. Memorial Sloan Kettering Cancer Center (MSK) was among the institutions participating in the trial. At the Hertz Summer Workshop, we spoke with 2024 Hertz Fellow David Hoyos, a researcher in the Benjamin Greenbaum Lab at MSK, about how mRNA technology could help advance the next generation of cancer vaccines. Hoyos is studying how to teach the immune system to recognize mutant p53, a protein associated with many cancers. His research focuses on Li-Fraumeni syndrome, an inherited condition that greatly increases the risk of several cancers, including breast cancer. While cancer vaccine trials are exploring ways to treat cancer or prevent its recurrence, Hoyos is investigating whether mRNA vaccines could one day help prevent or delay breast cancer in women with Li-Fraumeni syndrome. He also hopes the research will reveal how to train the immune system to target mutant p53 in a much broader range of cancers. #CancerVaccines #CancerResearch #breastcancer","https://x.com/HertzFoundation/status/2114097866645917717","HertzFoundation","90e445a5-8209-4a04-8d34-34554193af6e","Did we find the answer",{"_272":1308,"_248":1309},"tag:#cancers","#CANCERS","👋 We’re attending #ESMO26! For over 10 years, #oncology has been our top priority — close to 70% of our R&D budget is dedicated to advancing cancer research. Today, our pipeline includes 36 projects, with a strong focus","2026-10-21T14:16:27.000Z","2026-10-23T15:20:35.000Z",[1277,1278,1279,1280,1281,1282,1283,1284],{"_264":1273,"_266":1274,"_267":268,"_269":1275,"_271":1276},"yg1b3mi3ofijazokkmykovaod","👋 We’re attending #ESMO26! For over 10 years, #oncology has been our top priority — close to 70% of our R&D budget is dedicated to advancing cancer research. Today, our pipeline includes 36 projects, with a strong focus on rare #cancers. Meet us at booth No. 8064 🏢 and join our symposiums to learn more. Discover our commitment to oncology 🔗 https://f.mtr.cool/j3236wrjk8 #CancerResearch #patient @myESMO","https://x.com/Servier/status/2113651807893201128","Servier",{"_387":1306,"_19":398,"_248":1307,"_391":1287,"_393":-5,"_394":-5,"_395":1288},{"_387":1304,"_19":398,"_248":1305,"_391":1287,"_393":-5,"_394":-5,"_395":1288},{"_387":1300,"_19":398,"_248":1301,"_391":400,"_393":-5,"_394":1302,"_395":643},{"_387":641,"_19":398,"_248":642,"_391":400,"_393":-5,"_394":-5,"_395":643},{"_387":1296,"_19":398,"_248":1297,"_391":400,"_393":-5,"_394":1298,"_395":643},{"_387":1292,"_19":398,"_248":1293,"_391":1294,"_393":-5,"_394":-5,"_395":1295},{"_387":1289,"_19":398,"_248":1290,"_391":400,"_393":-5,"_394":-5,"_395":1291},{"_387":1285,"_19":389,"_248":1286,"_391":1287,"_393":-5,"_394":-5,"_395":1288},"LBA36","Clinical utility of circulating tumor DNA (ctDNA) for participants with resected, high-risk dMMR endometrial cancer (EC) receiving adjuvant treatment: Results from the ENGOT-en11/GOG-3053/KEYNOTE-B21 study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/264","Proffered paper: Gynaecological cancers","1844P","Gene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers","HR+ breast cancer","170O","RADIANT: A radiotherapy foundation model for treatment planning and outcome prediction across cancers","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/262","Proffered paper: AI and digital health","1331P","Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Updated results from the phase 2 dose-optimization part of REJOICE-Ovarian01",[1299,1299,1299],"NCT06161025","1259P","Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)",[1303,1303,1303],"NCT05642780","1240O","Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase","1239O","NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer","e628b496-28cb-43e8-b3a1-a85eca7926f3","🔹 Gustave Roussy au congrès de l’#ESMO26 🔹 🔹 Gustave Roussy au congrès de l’#ESMO26 🔹 @myESMO tient son congrès annuel du 23 au 27 octob",{"_272":1322,"_248":1323},"code:LBA82","LBA82","#LBA82 subgroup analysis RASolute 302 #PDAC ➡️HR for OS across subtypes 0.32-0.46 ➡️G12R 0.61 (0.29-1.30) ➡️RAS WT numbers small (3%) but still OS benefit! 🤔perhaps ORR and mPFS not as pronounced in these populations! ✅","2026-10-23T12:48:34.000Z","2026-10-23T17:53:38.000Z",[],{"_264":1318,"_266":1319,"_267":268,"_269":1320,"_271":1321},"ps2tkwknvu7ndsiz9jz4l2ojq","#LBA82 subgroup analysis RASolute 302 #PDAC ➡️HR for OS across subtypes 0.32-0.46 ➡️G12R 0.61 (0.29-1.30) ➡️RAS WT numbers small (3%) but still OS benefit! 🤔perhaps ORR and mPFS not as pronounced in these populations! ✅std second line treatment @myESMO #ESMO26 @OncoAlert","https://x.com/graokane/status/2113613553173402101","graokane","42c77921-439f-4201-badf-107bab273bf0","#LBA82 subgroup analysis RASolute 302 #PDAC #LBA82 subgroup analysis RASolute 302 #PDAC ➡️HR for OS across subtypes 0",{"_272":1335,"_248":1336},"drug:avelumab","avelumab","Proud to share our exploratory analysis from DISCUS at #ESMO26 @BartsECMC - 34% of patients never reached avelumab - 3C vs 6C increased transition (74% vs 57%), with fewer PD/death events - QoL remained stable on ICI and","2026-10-23T15:57:57.000Z","2026-10-23T22:19:17.000Z",[],{"_264":1332,"_266":1333,"_267":268,"_269":1334,"_271":994},"qedqs66mgwlr87m6lcwhjvocw","Proud to share our exploratory analysis from DISCUS at #ESMO26 @BartsECMC - 34% of patients never reached avelumab - 3C vs 6C increased transition (74% vs 57%), with fewer PD/death events - QoL remained stable on ICI and baseline PS was the only differentiating factor @OncoAlert","https://x.com/scocmem/status/2113757176804307246","be15e2d8-cac5-44e7-8f90-6457a5e58e6b","Proud to share our exploratory analysis from DISCUS at #ESMO26 @BartsECMC Proud to share our exploratory analysis from DISCUS at #ESMO26 @Ba",{"_272":1354,"_248":1355},"drug:cabazitaxel","cabazitaxel","#ESMO26: PROFIT real-world study of Ra-223 sequencing in mCRPC in Spain (n=224) 🔹 59% received Ra-223 within first 2 mPC lines; 41% in ≥3L 🔹 Earlier Ra-223 associated with longer OS: 12.4 vs 9.3 mo (p=0.024) 🔹 ≥5 inje","2026-10-24T10:01:40.000Z","2026-10-24T17:39:31.000Z",[1349],{"_264":1345,"_266":1346,"_267":268,"_269":1347,"_271":1348},"uopud9y48blskisq3b9vz30d2","#ESMO26: PROFIT real-world study of Ra-223 sequencing in mCRPC in Spain (n=224) 🔹 59% received Ra-223 within first 2 mPC lines; 41% in ≥3L 🔹 Earlier Ra-223 associated with longer OS: 12.4 vs 9.3 mo (p=0.024) 🔹 ≥5 injections strongly associated with longer OS: 14.1 vs 7.1 mo (p<0.001) 🔹 62.5% completed 5–6 injections 🔹 48.7% received subsequent mCRPC therapy; most commonly cabazitaxel or docetaxel 🔑 Earlier integration and treatment continuity with Ra-223 were associated with improved survival in routine practice. @urotoday","https://x.com/RKSayyid/status/2114049158000840746","RKSayyid",{"_387":1350,"_19":398,"_248":1351,"_391":400,"_393":-5,"_394":1352,"_395":496},"2300TIP","BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer",[1353,1353,1353],"NCT07365995","6aa9ffed-e309-4e09-9e82-6685531ba040","#ESMO26: PROFIT real-world study of Ra-223 sequencing in mCRPC in Spain (n=224) #ESMO26: PROFIT real-world study of Ra-223 sequencing in mCR",{"_272":1371,"_248":1372},"drug:bemarituzumab","bemarituzumab","#ESMO26 🧬 FORTITUDE-101/102 | FGFR2 🔎 Exploratory biomarker analysis in FGFR2b+ GC/GEJ 🧪 FGFR2 amplification: ~16–19% 📈 Bemarituzumab OS signal if amplified: 🔹 F101: HR 0.50 🔹 F102: HR 0.67 💡 Could FGFR2 amplifica","2026-10-23T15:33:34.000Z","2026-10-23T15:33:36.000Z",[1368],{"_264":1364,"_266":1365,"_267":268,"_269":1366,"_271":1367},"ema4hsay3euzdhr3gs7ikc0vw","#ESMO26 🧬 FORTITUDE-101/102 | FGFR2 🔎 Exploratory biomarker analysis in FGFR2b+ GC/GEJ 🧪 FGFR2 amplification: ~16–19% 📈 Bemarituzumab OS signal if amplified: 🔹 F101: HR 0.50 🔹 F102: HR 0.67 💡 Could FGFR2 amplification guide patient selection? @OncoAlert","https://x.com/DraMartinezLago/status/2113655077592256622","DraMartinezLago",{"_387":1369,"_19":398,"_248":1370,"_391":392,"_393":-5,"_394":-5,"_395":396},"2883RO","Efficacy of bemarituzumab in patients with advanced gastric and gastroesophageal junction cancer (GC/GEJ) by FGFR2 amplification status: Exploratory biomarker analysis from FORTITUDE-101 (F101) and FORTITUDE-102 (F102)","97862025-d0af-42b4-86c4-236987115d57","#ESMO26 🧬 FORTITUDE-101/102 | FGFR2 #ESMO26 🧬 FORTITUDE-101/102 | FGFR2 🔎 Exploratory biomarker analysis in FGFR2b+ GC/GEJ 🧪 FGFR2 ampli",{"_272":1387,"_248":1388},"drug:bemotrizumab","bemotrizumab","#ESMO26 🧬 TQB2102 | Phase II 👥 86 pts | 1L HER2+ GC/GEJ 💊 HER2 ADC + bemotrizumab ± capecitabine 🎯 ORR: • Doublet: 69.6% • Triplet: 84.2% (95.8% at 6 mg/kg) 📈 mPFS: 12.68 vs 11.04 mo ⏳ OS immature 🔎 Promising activ","2026-10-23T14:32:36.000Z","2026-10-23T14:34:01.000Z",[1384],{"_264":1381,"_266":1382,"_267":268,"_269":1383,"_271":1367},"k1gea0lz7jiu49jgbabpevxke","#ESMO26 🧬 TQB2102 | Phase II 👥 86 pts | 1L HER2+ GC/GEJ 💊 HER2 ADC + bemotrizumab ± capecitabine 🎯 ORR: • Doublet: 69.6% • Triplet: 84.2% (95.8% at 6 mg/kg) 📈 mPFS: 12.68 vs 11.04 mo ⏳ OS immature 🔎 Promising activity; randomized validation needed. @OncoAlert","https://x.com/DraMartinezLago/status/2113640091021156458",{"_387":1385,"_19":398,"_248":1386,"_391":392,"_393":-5,"_394":-5,"_395":396},"2876RO","TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II study","7fce215b-d882-479c-8689-0fe0d6ace9d4","#ESMO26 🧬 TQB2102 | Phase II #ESMO26 🧬 TQB2102 | Phase II 👥 86 pts | 1L HER2+ GC/GEJ 💊 HER2 ADC + bemotrizumab ± capecitabine 🎯 ORR: • ",{"_272":1401,"_248":1402},"code:4741RO","4741RO","Phase III NIAGARA: Molecular Subtypes and EFS Outcomes With Perioperative Durvalumab in Bladder Cancer At #ESMO26, Matthew D. Galsky presented an exploratory molecular analysis from the Phase III NIAGARA trial (4741RO), ","2026-10-24T10:31:37.000Z","2026-10-24T11:25:01.000Z",[],{"_264":1397,"_266":1398,"_267":268,"_269":1399,"_271":1400},"zdsqcrkvy0opd40es2zifipyt","Phase III NIAGARA: Molecular Subtypes and EFS Outcomes With Perioperative Durvalumab in Bladder Cancer At #ESMO26, Matthew D. Galsky presented an exploratory molecular analysis from the Phase III NIAGARA trial (4741RO), evaluating genomic alterations and transcriptome-defined subtypes in muscle-invasive bladder cancer (MIBC). Key findings: ▫️ Overall population: 24-month EFS was 68% with durvalumab plus neoadjuvant chemotherapy versus 60% with chemotherapy alone (HR 0.68; 95% CI 0.56–0.82). ▫️ Genomic subgroups: EFS HRs numerically favoured durvalumab in TP53-mutated (HR 0.51), FGFR3-mutated (HR 0.24), and TMB-high tumours (HR 0.44). ▫️ Molecular subtypes: EFS HRs favoured durvalumab in basal-squamous (HR 0.47; 95% CI 0.20–1.11), luminal (HR 0.52), and luminal-infiltrated (HR 0.67) subgroups, but not in the luminal-papillary subgroup (HR 1.35). Takeaway: Exploratory findings suggest broadly favourable EFS outcomes with perioperative durvalumab across multiple molecular subgroups. These analyses were not alpha-controlled and require cautious interpretation. @tompowles1 @ZakhariaYousef @oncodaily @myESMO https://oncodaily.com/genitourinary-oncology/niagara-esmo-2026 #ESMO26 #ESMO2026 #NIAGARA","https://x.com/OncoDailyGU/status/2113954914040750376","OncoDailyGU","96389a38-28d4-47b2-953a-4468751bd328","Phase III NIAGARA: Molecular Subtypes and EFS Outcomes With Perioperative Durvalumab in Bladder Cancer Phase III NIAGARA: Molecular Subtypes",{"_272":1414,"_248":1415},"code:2215O","2215O","🚨⭐🔵 #ESMO26 | Abstract 2215O | PEACE-1 Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer (mCSPC) 🎤 Presented b","2026-10-24T09:02:52.000Z","2026-10-24T10:24:17.000Z",[],{"_264":1411,"_266":1412,"_267":268,"_269":1413,"_271":1040},"xcs1sqwwqisqsxmgd5ysoundq","🚨⭐🔵 #ESMO26 | Abstract 2215O | PEACE-1 Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer (mCSPC) 🎤 Presented by Prof. Karim Fizazi 🇫🇷 @OncoAlert @myESMO 🔬 7.7 years of follow-up: Does upfront treatment intensification translate into durable survival? PEACE-1 provides a compelling answer! 📊 PHASE III | N=1,173 Randomized 2×2 factorial design evaluating abiraterone + prednisone and/or prostate radiotherapy added to standard of care (ADT ± docetaxel). Median follow-up: 7.7 years. 📈 1️⃣ OVERALL POPULATION ✅ OS HR 0.75 (95% CI 0.65–0.87) ✅ p=0.0001 Median OS: 🔹 With abiraterone: 6.1 years 🔹 Without abiraterone: 4.6 years ➡️ A sustained 25% relative reduction in the hazard of death. 💥 2️⃣ TRIPLET THERAPY | N=710 ADT + docetaxel + abiraterone vs ADT + docetaxel: ✅ Median OS: 6.2 vs 4.4 years ✅ HR 0.68 (95% CI 0.56–0.82) ⭐ 1.8 additional years in median survival! 📊 8-YEAR OVERALL SURVIVAL ✅ Triplet: 40.3% 🔹 Doublet: 27.1% ➡️ Absolute difference: +13.2 percentage points. These are clinically meaningful long-term outcomes, beyond early response rates or surrogate endpoints. 🔬 3️⃣ DOES METASTATIC VOLUME MATTER? 🔵 HIGH-VOLUME DISEASE ✅ Median OS: 4.6 vs 3.5 years ✅ HR approximately 0.68 A clear and durable survival advantage. 🔵 LOW-VOLUME DISEASE 📈 Median OS: 7.8 vs 6.2 years HR 0.74 (95% CI 0.52–1.05) Numerically favorable, although the subgroup CI crossed 1. 📌 No significant interaction by disease volume (p=0.56). ⚠️ This does not establish identical treatment benefit in both subgroups. ⭐ MY POINT OF VIEW | CLINICAL PEARL Long-term follow-up is where a treatment strategy proves its true value. Unlike early response signals, PEACE-1 provides mature evidence that upfront systemic intensification can translate into substantially longer survival. 💡 In appropriately selected patients with de novo mCSPC who are candidates for docetaxel, these findings strongly reinforce the role of upfront triplet therapy. The clinical question is increasingly not simply whether to intensify, but which patients should receive a triplet, how best to integrate local treatment, and how to preserve quality of life. 🎯 Precision matters—but so does acting early when a proven survival advantage is available. 👏 Congratulations to Prof. Karim Fizazi and the entire PEACE-1 team for this important long-term contribution to prostate cancer care! @urologysummit @gbanna74 @ravikanesvaran @Uromigos @LosUromigos @neerajaiims @Silke_Gillessen @EfstathiouEleni @AOmlin @declangmurphy @cdanicas @montypal @DrScottTagawa @ecancer @UrologyTimes @urotoday @wearemedsir @OpenMedicineHQ #ProstateCancer #mCSPC #mHSPC #GUOncology #PEACE1 #TripletTherapy","https://x.com/nataliagandur/status/2113939631079113083","9f961552-1adc-412d-8326-c14676e4684e","🚨⭐🔵 #ESMO26 | Abstract 2215O | PEACE-1 🚨⭐🔵 #ESMO26 | Abstract 2215O | PEACE-1 Long-term overall survival with abiraterone acetate plus p",{"_272":1427,"_248":1428},"code:170O","RADIANT trained on 119,782 RT cases and tested segmentation, dose and outcome prediction across sites. What I want next is clinical utility: does using it improve planning decisions, toxicity or outcomes? Accuracy alone ","2026-10-22T23:24:55.000Z","2026-10-24T19:00:02.000Z",[],{"_264":1423,"_266":1424,"_267":268,"_269":1425,"_271":1426},"tmv0uipd7k9s3s69w4tbfatfo","RADIANT trained on 119,782 RT cases and tested segmentation, dose and outcome prediction across sites. What I want next is clinical utility: does using it improve planning decisions, toxicity or outcomes? Accuracy alone isn't enough. #ESMO26 #radonc https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/presentation/list?q=170O","https://x.com/jryckman3/status/2113411308284789113","jryckman3","1e6a35f2-f814-4a95-a3e3-d2031eccddb8","RADIANT trained on 119,782 RT cases and tested segmentation, dose and outcome prediction across sites",{"_272":1441,"_248":1442},"tag:#testicularcancer","#TESTICULARCANCER","Promising early data in refractory GCT at #ESMO26 CLDN6-targeted ADC ixotatug vedotin (TORL-1-23): • ORR 45.5% (5/11) • DCR 72.7% • Responses even after HDCT/ASCT Encouraging phase I data in a population with high unmet ","2026-10-23T11:57:56.000Z","2026-10-24T13:15:05.000Z",[],{"_264":1437,"_266":1438,"_267":268,"_269":1439,"_271":1440},"oyjcb3648m6bg13ygyxljwpro","Promising early data in refractory GCT at #ESMO26 CLDN6-targeted ADC ixotatug vedotin (TORL-1-23): • ORR 45.5% (5/11) • DCR 72.7% • Responses even after HDCT/ASCT Encouraging phase I data in a population with high unmet need. Further validation warranted. #TesticularCancer","https://x.com/pokrivcak/status/2113600811808825807","pokrivcak","dd7c9ebf-01c8-42ed-bfa5-5521d125d097","TORL-1-23: Safety and Efficacy of Ixotatug Vedotin, a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors",{"_272":1455,"_248":1456},"code:KN-866","KN-866","🎯 Starting the GU oral session! #ESMO26 @JensBedke presented the ph3 study in MIBC KN-866 A negative study of Cis-Gem + Pembro vs Cis-Gem periop.🤷‍♂️ What about NIAGARA study? 🤨 @OncoAlert @myESMO @DrFelixGuerrero @Gu","2026-10-23T11:57:24.000Z","2026-10-23T12:15:51.000Z",[],{"_264":1451,"_266":1452,"_267":268,"_269":1453,"_271":1454},"zikhij68ad4oyrbpy97791r1u","🎯 Starting the GU oral session! #ESMO26 @JensBedke presented the ph3 study in MIBC KN-866 A negative study of Cis-Gem + Pembro vs Cis-Gem periop.🤷‍♂️ What about NIAGARA study? 🤨 @OncoAlert @myESMO @DrFelixGuerrero @GuardConsortium @UroTarget","https://x.com/cdanicas/status/2113605316520837547","cdanicas","e2d6e4c7-1392-47b1-b0cf-2aa182aadea0","🎯 Starting the GU oral session",{"_272":1468,"_248":1469},"tag:#daslhicap","#DASLHICAP","#ESMO26 #DASLHiCaP @ANZUPtrials","2026-10-24T17:09:53.000Z","2026-10-24T21:19:00.000Z",[],{"_264":1465,"_266":1460,"_267":268,"_269":1466,"_271":1467},"lqh5qdh7j7nnue0ywwp2ozobm","https://x.com/Prof_IanD/status/2114104395394936882","Prof_IanD","f2dde502-c900-452e-9e58-8234a632a0a8","#ESMO26 #DASLHiCaP #ProstateCancer #pcsm Thread 👇 #ESMO26 #DASLHiCaP #ProstateCancer #pcsm Thread 👇 #ESMO26 #DASLHiCaP #ProstateCancer #pc",{"_272":1481,"_248":1482},"nct:NCT05029882","NCT05029882","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 First-in-Human Study 🎙️Dr. David Sommerh","2026-10-08T11:45:00.000Z","2026-10-24T07:45:00.000Z",[],{"_264":1478,"_266":1479,"_267":268,"_269":1480,"_271":729},"wf8l0vgjgqzq47iko7iyl96cv","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 First-in-Human Study 🎙️Dr. David Sommerhalder 🔢2658RO 🎯Median OS 13.8mo (EGFR WT, n=48) and 16.2mo (EGFR MUT, n=41) in Heavily Pretreated Pts 🎯Longer OS in High c-Met Expressers (25.2mo, EGFR WT ≥3+/≥10%) ☑️NCT05029882 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2113899546254389469","f86538f4-0367-4ffc-a728-e3cfa7664969","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patien",{"_272":1496,"_248":1497},"code:SUNRAY-01","SUNRAY-01","Join us at #ESMO2026 for an oral presentation on 1L olomorasib plus chemoimmunotherapy in KRAS G12C-mutant NSCLC, from the SUNRAY-01 Safety Lead-in cohort trial. 2652RO | Oct. 25 | 9:19 - 09:24 | Barcelona Auditorium Hal","2026-10-22T14:00:01.000Z",[1493],{"_264":1490,"_266":1491,"_267":268,"_269":1492,"_271":639},"rruifku839yzco4eeu6l19mdn","Join us at #ESMO2026 for an oral presentation on 1L olomorasib plus chemoimmunotherapy in KRAS G12C-mutant NSCLC, from the SUNRAY-01 Safety Lead-in cohort trial. 2652RO | Oct. 25 | 9:19 - 09:24 | Barcelona Auditorium Hall 9 View program details: https://e.lilly/3VmFpLN #LungCancer","https://x.com/LillyOncMed/status/2113269144166522952",{"_387":1494,"_19":398,"_248":1495,"_391":400,"_393":-5,"_394":-5,"_395":621},"2683P","First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01","5a41dd66-d5eb-4815-a124-68bee465953e","Join us at #ESMO2026 for an oral presentation on 1L olomorasib plus chemoimmunotherapy in KRAS G12C-mutant NSCLC, from the SUNRAY-01 Safety ",{"_272":1509,"_248":1510},"tag:#oncoalert5k","#ONCOALERT5K","A Great time at the #OncoAlert5k Running Club Run at #ESMO26 Huge shout out to our members that despite the cold weather and darkness, brought a positive healthy attitude and just plain BROUGHT IT!! Looking forward to ou","2026-10-24T16:10:43.000Z","2026-10-24T16:21:49.000Z",[],{"_264":1506,"_266":1507,"_267":268,"_269":1508,"_271":1026},"roln1lbxyjgcpomv2d8eb0aa6","A Great time at the #OncoAlert5k Running Club Run at #ESMO26 Huge shout out to our members that despite the cold weather and darkness, brought a positive healthy attitude and just plain BROUGHT IT!! Looking forward to our Next Run in OUR HOME CITY of San Antonio Tx for #SABCS26 @cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein3","https://x.com/OncoAlert/status/2114026811231199642","31d49694-9b5b-4123-9654-dda63bffd90f","A Great time at the #OncoAlert5k Running Club Run at #ESMO26 A Great time at the #OncoAlert5k Running Club Run at #ESMO26 Huge shout out to ",{"_272":1524,"_248":1525},"drug:drozuntecan","drozuntecan","🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors First clinical data beyond lung cancer for the B7-H3 ADC elfetabart drozuntecan + PD-L1×VEGF-A bsAb pumitamig! 📊 N=139 efficacy-evaluable: uORR 48.9% | cORR 39.6% | DC","2026-10-19T01:40:00.000Z","2026-10-24T13:18:41.000Z",[1522],{"_264":1519,"_266":1520,"_267":268,"_269":1521,"_271":613},"voyoya5j0svy4jge50hcu0v9l","🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors First clinical data beyond lung cancer for the B7-H3 ADC elfetabart drozuntecan + PD-L1×VEGF-A bsAb pumitamig! 📊 N=139 efficacy-evaluable: uORR 48.9% | cORR 39.6% | DCR 87.8% 👀 Melanoma (n=26): uORR 30.8% | cORR 26.9% | DCR 80.8% Safety appeared manageable, with mainly G1–2 GI/hematologic TRAEs, no DLTs or treatment-related deaths, and 2 investigator-reported ILD cases 👍🏼 One question: is the activity driven by the IO, the antiangiogenic effect, or a synergy between the two?? 🤔 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma","https://x.com/MarioBalsaMD/status/2113983520045498516",{"_387":1350,"_19":398,"_248":1351,"_391":400,"_393":-5,"_394":1523,"_395":496},[1353,1353,1353],"1b990677-cae5-403f-8d03-4c349f4d6519","🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors 🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors First clinical data beyond lung canc",{"_272":1537,"_248":1538},"tag:#crcsm","#CRCSM","CheckMate 8HW final OS at #ESMO26: NIVO+IPI in centrally confirmed MSI-H/dMMR mCRC ▪️ All lines vs NIVO: HR 0.61 (0.46–0.82), p=0.0009; 5-yr OS 74% vs 62% ▪️ 1L vs NIVO: HR 0.66 (0.44–0.99), p=0.043, missed prespecified ","2026-10-21T16:45:30.000Z","2026-10-24T17:11:01.000Z",[],{"_264":1534,"_266":1535,"_267":268,"_269":1536,"_271":1171},"usz7dk3we334lzqqs19vx5v9h","CheckMate 8HW final OS at #ESMO26: NIVO+IPI in centrally confirmed MSI-H/dMMR mCRC ▪️ All lines vs NIVO: HR 0.61 (0.46–0.82), p=0.0009; 5-yr OS 74% vs 62% ▪️ 1L vs NIVO: HR 0.66 (0.44–0.99), p=0.043, missed prespecified boundary (p<0.0058); 5-yr OS 77% vs 66% ▪️ 1L vs chemo: OS HR 0.37, p<0.0001 ▪️ Median f/u ~68 mo; safety stable, low grade 3/4 #CRCSM #MSIH","https://x.com/alantanmd/status/2113993624958484808","e7dae91e-e806-4701-b027-eda4c49c8c61","📺 WATCH: @FASinicropeMD, of @MayoClinic, previews 2 colorectal cancer studies to watch at the 2026 ESMO Congress, including adjuvant treatm",{"_272":1557,"_248":1558},"tag:#mcrpc","#MCRPC","Important data from #ESMO2026 in #mCRPC: 🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH). ⚠️ Patients with CH-only HRR alterations did not appear to benefit ","2026-10-23T16:00:44.000Z","2026-10-23T22:27:20.000Z",[1551,1552],{"_264":1547,"_266":1548,"_267":268,"_269":1549,"_271":1550},"mavwq9txzr0alsnrosbzhif4g","Important data from #ESMO2026 in #mCRPC: 🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH). ⚠️ Patients with CH-only HRR alterations did not appear to benefit from PARPi monotherapy. Distinguishing CH from tumor-derived mutations is critical for treatment selection. #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert","https://x.com/YuWeiChenMD/status/2113759202812592278","YuWeiChenMD",{"_387":1554,"_19":398,"_248":1555,"_391":1204,"_393":-5,"_394":1556,"_395":1206},{"_387":1202,"_19":398,"_248":1203,"_391":1204,"_393":-5,"_394":1553,"_395":1206},[1207],"2218RO","Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)",[1207],"25dcd516-62f2-46fa-afaa-d32f0c0b2484","Important data from #ESMO2026 in #mCRPC: Important data from #ESMO2026 in #mCRPC: 🧬 56% of HRR alterations detected by liquid biopsy were p",{"_272":1569,"_248":1570},"tag:#podium2screen","#PODIUM2SCREEN","An @OncoAlert #Podium2Screen from the #ESMO26 Presidential Session 👇","2026-10-24T09:24:45.000Z","2026-10-24T16:09:24.000Z",[],{"_264":1567,"_266":1562,"_267":268,"_269":1568,"_271":1012},"lkob3m3nhld1v3ct4c7hduvs9","https://x.com/JankovicK/status/2114026480359571577","86dad846-d5a0-49f4-9480-4f6e973af5cd","From the podium to your screen",{"_272":1583,"_248":1584},"tag:#oncologycommunity","#ONCOLOGYCOMMUNITY","Some of oncology's biggest minds gather in Madrid this week for #ESMO26. One thread we will be watching: the growing evidence that priming the immune system to recognize a tumor can make existing immunotherapies work for","2026-10-22T14:00:02.000Z","2026-10-24T18:30:02.000Z",[],{"_264":1579,"_266":1580,"_267":268,"_269":1581,"_271":1582},"o9n2mpysqfuyg6neocb5671ip","Some of oncology's biggest minds gather in Madrid this week for #ESMO26. One thread we will be watching: the growing evidence that priming the immune system to recognize a tumor can make existing immunotherapies work for more people. Many routes, one destination. Good science ahead. $SONA #OncologyCommunity #Immunotherapy","https://x.com/SonaNanotech/status/2113269147815584139","SonaNanotech","79c6427c-88bc-4f92-9a10-4d38b23568b2","Some of oncology's biggest minds gather in Madrid this week for #ESMO26",{"_272":1597,"_248":1598},"tag:#liquidbiopsy","#LIQUIDBIOPSY","@ChristianRolfo (@RolfoLab) from @OhioStateMedOnc at #ESMO26 on how #liquidbiopsy can make early phase drug development faster, better and more efficient 8 applications, from patient selection to early signals activity a","2026-10-22T15:00:34.000Z","2026-10-23T14:39:40.000Z",[],{"_264":1593,"_266":1594,"_267":268,"_269":1595,"_271":1596},"y1o9mzm09x3mkpm2lj4yne3ex","@ChristianRolfo (@RolfoLab) from @OhioStateMedOnc at #ESMO26 on how #liquidbiopsy can make early phase drug development faster, better and more efficient 8 applications, from patient selection to early signals activity and resistance. @isliquidbiopsy @myESMO","https://x.com/RobertoBoreaMD/status/2113641511166582872","RobertoBoreaMD","800d2f35-6365-4732-a023-efaa567f9c3d","@ChristianRolfo (@RolfoLab) from @OhioStateMedOnc at #ESMO26 on how #liquidbiopsy can make early phase drug development faster, better and m",{"_272":1613,"_248":1614},"drug:zimberelimab","zimberelimab","TROPHY-U-01 Cohort 7: SG + EV + zimberelimab demonstrated promising efficacy (ORR 81%, n=21). Looking forward to results from larger phase II/III trials! #ESMO26","2026-10-23T12:06:15.000Z","2026-10-23T17:30:10.000Z",[1610],{"_264":1607,"_266":1602,"_267":268,"_269":1608,"_271":1609},"cyhsthi0o3auenlgccxpjnw36","https://x.com/KohjiToncol/status/2113602903491629064","KohjiToncol",{"_387":1611,"_19":398,"_248":1612,"_391":1193,"_393":-5,"_394":-5,"_395":1194},"4742O","Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7","7530a0da-0aa8-4c2e-8eae-ff1f68e3f731","At #ESMO26, Randy Sweis, MD, presents interim results from cohort 7 of the phase 1b TROPHY-U-01 trial, testing SG + EV + zimberelimab as fir",{"_272":1629,"_248":1630},"drug:ribociclib","ribociclib","Maintained iDFS benefit (Δ 5.3%) and favorable OS (Δ 2.1%) with adjuvant ribociclib after 6 years of follow up (all patients off ribo). Efficacy comparable to abema (monarchE), with different toxicity profile and wider p","2026-10-23T12:51:15.000Z","2026-10-24T21:47:36.000Z",[1626],{"_264":1623,"_266":1624,"_267":268,"_269":1625,"_271":657},"upof2kksfglci0jcaiw9rymbb","Maintained iDFS benefit (Δ 5.3%) and favorable OS (Δ 2.1%) with adjuvant ribociclib after 6 years of follow up (all patients off ribo). Efficacy comparable to abema (monarchE), with different toxicity profile and wider population (N+ and high-risk N0). #ESMO26 #ESMOAmbassadors","https://x.com/PTarantinoMD/status/2113614225822335063",{"_387":1627,"_19":389,"_248":1628,"_391":702,"_393":-5,"_394":-5,"_395":703},"LBA25","Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes","78fa9f5d-3c1c-4550-be20-a3b26ffce19a","Maintained iDFS benefit (Δ 5",{"_272":1646,"_248":1647},"drug:lazertinib","lazertinib","The speed at which COCOON is rewriting the story of EGFR treatment is extraordinary! Grade ≥2 AEs: 75% → 42%. Now, early data with simplified prophylaxis + lazertinib lead-in: 39% → 18%. Not just managing toxicity. Chang","2026-10-24T06:51:05.000Z","2026-10-24T08:18:58.000Z",[1643],{"_264":1639,"_266":1640,"_267":268,"_269":1641,"_271":1642},"j6kewf4umbotteegzb25d32q4","The speed at which COCOON is rewriting the story of EGFR treatment is extraordinary! Grade ≥2 AEs: 75% → 42%. Now, early data with simplified prophylaxis + lazertinib lead-in: 39% → 18%. Not just managing toxicity. Changing its trajectory. #ESMO26 #LungCancer","https://x.com/APassaroMD/status/2113900687914684746","APassaroMD",{"_387":1644,"_19":398,"_248":1645,"_391":1200,"_393":-5,"_394":-5,"_395":1201},"2700RO","Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort","c3fb725e-1248-43ed-94fe-891a1156acae","💅 Optimizing dermatologic prophylaxis and lead-in lazertinib significantly reduce Dermatolgic AEs",{"_272":1683,"_248":1684},"drug:enfortumab","enfortumab","De camino a #ESMO26 con novedades importantes en cáncer de vejiga La Comisión Europea aprueba enfortumab vedotin + pembrolizumab como tratamiento perioperatorio del cáncer de vejiga músculo-invasivo, independientemente d","2026-10-09T00:00:00.000Z","2026-10-23T15:00:46.000Z",[1660,1661,1662,1663,1664,1665,1666,1667],{"_264":1656,"_266":1657,"_267":268,"_269":1658,"_271":1659},"gsplo27drmv1crii4k19gt2co","De camino a #ESMO26 con novedades importantes en cáncer de vejiga La Comisión Europea aprueba enfortumab vedotin + pembrolizumab como tratamiento perioperatorio del cáncer de vejiga músculo-invasivo, independientemente de la elegibilidad para cisplatino Un nuevo escenario terapéutico que dará mucho que hablar en Madrid @OncoAlert https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/","https://x.com/LosUromigos/status/2113241849745801540","LosUromigos",{"_387":1681,"_19":398,"_248":1682,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":1191,"_19":398,"_248":1192,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":1679,"_19":398,"_248":1680,"_391":998,"_393":-5,"_394":-5,"_395":999},{"_387":996,"_19":398,"_248":997,"_391":998,"_393":-5,"_394":-5,"_395":999},{"_387":1611,"_19":398,"_248":1612,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":1675,"_19":398,"_248":1676,"_391":400,"_393":-5,"_394":1677,"_395":1673},{"_387":1670,"_19":398,"_248":1671,"_391":400,"_393":-5,"_394":1672,"_395":1673},{"_387":1668,"_19":389,"_248":1669,"_391":529,"_393":-5,"_394":-5,"_395":530},"LBA2","Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial","4771TIP","GB-4362, an MMAE-neutralizing antibody, in combination with enfortumab vedotin (EV) and pembrolizumab in advanced urothelial cancer: Phase 1 trial-in-progress",[1674,1674,1674],"Urothelial cancer","NCT07484022","4761P","Enfortumab Vedotin Plus Pembrolizumab (EV+P) For Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Updated Exploratory Analysis of EV-302 in Older Patients (pts) and Those With Comorbidities",[1678,1678,1678],"NCT04223856","4738RO","Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEY","4733O","Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905","b5b0f143-b2ec-4eca-ade8-b2d02d7fba73","De camino a #ESMO26 con novedades importantes en cáncer de vejiga De camino a #ESMO26 con novedades importantes en cáncer de vejiga La Comis",{"_272":1696,"_248":1697},"drug:emactuzumab","emactuzumab","#ESMO26 🚀 TANGENT | Phase III 👥 136 pts | TGCT 💊 Emactuzumab (anti-CSF-1R) vs placebo 💉 5 infusions over 8 weeks 🎯 6-mo ORR (RECIST): 30% vs 2% 📈 ORR (TVS): 54% vs 7% ✅ Improved pain, stiffness & function (p<0.001)","2026-10-24T12:57:30.000Z","2026-10-24T15:02:14.000Z",[],{"_264":1693,"_266":1694,"_267":268,"_269":1695,"_271":1367},"ihvcgypl07vzeuoy2o6vegmn4","#ESMO26 🚀 TANGENT | Phase III 👥 136 pts | TGCT 💊 Emactuzumab (anti-CSF-1R) vs placebo 💉 5 infusions over 8 weeks 🎯 6-mo ORR (RECIST): 30% vs 2% 📈 ORR (TVS): 54% vs 7% ✅ Improved pain, stiffness & function (p<0.001) ⚠️ G≥3 TRAEs: 48% vs 2% 💡 Effective short-course therapy! @OncoAlert","https://x.com/DraMartinezLago/status/2113978187491205372","aeda9e32-14c5-408b-b35d-0c775dd94b67","Results from the TANGENT trial in TGCT showed that emactuzumab is active and tolerable vs placebo",{"_272":1710,"_248":1711},"drug:darovasertib","darovasertib","Updated findings from the OptimUM trials presented at #ESMO26 support the use of darovasertib + crizotinib in the treatment of uveal #Melanoma Neoadjuvant darovasertib shrank tumors in 85.7% of patients!💡 Read more here","2026-10-23T10:39:01.000Z","2026-10-24T16:56:04.000Z",[],{"_264":1706,"_266":1707,"_267":268,"_269":1708,"_271":1709},"msxqhy3cru12j37nfs85agdja","Updated findings from the OptimUM trials presented at #ESMO26 support the use of darovasertib + crizotinib in the treatment of uveal #Melanoma Neoadjuvant darovasertib shrank tumors in 85.7% of patients!💡 Read more here: 🔗 https://bit.ly/4zMvXA1","https://x.com/CancerTherAdvsr/status/2114038224586699130","CancerTherAdvsr","a65efd49-0943-4b64-a785-28614245cb0f","@MeredithMcKean joined by Dr",{"_272":1724,"_248":1725},"drug:cabozantinib","cabozantinib","👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26! Promising results with cabozantinib in advanced thyroid cancer: ORR 24%, DCR 89.7% and median PFS 16.1 months. ","2026-10-23T15:30:59.000Z","2026-10-24T14:33:48.000Z",[],{"_264":1720,"_266":1721,"_267":268,"_269":1722,"_271":1723},"flqejxt2pp8gm3egbssg2j67t","👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26! Promising results with cabozantinib in advanced thyroid cancer: ORR 24%, DCR 89.7% and median PFS 16.1 months. Great work by @GrupoGetne 🇪🇸! @Ja_Capdevila @OncoAlert","https://x.com/DrVilmaPBarcia/status/2113655465334952193","DrVilmaPBarcia","c9df8130-0ec0-46ee-b6e4-8c5fadaa26e6","👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26",{"_272":1737,"_248":1738},"code:KEYNOTE-869","KEYNOTE-869","Phase Ib/II EV-103: Long-Term Outcomes With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer At #ESMO26, Jose Pablo Maroto Rey presented long-term results from EV-103/KEYNOTE-869 (4740RO), evaluating first-line","2026-10-24T10:05:01.000Z","2026-10-24T17:00:02.000Z",[],{"_264":1734,"_266":1735,"_267":268,"_269":1736,"_271":1400},"vilsi780y15yvg37u8h1a3yf5","Phase Ib/II EV-103: Long-Term Outcomes With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer At #ESMO26, Jose Pablo Maroto Rey presented long-term results from EV-103/KEYNOTE-869 (4740RO), evaluating first-line enfortumab vedotin (EV) with or without pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Key findings: ▫️ EV + pembrolizumab (pooled DE/A/K; n=121): Median DOR was 29.6 months, median PFS was 10.4 months, and median OS was 27.7 months. ▫️ Five-year OS: 33.0% in the pooled EV + pembrolizumab cohorts and 23.9% in the EV monotherapy cohort (K; n=73). ▫️ Grade ≥3 treatment-related AEs: 64.5% with EV + pembrolizumab and 47.9% with EV monotherapy. No new safety signals were observed. Takeaway: Long-term follow-up demonstrated sustained responses and survival with first-line EV plus pembrolizumab. No formal between-arm statistical comparisons were performed in Cohort K. @oncodaily @myESMO @tompowles1 @DrRosenbergMSK https://oncodaily.com/genitourinary-oncology/ev-103-esmo-2026 #ESMO26 #ESMO2026 #EV103","https://x.com/OncoDailyGU/status/2113934781180203053","3ae9377f-b7e1-48b8-a277-4acbf16ec1ab","Phase Ib/II EV-103: Long-Term Outcomes With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer Phase Ib/II EV-103: Long-Term Outcome",{"_272":1749,"_248":1750},"code:788RO","788RO","#ESMO26 | 788RO ECLYPse: Ph2 EC beyond progression in combination with FOLFIRI in BRAF V600E mCRC @myESMO @OncoAlert https://t.co/SPahzMo1m0","2026-10-19T09:06:00.000Z","2026-10-24T14:56:11.000Z",[],{"_264":1747,"_266":1742,"_267":268,"_269":1748,"_271":1081},"he9p7zc7e5z5i5wq5j07abkc8","https://x.com/DaisukeKotani/status/2112107988689260587","18ebc941-a84f-4ea7-97e0-083845d99026","#ESMO26 | 788RO ECLYPse: Ph2 EC beyond progression in combination with FOLFIRI in BRAF V600E mCRC @myESMO @OncoAlert #ESMO26 | 788RO ECLYPse",{"_272":1762,"_248":1763},"tag:#weareoncoalert","#WEAREONCOALERT","WE are HERE #ESMO26 #WeAreOncoAlert 🚨 OUR DAILY #ESMO26 NEWSLETTER STARTS TOMORROW REGISTER for Free 👉 https://buff.ly/N5gYtAc DIRECT TO YOUR INBOX Every MORNING!! Follow OncoAlert on Social or at http://www.OncoAlert3","2026-10-23T10:13:12.000Z","2026-10-23T20:16:13.000Z",[],{"_264":1759,"_266":1760,"_267":268,"_269":1761,"_271":1026},"oci6hoj4w5bbfj01zabo39n9m","WE are HERE #ESMO26 #WeAreOncoAlert 🚨 OUR DAILY #ESMO26 NEWSLETTER STARTS TOMORROW REGISTER for Free 👉 https://buff.ly/N5gYtAc DIRECT TO YOUR INBOX Every MORNING!! Follow OncoAlert on Social or at http://www.OncoAlert360.com @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3","https://x.com/OncoAlert/status/2113574454605287717","ca1d7b5b-701b-4c47-9e4d-2399084c86f0","WE are HERE #ESMO26 WE are HERE #ESMO26 #WeAreOncoAlert 🚨 OUR DAILY #ESMO26 NEWSLETTER STARTS TOMORROW REGISTER for Free 👉 https://buff",{"_272":1783,"_248":1784},"drug:abemaciclib","abemaciclib","Overall survival numerically favored abemaciclib + fulvestrant following disease progression on prior Al/CDK4/6i; median 32.1 vs 24.6 months HR 0.80, 95% CI 0.60-1.06) @KalinskyKevin @OncoAlert #ESMO26","2026-10-23T14:22:05.000Z","2026-10-24T12:27:11.000Z",[1775,1776],{"_264":1772,"_266":1767,"_267":268,"_269":1773,"_271":1774},"e0jt156yms651al16z1egt0om","https://x.com/DrSGraff/status/2113924023524765836","DrSGraff",{"_387":1781,"_19":398,"_248":1782,"_391":1247,"_393":-5,"_394":-5,"_395":1248},{"_387":1777,"_19":398,"_248":1778,"_391":400,"_393":-5,"_394":1779,"_395":1197},"4498P","Association of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE",[1780,1780,1780],"NCT03155997","1RO","Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy","6c1e66b4-1bd1-46c6-bbec-7a461d393213","Overall survival numerically favored abemaciclib + fulvestrant following disease progression on prior Al/CDK4/6i; median 32",{"_272":1802,"_248":1803},"tag:#hnscc","#HNSCC","@Rakuten Medical #ESMO26 I like it that it postpones other new immune checkpoint options to a later line effectively leaving new options after relapse. Probably has very good abscopal effect in their treatment. May be co","2026-10-21T15:08:39.000Z","2026-10-24T07:49:21.000Z",[1797],{"_264":1793,"_266":1794,"_267":268,"_269":1795,"_271":1796},"y83qo8bsc3cg9hj2ahukslvjo","@Rakuten Medical #ESMO26 I like it that it postpones other new immune checkpoint options to a later line effectively leaving new options after relapse. Probably has very good abscopal effect in their treatment. May be combined with other later line chckpt inhibitors even.","https://x.com/Water46333865/status/2113801828152619073","Water46333865",{"_387":1798,"_19":398,"_248":1799,"_391":1800,"_393":-5,"_394":1801,"_395":1799},"NCT06295731","- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","https://clinicaltrials.gov/study/NCT06295731",[1798],"33ba464a-b564-437f-9239-d12605bdde13","#ESMO26 #ESMO26 Oneof the best summaries that you can see these days about the management of HPV+ early disease #HNSCC Kudos Dr Sandra Schmi",{"_272":1817,"_248":1818},"tag:#aiom","#AIOM","Apre a Madrid #ESMO26. Gli oncologi #AIOM: \"In Italia garantito l’accesso all’89% dei farmaci anticancro approvati da EMA, ma ancora troppo lunghi i tempi d'attesa\". L'articolo: https://www.medinews.it/comunicati/tumori-",5,"2026-10-23T08:55:19.000Z","2026-10-23T13:26:32.000Z",[],{"_264":1813,"_266":1814,"_267":268,"_269":1815,"_271":1816},"cizaap8xcw9lfx2fhatlusvzw","Apre a Madrid #ESMO26. Gli oncologi #AIOM: \"In Italia garantito l’accesso all’89% dei farmaci anticancro approvati da EMA, ma ancora troppo lunghi i tempi d'attesa\". L'articolo: https://www.medinews.it/comunicati/tumori-in-europa-meno-78-di-morti-negli-uomini-dal-2020-al-2026-in-italia-servono-ancora-15-mesi-per-accedere-alle-nuove-terapie/ @myESMO","https://x.com/AIOMtweet/status/2113555106092200149","AIOMtweet","84dd3393-3bd6-4e5c-b193-af9606874251","A Madrid 40mila oncologi da tutto il mondo per il congresso della società europea di oncologia medica",{"_272":1830,"_248":1831},"tag:#oncoalertaf","#ONCOALERTAF","Dear #ESMO26 We Are ALL @OncoAlert 🚨 For Colleagues...By Colleagues @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @so","2026-10-23T13:37:12.000Z","2026-10-24T10:36:07.000Z",[],{"_264":1827,"_266":1828,"_267":268,"_269":1829,"_271":1026},"ekw8e9mjyeaspyk67e0octlv5","Dear #ESMO26 We Are ALL @OncoAlert 🚨 For Colleagues...By Colleagues @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @scocmem @niklas_kluemper @Markuseckstein3 @AndreaNecchi @weoncologists","https://x.com/OncoAlert/status/2113896439306736117","755f89a6-d425-458c-9cfd-028a61014223","📌Keynote lecture 1 📌Keynote lecture 1 CNS disease as the next frontier in oncology care: Glioblastoma, metastases, and leptomeningeal dise",{"_272":1843,"_248":1844},"drug:cemiplimab","cemiplimab","R2810-ONC-1901 Neoadjuvant cemiplimab: single-arm phase II, resectable II-IV (M0) cSCC → surgery. pCR 51%; 54-mo EFS 76.2%, OS 79.4%. Postop RT, cemiplimab or observation: investigator choice. This can't establish safe R","2026-10-23T13:16:00.000Z","2026-10-24T22:38:02.000Z",[],{"_264":1840,"_266":1841,"_267":268,"_269":1842,"_271":1426},"m0iopjfnk1wman4keysgl37k3","R2810-ONC-1901 Neoadjuvant cemiplimab: single-arm phase II, resectable II-IV (M0) cSCC → surgery. pCR 51%; 54-mo EFS 76.2%, OS 79.4%. Postop RT, cemiplimab or observation: investigator choice. This can't establish safe RT omission. #ESMO26 #OncTwitter https://doi.org/10.1200/JCO-26-02166","https://x.com/jryckman3/status/2114124282095714667","d48aafb5-4da2-42ce-95ae-35367ac117d2","‼️ #ESMO26 simultaneous publication by Gross, et al",{"_272":1859,"_248":1860},"drug:ramucirumab","ramucirumab","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab as Second-Line Therapy for Taxane-Pretreated Patients With Advanced or Metastatic Gastroesophageal Adenoca","2026-10-22T16:02:12.000Z","2026-10-23T19:01:43.000Z",[1856],{"_264":1853,"_266":1854,"_267":268,"_269":1855,"_271":1026},"qhqwi23ct60macv874tw4unxx","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab as Second-Line Therapy for Taxane-Pretreated Patients With Advanced or Metastatic Gastroesophageal Adenocarcinoma: Final Results of the Phase III IKFs602/AIO RAMIRIS Study 🔬 Phase III (n=317): FOLFIRI + ramucirumab vs paclitaxel + ramucirumab, second-line, in taxane-pretreated advanced GEA. Co-primary endpoints: OS and ORR. ➡️ Median OS 8.7 vs 7.5 mo; HR 0.95; p=.33 ➡️ ORR 25.3% vs 22.6% (p=.29); median PFS 5.5 vs 3.7 mo, HR 0.7 (p=.003) ➡️ Grade 3–5 AEs 70% vs 68% ✅ Co-primary endpoints were not met; PFS was clearly improved, supporting personalized treatment decisions in taxane-pretreated advanced GEA. 🎙️ Magdalena Scheck (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Faculty @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, , @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,","https://x.com/OncoAlert/status/2113299893473128857",{"_387":1857,"_19":398,"_248":1858,"_391":392,"_393":-5,"_394":-5,"_395":396},"2878RO","FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study","594d8404-eb34-4098-b4dc-c5be29117981","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 FOLFIRI Plus Ramucirumab Versus ",{"_272":1872,"_248":1873},"gene:LAG3","LAG3","🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials: 🤰 Melanoma in pregnancy: very limited data","2026-10-24T09:01:39.000Z","2026-10-24T18:39:02.000Z",[],{"_264":1869,"_266":1870,"_267":268,"_269":1871,"_271":1026},"u838hjtndw5e55ead92hqgjvy","🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials: 🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3 Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3 Immunotherapy is never just about the tumor 👇 #ESMO26 #Melanoma @DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein","https://x.com/OncoAlert/status/2113939561466171547","2ef5a7be-5347-4511-8921-450fdb1b39d6","🎬 New #OAOnTheGo 🎥 from #ESMO26 🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr",{"_272":1889,"_248":1890},"drug:visugromab","visugromab","At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing antibody visugromab + nivolumab produced encouraging response with no new safety si","2026-10-24T09:33:45.000Z","2026-10-24T21:18:33.000Z",[1886],{"_264":1882,"_266":1883,"_267":268,"_269":1884,"_271":1885},"qvq6c48oatgiifbit5hcnd1ng","At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing antibody visugromab + nivolumab produced encouraging response with no new safety signals @AndreaNecchi dlvr.it/TW32cC","https://x.com/NatureMedicine/status/2114104283142722002","NatureMedicine",{"_387":1887,"_19":398,"_248":1888,"_391":998,"_393":-5,"_394":-5,"_395":999},"4757RO","Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)","a147877e-08dd-4310-a02a-35470508119b","At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing ant",{"_272":1913,"_248":1914},"drug:amivantamab","amivantamab","🦋 Making amivantamab + lazertinib safer: new COCOON data at #ESMO26! New results from the COCOON study suggest that simplified dermatologic prophylaxis, combined with subcutaneous amivantamab + lazertinib, may substanti","2026-10-24T06:51:02.000Z","2026-10-24T06:57:48.000Z",[1902,1903,1904],{"_264":1899,"_266":1900,"_267":268,"_269":1901,"_271":954},"hdqkaq5zeoamg032x4ucvntk4","🦋 Making amivantamab + lazertinib safer: new COCOON data at #ESMO26! New results from the COCOON study suggest that simplified dermatologic prophylaxis, combined with subcutaneous amivantamab + lazertinib, may substantially reduce treatment-related skin toxicity in first-line EGFR-mutant NSCLC. Key findings:Grade ≥2 dermatologic AEs: 39% with standard initiation vs 18% with a one-cycle lazertinib lead-in. Simplified prophylaxis appears to provide protection comparable to the original COCOON regimen. Sc markedly reduces IRR reactions.The new cohorts were non-randomized, and the comparison between initiation strategies was exploratory. Personal take: No doubt about less ami less tox. Question is if efficacy remains the same in the era of Flaura2?! #ESMOAmbassador #ESMO26 #LungCancer #NSCLC #EGFR #COCOON #Oncology #CancerResearch","https://x.com/Alfdoc2/status/2113887665351258196",{"_387":1644,"_19":398,"_248":1645,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1909,"_19":398,"_248":1910,"_391":1911,"_393":-5,"_394":1912,"_395":1910},{"_387":1905,"_19":398,"_248":1906,"_391":1907,"_393":-5,"_394":1908,"_395":1906},"NCT07276399","- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","https://clinicaltrials.gov/study/NCT07276399",[1905],"NCT06385080","- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","https://clinicaltrials.gov/study/NCT06385080",[1909],"d9aa9974-5855-441e-9fe7-87e3ee0ba921","#ESMO26 Dr",{"_272":1926,"_248":1927},"code:HOPE-001","HOPE-001","後方ラインのCLDN18.2 ADCアルコタツグタバテカン、PFSが0.4台でOSが0.5台…。予想してたよりもはるかにすごい、、G-HOPE-001試験 #ESMO26","2026-10-23T11:42:28.000Z","2026-10-23T13:14:18.000Z",[],{"_264":1923,"_266":1918,"_267":268,"_269":1924,"_271":1925},"ilfcja10nc4qiudwm6xaxd728","https://x.com/m0370/status/2113620028075692508","m0370","01b2e3bb-fe6c-4e74-976e-60bb2005d61d","後方ラインのCLDN18",{"_272":1940,"_248":1941},"gene:DLL3","DLL3","👏👏 Amazing rapid orals session in #Neuroendocrinetumirs at #ESMO26!!!! Congratulations to the presenters and the discussants!! New Pb-based Radioligands and DLL3 driven drugs are promising new strategies in the field. ","2026-10-23T12:00:24.000Z","2026-10-24T14:45:14.000Z",[],{"_264":1936,"_266":1937,"_267":268,"_269":1938,"_271":1939},"i3fmmtgudv7jkqmjvvptwzu94","👏👏 Amazing rapid orals session in #Neuroendocrinetumirs at #ESMO26!!!! Congratulations to the presenters and the discussants!! New Pb-based Radioligands and DLL3 driven drugs are promising new strategies in the field. @Ja_Capdevila @OncoThor @GrupoGetne @myESMO @OncoAlert @Netespana","https://x.com/drenriquegrande/status/2113644057570185713","drenriquegrande","33077416-18db-4772-a253-98789f906844","👏👏 Amazing rapid orals session in #Neuroendocrinetumirs at #ESMO26",{"_272":1962,"_248":1914},"drug:telisotuzumab","telisotuzumab","#ESMO26 Dr. David Sommerhalder presents OS from M21-404: telisotuzumab adizutecan (Temab-A), a c-MET directed ADC with a topo-1 payload. mPFS 6.8m OS 13.8m in EGFR wild type. mPFS 10.9m OS 16.2m in EGFR mutant. cMET expr","2026-10-14T12:00:00.000Z","2026-10-24T12:45:00.000Z",[1954,1955],{"_264":1950,"_266":1951,"_267":268,"_269":1952,"_271":1953},"yi5cr6a9d43u9hyw1q0jzuyvl","#ESMO26 Dr. David Sommerhalder presents OS from M21-404: telisotuzumab adizutecan (Temab-A), a c-MET directed ADC with a topo-1 payload. mPFS 6.8m OS 13.8m in EGFR wild type. mPFS 10.9m OS 16.2m in EGFR mutant. cMET expression predicts outcomes in EGFRwt, not so in EGFRmt.","https://x.com/StephenVLiu/status/2113899551618637853","StephenVLiu",{"_387":1960,"_19":398,"_248":1961,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1956,"_19":398,"_248":1957,"_391":1958,"_393":-5,"_394":-5,"_395":1959},"791RO","Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/263","Rapid oral: Gastrointestinal tumours, lower digestive","2658RO","Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study","81d2f255-e14f-4063-8b54-49595298b238",{"_272":1973,"_248":1974},"tag:#sarcoma","#SARCOMA","Welcome to Madrid! 🇪🇸 @ManuPalmerini and I are looking forward to bringing you updated #sarcoma insights from @myESMO #ESMO26. Have a good night’s rest and see you all bright and early tomorrow. #ESMOAmbassadors","2026-10-22T21:13:51.000Z","2026-10-24T14:41:26.000Z",[],{"_264":1971,"_266":1966,"_267":268,"_269":1972,"_271":1130},"dchd0vugja343dset2lfefm9l","https://x.com/herbloong/status/2113378323346903437","ebb404bb-68e4-465b-8db9-663907a758f1","Welcome to Madrid",{"_272":1987,"_248":1988},"tag:#precisiononcology","#PRECISIONONCOLOGY","🚨 ⭐ Mark your calenders and register for an event around #ESMO26 Meeting, Madrid, Spain @myESMO 📌 I’m looking forward to joining the International Alliance for Personalised Medicine Alliance @united4cancer event on 23 ","2026-10-21T08:52:17.000Z","2026-10-24T15:55:02.000Z",[],{"_264":1983,"_266":1984,"_267":268,"_269":1985,"_271":1986},"p0e2w1rcsjdk3vonemdwcn3i8","🚨 ⭐ Mark your calenders and register for an event around #ESMO26 Meeting, Madrid, Spain @myESMO 📌 I’m looking forward to joining the International Alliance for Personalised Medicine Alliance @united4cancer event on 23 October 2026 in Madrid. 👉 The event will bring together experts and stakeholders to discuss the challenges and opportunities in personalised medicine, fostering dialogue on how to translate innovation into meaningful benefits for patients. 👉 Looking forward to the discussions and to connecting with colleagues in Madrid! #128467;️ October 23rd, 2026 Venue;IFEMA Congress Centre, Room A4.2, Mezzanine Level, Madrid @OncoAlert @oncodaily Register here free event link: https://docs.google.com/forms/d/e/1FAIpQLSdIzkMdzJ2L359NIW_ep0-c_2iHKZAG0cgitf1aCCXCKh6RWA/viewform","https://x.com/VivekSubbiah/status/2112920298412560626","VivekSubbiah","34e98629-1493-45cc-b244-90018f153fde","🚨 ⭐ Mark your calenders and register for an event around #ESMO26 Meeting, Madrid, Spain @myESMO 🚨 ⭐ Mark your calenders and register for a",{"_272":2002,"_248":2003},"gene:AKT","AKT","Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026","2026-10-23T12:20:18.000Z","2026-10-24T15:50:39.000Z",[2000],{"_264":1997,"_266":1992,"_267":268,"_269":1998,"_271":1999},"iz510io8m5rwo4grlslx7pjp4","https://x.com/hoperugo/status/2113890866066751612","hoperugo",{"_387":1202,"_19":398,"_248":1203,"_391":1204,"_393":-5,"_394":2001,"_395":1206},[1207],"eb253426-4d2e-48f7-a72a-5d30e36ea10d","Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026 Peter Faschin",{"_272":2019,"_248":2020},"gene:TROP2","TROP2","TROPION-Breast02 brain mets analysis at #ESMO26 (Dent). 1L Dato-DXd vs chemo, mTNBC, n=61 with BMs: CNS PFS 9.5 vs 2.6 mo, HR 0.27 icORR (measurable) 62.5% vs 37.5% Untreated BMs: OS HR 0.35 Longest icDoR ~27 mo Preferre","2026-10-22T17:13:56.000Z","2026-10-24T08:07:02.000Z",[2016],{"_264":2012,"_266":2013,"_267":268,"_269":2014,"_271":2015},"pqybcapw0jaqmy3ypx57nf6c7","TROPION-Breast02 brain mets analysis at #ESMO26 (Dent). 1L Dato-DXd vs chemo, mTNBC, n=61 with BMs: CNS PFS 9.5 vs 2.6 mo, HR 0.27 icORR (measurable) 62.5% vs 37.5% Untreated BMs: OS HR 0.35 Longest icDoR ~27 mo Preferred Trop2 ADC for brain Mets! @RebeccaDSing Exploratory, small n, real CNS signal. #bcsm","https://x.com/drsarahsam/status/2113905090897568042","drsarahsam",{"_387":2017,"_19":398,"_248":2018,"_391":1200,"_393":-5,"_394":-5,"_395":1201},"2631RO","First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study","4aa1d09b-73da-4146-9b90-fa210f6904bc","TROPION-Breast02 brain mets analysis at #ESMO26 (Dent)",{"_272":2033,"_248":2034},"gene:PIK3CA","PIK3CA","VIKTORIA-1 #ESMO26 In PIK3CA-mutated HR+/HER2− advanced #BreastCancer post-CDK4/6i, gedatolisib-based regimens improved PFS vs alpelisib + fulvestrant, with fewer treatment discontinuations due to adverse events (4–5% vs","2026-10-24T08:23:23.000Z","2026-10-24T11:41:28.000Z",[],{"_264":2029,"_266":2030,"_267":268,"_269":2031,"_271":2032},"q3zrenoacd995btowzizhtaj0","VIKTORIA-1 #ESMO26 In PIK3CA-mutated HR+/HER2− advanced #BreastCancer post-CDK4/6i, gedatolisib-based regimens improved PFS vs alpelisib + fulvestrant, with fewer treatment discontinuations due to adverse events (4–5% vs 19%). @OncoAlert #bcsm @GustaveRoussy","https://x.com/Dr_Oncologista/status/2113920013010702638","Dr_Oncologista","398e2750-3519-4479-a236-f1c538a7e061","VIKTORIA-1 #ESMO26 VIKTORIA-1 #ESMO26 In PIK3CA-mutated HR+/HER2− advanced #BreastCancer post-CDK4/6i, gedatolisib-based regimens improved P",{"_272":2048,"_248":2049},"code:KEYNOTE-564","KEYNOTE-564","Is adjuvant pembrolizumab still the standard for high-risk ccRCC after 7 years? 🤔 The KEYNOTE-564 final analysis says YES 👇 ✅ 7-yr OS 82.3% vs 76.6% ✅ 7-yr DFS 57.2% vs 44.6% This is just the abstract. The full data hi","2026-10-16T00:00:00.000Z","2026-10-23T22:52:41.000Z",[2047],{"_264":2043,"_266":2044,"_267":268,"_269":2045,"_271":2046},"cljq1ywowbwy78gygrgqx1lvy","Is adjuvant pembrolizumab still the standard for high-risk ccRCC after 7 years? 🤔 The KEYNOTE-564 final analysis says YES 👇 ✅ 7-yr OS 82.3% vs 76.6% ✅ 7-yr DFS 57.2% vs 44.6% This is just the abstract. The full data hits the stage at #ESMO26 🎤 #OncoAlert4SIGHT 🚨 #KidneyCancer","https://x.com/weoncologists/status/2113580241318817802","weoncologists",{"_387":397,"_19":398,"_248":399,"_391":400,"_393":-5,"_394":-5,"_395":401},"b6a67c9b-d7f4-417c-b1c6-050112212c41","Is adjuvant pembrolizumab still the standard for high-risk ccRCC after 7 years",{"_272":2061,"_248":2062},"gene:TP53","TP53","#ESMO26 | NIAGARA Perioperative durva+ chemo improved EFS in molecular subtypes of MIBC. TMB-high: HR 0.44 TP53-mut: HR 0.51 FGFR3-mut: HR 0.24 B-s and luminal-Inf tumors showed immune signatures and greater pCR @SCUColo","2026-10-24T07:21:16.000Z","2026-10-24T11:00:44.000Z",[],{"_264":2058,"_266":2059,"_267":268,"_269":2060,"_271":829},"umxzzo1oubc4xonk37e2b2oww","#ESMO26 | NIAGARA Perioperative durva+ chemo improved EFS in molecular subtypes of MIBC. TMB-high: HR 0.44 TP53-mut: HR 0.51 FGFR3-mut: HR 0.24 B-s and luminal-Inf tumors showed immune signatures and greater pCR @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily","https://x.com/zapatalaguadomd/status/2113925651962937494","ba728c00-9f72-449d-83ed-dc067ae1266f","#ESMO26 | NIAGARA Perioperative durva+ chemo improved EFS in molecular subtypes of MIBC",{"_272":2093,"_248":2094},"drug:encorafenib","encorafenib","Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial #ESMO26 #ESMOAmbassadors 👉 mPFS: 7.1 👉 mOS: NR 👉ORR 15% 🧐Interes",7,"2026-10-24T12:56:43.000Z","2026-10-24T18:22:32.000Z",[2076,2077,2078,2079],{"_264":2072,"_266":2073,"_267":268,"_269":2074,"_271":2075},"s2g3wxylknrrv4d9ec8xxxt00","Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial #ESMO26 #ESMOAmbassadors 👉 mPFS: 7.1 👉 mOS: NR 👉ORR 15% 🧐Interesting signal to continue EC, more translational data would be great @myESMO @ASCO","https://x.com/ArndtVogel/status/2113977989767557189","ArndtVogel",{"_387":2089,"_19":398,"_248":2090,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":1741,"_19":398,"_248":2088,"_391":1958,"_393":-5,"_394":-5,"_395":1959},{"_387":2084,"_19":398,"_248":2085,"_391":2086,"_393":-5,"_394":2087,"_395":2085},{"_387":2080,"_19":398,"_248":2081,"_391":2082,"_393":-5,"_394":2083,"_395":2081},"NCT06640166","- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","https://clinicaltrials.gov/study/NCT06640166",[2080],"NCT06578559","- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","https://clinicaltrials.gov/study/NCT06578559",[2084],"Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial","2071O","STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/250","Proffered paper: Melanoma and other skin tumours","0f51bdcb-23f7-4c9a-8f3a-41e297f7579e","Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse pha",{"_272":2126,"_248":2127},"tag:#nsclc","#NSCLC","🧿 Shaping the future of #NSCLC at #ESMO26 Delighted to co-chair today’s symposium in Madrid with @MARIANOPROVENCI, Enriqueta Felip & Marcia K. Horn @Exon20Group Translating scientific advances into better outcomes f","2026-10-22T19:00:00.000Z","2026-10-24T07:44:58.000Z",[2106,2107,2108,2109,2110,2111,2112,2113],{"_264":2103,"_266":2104,"_267":268,"_269":2105,"_271":1642},"fos7kf0aj8buszuypwc8r5ugr","🧿 Shaping the future of #NSCLC at #ESMO26 Delighted to co-chair today’s symposium in Madrid with @MARIANOPROVENCI, Enriqueta Felip & Marcia K. Horn @Exon20Group Translating scientific advances into better outcomes for patients, today and tomorrow.","https://x.com/APassaroMD/status/2113503094231204217",{"_387":2122,"_19":398,"_248":2123,"_391":400,"_393":-5,"_394":2124,"_395":405},{"_387":2119,"_19":398,"_248":2120,"_391":400,"_393":-5,"_394":-5,"_395":2121},{"_387":2114,"_19":398,"_248":2115,"_391":400,"_393":-5,"_394":2116,"_395":2117},{"_387":2017,"_19":398,"_248":2018,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1198,"_19":398,"_248":1199,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1960,"_19":398,"_248":1961,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":619,"_19":398,"_248":620,"_391":400,"_393":-5,"_394":-5,"_395":621},{"_387":1494,"_19":398,"_248":1495,"_391":400,"_393":-5,"_394":-5,"_395":621},"2551TIP","Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer",[2118,2118,2118],"NSCLC, early stage","NCT07541170","209P","AI-driven quantification of PD-L1 tumor proportion score (TPS) from immunohistochemistry slides in non-small cell lung cancer (NSCLC)","AI for clinical workflows and decision-making","131P","Prospective validation of artificial intelligence (AI)–assisted RECIST 1.1 in a phase 1 study of fetrastobart vedotin in patients with non-small cell lung cancer (NSCLC)",[2125,2125,2125],"NCT05208762","fcc804e5-69c6-4c05-9c79-d23e1dabc3f9","🧿 Shaping the future of #NSCLC at #ESMO26 🧿 Shaping the future of #NSCLC at #ESMO26 Delighted to co-chair today’s symposium in Madrid with",{"_272":2139,"_248":2140},"drug:sintilimab","sintilimab","🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage? Randomized phase II in >=2L anti-PD-1-resistant melanoma! Notably 73% acral/mucosal!!! ▪️PFS: 4.37 vs 1.61m (HR 0.44) 💥 ORR: 44% vs 8% -Ac","2026-10-16T12:00:00.000Z","2026-10-23T15:37:38.000Z",[],{"_264":2136,"_266":2137,"_267":268,"_269":2138,"_271":613},"zth9mi308zoog195t00ory9bw","🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage? Randomized phase II in >=2L anti-PD-1-resistant melanoma! Notably 73% acral/mucosal!!! ▪️PFS: 4.37 vs 1.61m (HR 0.44) 💥 ORR: 44% vs 8% -Acral: ORR 45% vs 8% -Mucosal: ORR 50% vs 0% IL-2-free + reduced-intensity lymphodepletion 👀 and the discussant questioned whether 50% dose sintilimab really changes much… @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma","https://x.com/MarioBalsaMD/status/2113656100012589476","a1b4f0eb-409b-48b0-ab92-199cb1295ed6","🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage",{"_272":2163,"_248":2164},"tag:#sclc","#SCLC","The moment I saw the overall survival curves, I wanted to stand up and applaud! 👏 40,000 of us at #ESMO26, sharing the same excitement and hope not for ourselves, but for our patients. ❤️ A truly emotional moment in #SC","2026-10-22T13:01:52.000Z","2026-10-24T22:03:18.000Z",[2153,2154,2155,2156,2157,2158,2159,2160],{"_264":2149,"_266":2150,"_267":268,"_269":2151,"_271":2152},"ruji5da44k6ld27v1hnk2119k","The moment I saw the overall survival curves, I wanted to stand up and applaud! 👏 40,000 of us at #ESMO26, sharing the same excitement and hope not for ourselves, but for our patients. ❤️ A truly emotional moment in #SCLC. #DeLLphi305 @StephenVLiu @sands_jacob @lungoncdoc","https://x.com/ErulEnes/status/2114026261475361270","ErulEnes",{"_387":2122,"_19":398,"_248":2123,"_391":400,"_393":-5,"_394":2162,"_395":405},{"_387":2119,"_19":398,"_248":2120,"_391":400,"_393":-5,"_394":-5,"_395":2121},{"_387":2114,"_19":398,"_248":2115,"_391":400,"_393":-5,"_394":2161,"_395":2117},{"_387":2017,"_19":398,"_248":2018,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1198,"_19":398,"_248":1199,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1960,"_19":398,"_248":1961,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":619,"_19":398,"_248":620,"_391":400,"_393":-5,"_394":-5,"_395":621},{"_387":1494,"_19":398,"_248":1495,"_391":400,"_393":-5,"_394":-5,"_395":621},[2118,2118,2118],[2125,2125,2125],"340a9b59-4a18-4364-b154-17f5c2c034d4","The moment I saw the overall survival curves, I wanted to stand up and applaud",{"_272":2176,"_248":2177},"code:POTOMAC","POTOMAC","#ESMO26 Data from POTOMAC focusing on papillary-only high-risk NMIBC. Durva + BCG reduced high-risk events (13% vs 20%) and improved cystectomy-free survival (HR 0.59) The benefit–toxicity remains key given the higher ra","2026-10-24T08:24:13.000Z","2026-10-24T14:00:01.000Z",[],{"_264":2173,"_266":2174,"_267":268,"_269":2175,"_271":994},"g4x9cyad5tdbmesw4y8igg8g0","#ESMO26 Data from POTOMAC focusing on papillary-only high-risk NMIBC. Durva + BCG reduced high-risk events (13% vs 20%) and improved cystectomy-free survival (HR 0.59) The benefit–toxicity remains key given the higher rates of G3/4 AEs (23% vs 3%) @OncoAlert","https://x.com/scocmem/status/2113910780034707742","95a9c47d-2cee-4f8c-a79d-ddf2593a4e91","#ESMO26 Data from POTOMAC focusing on papillary-only high-risk NMIBC",{"_272":2194,"_248":2195},"drug:cetuximab","cetuximab","Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC #ESMO26 #ESMOAmbassadors 👉ORR: 25% vs 50%, DCR: 75 vs 90% 👉 no new safety signals 🧐Supports th","2026-10-12T00:00:00.000Z","2026-10-24T13:28:45.000Z",[2189,2190,2191],{"_264":2186,"_266":2187,"_267":268,"_269":2188,"_271":2075},"uvg4atpki52hzehlxy3a8f6gq","Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC #ESMO26 #ESMOAmbassadors 👉ORR: 25% vs 50%, DCR: 75 vs 90% 👉 no new safety signals 🧐Supports the combination with CTx @myESMO @ASCO","https://x.com/ArndtVogel/status/2113984837975523708",{"_387":1741,"_19":398,"_248":2088,"_391":1958,"_393":-5,"_394":-5,"_395":1959},{"_387":2084,"_19":398,"_248":2085,"_391":2086,"_393":-5,"_394":2193,"_395":2085},{"_387":2080,"_19":398,"_248":2081,"_391":2082,"_393":-5,"_394":2192,"_395":2081},[2080],[2084],"c05d4c58-f003-4c5d-a0b4-ee1535ba8e15","Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC Preliminary clini",{"_272":2211,"_248":2212},"drug:toripalimab","toripalimab","Promising data in locally advanced penile cancer at #ESMO26! Neoadjuvant toripalimab + TIP achieved 84% ORR and 48% pCR in a phase II study (n=25). @OncoAlert #HuiHan","2026-10-19T04:40:00.000Z","2026-10-24T13:00:21.000Z",[2207],{"_264":2204,"_266":2199,"_267":268,"_269":2205,"_271":2206},"omjkltb952p4dh3ocjqyrzc8w","https://x.com/dmukherji/status/2113595068271763785","dmukherji",{"_387":2208,"_19":398,"_248":2209,"_391":1204,"_393":-5,"_394":2210,"_395":1206},"1209RO","Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial",[1207],"58d570f7-97d1-419f-89c6-30abe5e9cef7","Promising data in locally advanced penile cancer at #ESMO26",{"_272":2225,"_248":2226},"code:PSMA-617","PSMA-617","Re-LuPSMA: Interim Safety of a Ph II Trial of 177Lu-PSMA-617 Retreatment in mCRPC @urotoday #ESMO26 @CalaisJeremie 📌n=20/40 📌Median retreatment cycles: 3 (IQR 2–5) 📌165 AEs, 88 possibly TR: Gr1 (n=53); Gr2 (n=14); Gr3","2026-10-20T14:48:00.000Z","2026-10-24T22:22:06.000Z",[],{"_264":2221,"_266":2222,"_267":268,"_269":2223,"_271":2224},"evwxovwzlciw0uzbcq6dsaw03","Re-LuPSMA: Interim Safety of a Ph II Trial of 177Lu-PSMA-617 Retreatment in mCRPC @urotoday #ESMO26 @CalaisJeremie 📌n=20/40 📌Median retreatment cycles: 3 (IQR 2–5) 📌165 AEs, 88 possibly TR: Gr1 (n=53); Gr2 (n=14); Gr3 (n=13); Gr 4 (n=8) 📌Most common TRAEs: leukopenia (n=12), anemia (n=15), thrombocytopenia (n=10), xerostomia (n=10)","https://x.com/zklaassen_md/status/2113637996943515837","zklaassen_md","001e5e8d-cb81-4f7f-8e2f-994ab4f2ac01","Re-LuPSMA: Interim Safety of a Ph II Trial of 177Lu-PSMA-617 Retreatment in mCRPC @urotoday #ESMO26 @CalaisJeremie Re-LuPSMA: Interim Safety",{"_272":2239,"_248":2240},"tag:#lungcancer","#LUNGCANCER","One of the best things about #ESMO26? Reconnecting with great friends and inspiring colleagues! Wonderful to catch up with @g_mountzios. Different journeys, one shared ambition: improving our patients’ lives and working ",10,"2026-10-20T20:29:23.000Z","2026-10-24T11:10:56.000Z",[],{"_264":2236,"_266":2237,"_267":268,"_269":2238,"_271":954},"kesiunlt0497aymcbgn2te7ga","One of the best things about #ESMO26? Reconnecting with great friends and inspiring colleagues! Wonderful to catch up with @g_mountzios. Different journeys, one shared ambition: improving our patients’ lives and working towards a future where we can cure cancer. Science brings us together. Friendship makes the journey even better! 💙 #ESMOAmbassador #ESMO26 #Oncology #LungCancer #CancerResearch","https://x.com/Alfdoc2/status/2113583483658342876","4388aff3-721c-42da-a5b8-81f6e878e90d","One of the best things about #ESMO26",{"_272":2252,"_248":2253},"drug:lenvatinib","lenvatinib","Getting ready for the #RapidOral session in #NETs at @myESMO #ESMO26 @FRANCES88189587 @GCarboneroLab #MariannePavel #AnjaRinke #WiN #ESMOAmbassadors","2026-10-13T12:00:00.000Z","2026-10-24T17:20:10.000Z",[],{"_264":2249,"_266":2244,"_267":268,"_269":2250,"_271":2251},"w88j3rhdoili3c1puhi8j7vgy","https://x.com/DrAngelaLamarca/status/2113636779240927326","DrAngelaLamarca","6b22f0e8-db8d-4f90-b74c-36fb24d69a82","Getting ready for the #RapidOral session in #NETs at @myESMO #ESMO26 Getting ready for the #RapidOral session in #NETs at @myESMO #ESMO26 @F",{"_272":2265,"_248":2266},"drug:tislelizumab","tislelizumab","🎯 #ESMO2026 2º day Rapid oral GU non-prostate session. @Uro_Oncologist presented the HRQL of EV-304 periop MIBC!! EV +pembro was not associated with a clinically meaningful detriment in general HRQoL or cystectomy-speci","2026-10-24T09:54:19.000Z",[2264],{"_264":2261,"_266":2262,"_267":268,"_269":2263,"_271":1454},"tbmej8ykajtom81v96bm0vzhp","🎯 #ESMO2026 2º day Rapid oral GU non-prostate session. @Uro_Oncologist presented the HRQL of EV-304 periop MIBC!! EV +pembro was not associated with a clinically meaningful detriment in general HRQoL or cystectomy-specific HRQoL!! @OncoAlert @myESMO @GuardConsortium @DrChoueiri @tompowles1 @urotoday @PGrivasMDPhD","https://x.com/cdanicas/status/2113913260277665962",{"_387":388,"_19":389,"_248":390,"_391":392,"_393":-5,"_394":-5,"_395":396},"dff7b13c-ad69-44ca-a6ee-efb62fc9f875","🎯 #ESMO2026 2º day Rapid oral GU non-prostate session",{"_272":2303,"_248":2304},"tag:#melanoma","#MELANOMA","Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after surgery showed positive results, according to research presented at this year’s #E","2026-10-23T20:54:30.000Z","2026-10-24T14:57:22.000Z",[2279,2280,2281,2282,2283,2284,2285,2286],{"_264":2275,"_266":2276,"_267":268,"_269":2277,"_271":2278},"j1r6zxwduldk8zhka82pesp42","Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after surgery showed positive results, according to research presented at this year’s #ESMO26 meeting in Madrid. The study found that adding a specially tailored cancer vaccine to standard treatment with immunotherapy successfully reduced the risk of melanoma coming back by 42% compared with standard immunotherapy alone. “The idea of this treatment is that by specifically boosting a patient’s immune system to recognize their own tumor cells, we can reduce the risk that the cancer comes back,” says Dr. Michael Postow, Chief of the Melanoma Service at MSK. “Even when we can’t see any cancer on a CT or PET scan, we know that often it’s still there — because such a high proportion of patients eventually have a cancer recurrence. That’s why there is tremendous need for this type of treatment.” Read more about one of the three MSK patients treated in the trial: https://bit.ly/3W0Voj2","https://x.com/MSKCancerCenter/status/2113735841184944170","MSKCancerCenter",{"_387":2089,"_19":398,"_248":2090,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":2301,"_19":398,"_248":2302,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":2299,"_19":398,"_248":2300,"_391":400,"_393":-5,"_394":-5,"_395":2294},{"_387":2296,"_19":398,"_248":2297,"_391":400,"_393":-5,"_394":2298,"_395":2294},{"_387":2291,"_19":398,"_248":2292,"_391":400,"_393":-5,"_394":2293,"_395":2294},{"_387":527,"_19":389,"_248":528,"_391":529,"_393":-5,"_394":-5,"_395":530},{"_387":2289,"_19":389,"_248":2290,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":2287,"_19":389,"_248":2288,"_391":2091,"_393":-5,"_394":-5,"_395":2092},"LBA55","Autologous tumor-infiltrating lymphocytes (GC101 TIL) in advanced melanoma: Extended follow-up of a randomized, open-label, pivotal phase II trial","LBA54","Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma","2099P","Impact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial",[2295,2295,2295],"Melanoma","NCT04949113","2081P","Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity",[2295,2295,2295],"2079P","Transcriptomic and epigenomic profiling of TIL products identifies determinants of clinical benefit in advanced melanoma","2072O","Efficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study","81df9bd1-8b05-4a56-8276-46fa9e485193","Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after su",{"_272":2318,"_248":1914},"drug:lorlatinib","lorlatinib","Proud to share our long-term real-world experience with lorlatinib in ALK+ NSCLC from Kuwait Cancer Control Center at #ESMO2026 Single-Center Retrospective cohort (N=26): ORR: 83% DCR: 96% Longest ongoing exposure: >8","2026-10-24T07:16:02.000Z","2026-10-24T13:34:17.000Z",[2317],{"_264":2313,"_266":2314,"_267":268,"_269":2315,"_271":2316},"odrehulapuljdyaslj8a6x0tv","Proud to share our long-term real-world experience with lorlatinib in ALK+ NSCLC from Kuwait Cancer Control Center at #ESMO2026 Single-Center Retrospective cohort (N=26): ORR: 83% DCR: 96% Longest ongoing exposure: >85 months #LCSM #ALK","https://x.com/DrZ_84/status/2113987443242455333","DrZ_84",{"_387":1198,"_19":398,"_248":1199,"_391":1200,"_393":-5,"_394":-5,"_395":1201},"594fb838-594f-476d-9294-077ed7f00114",{"_272":2334,"_248":2335},"drug:palbociclib","palbociclib","🟣❓ ¿Puede la combinación de biomarcadores circulantes ayudar a identificar a pacientes con cáncer de mama metastásico con mayor riesgo de progresión? 🔬 En el marco de #ESMO26, @GEICAM presenta nuevos resultados de un a",8,"2026-10-08T00:00:00.000Z","2026-10-24T21:04:59.000Z",[2331],{"_264":2328,"_266":2329,"_267":268,"_269":2330,"_271":698},"yevnvqm8od8e3f2aicxtcdwoi","🟣❓ ¿Puede la combinación de biomarcadores circulantes ayudar a identificar a pacientes con cáncer de mama metastásico con mayor riesgo de progresión? 🔬 En el marco de #ESMO26, @GEICAM presenta nuevos resultados de un análisis retrospectivo del ensayo clínico fase II FLIPPER (GEICAM/2014-12), liderado por los doctores Federico Rojo y Joan Albanell, que demostró el beneficio de administrar palbociclib (inhibidor de CDK4/6) junto con fulvestrant (terapia endocrina) como primera línea de tratamiento en pacientes postmenopáusicas con cáncer de mama metastásico RH+/HER2−. 🩸 Este nuevo análisis traslacional mediante biopsia líquida evalúa el potencial pronóstico y predictivo del ADN tumoral circulante (ctDNA) y la actividad enzimática de la timidina quinasa (TKa), biomarcador de proliferación tumoral. 📊 El análisis incluyó 903 muestras de plasma secuenciales de 187 (99%) pacientes. Tanto la detección de ≥2 mutaciones en ctDNA como unos niveles elevados de TKa -antes de iniciar el tratamiento y a las 12 semanas- se asociaron de forma independiente con progresión temprana y menor supervivencia. 🔎 La detección de ≥2 mutaciones se asoció más estrechamente con peor pronóstico en pacientes tratadas con fulvestrant, mientras que una TKa elevada se asoció con peor pronóstico en quienes recibieron fulvestrant en combinación con palbociclib. 🧬 La integración de ambos biomarcadores identificó un subgrupo de alto riesgo que representaba el 7% de las pacientes analizadas, con una supervivencia libre de progresión aproximadamente dos veces más corta y una probabilidad de progresión temprana de la enfermedad más de seis veces superior. 🧪 El seguimiento molecular reveló un aumento de las mutaciones en ESR1 y TP53 en el momento de la progresión, reflejando la evolución del perfil molecular del tumor durante el tratamiento y aportando información sobre los posibles mecanismos asociados a la resistencia. 🎯 Estos resultados, presentados en formato póster por el Dr. Federico Rojo, Coordinador de transGEICAM e investigador principal del estudio, respaldan el potencial de integrar biomarcadores circulantes para mejorar la estratificación del riesgo y avanzar en la investigación de estrategias terapéuticas más personalizadas. 🔗 https://www.geicam.org/wp-content/uploads/2026/10/ESMO-2026_FLIPPER-TKa_ctDNA_v4.pdf 🟣 #ESMO2026 🔬 @myESMO #CáncerDeMama #BreastCancer #Oncología #InvestigaciónOncológica #Biomarcadores #BiopsiaLíquida #MedicinaPersonalizada #PrecisionOncology","https://x.com/GEICAM/status/2113619233800163734",{"_387":2332,"_19":389,"_248":2333,"_391":1247,"_393":-5,"_394":-5,"_395":1248},"LBA16","VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)","26e2ec17-5695-4d30-90bd-01e9baa4697b","🟣❓ ¿Puede la combinación de biomarcadores circulantes ayudar a identificar a pacientes con cáncer de mama metastásico con mayor riesgo de p",{"_272":2351,"_248":2352},"code:CAPITELLO-281","CAPITELLO-281","From biology to patient benefit. CAPItello-281 brings PTEN-targeted therapy closer to clinical reality. Proud to contribute to this research. @myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @Annals_Oncology @tompowles1","2026-10-23T11:55:00.000Z","2026-10-24T09:30:13.000Z",[2347],{"_264":2344,"_266":2339,"_267":268,"_269":2345,"_271":2346},"u42j6r5r2jzb1hfwecnap0amz","https://x.com/DrYukselUrun/status/2113645014882398350","DrYukselUrun",{"_387":2348,"_19":389,"_248":2349,"_391":1204,"_393":-5,"_394":2350,"_395":1206},"LBA56","Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281",[1207],"023c8fb8-2b56-463f-aa4d-2f76decd9e89","From biology to patient benefit",{"_272":2368,"_248":2369},"drug:atirmociclib","atirmociclib","Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented by the great @antgiorda 🇮🇹 in patients with endocrine-resistant disease @Onco","2026-10-22T22:01:00.000Z","2026-10-24T07:49:11.000Z",[2365],{"_264":2361,"_266":2362,"_267":268,"_269":2363,"_271":2364},"oxzwn2fsrk5tf3covxut30xw4","Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented by the great @antgiorda 🇮🇹 in patients with endocrine-resistant disease @OncoAlert @myESMO @Annals_Oncology","https://x.com/matteolambe/status/2113889857181209084","matteolambe",{"_387":2366,"_19":398,"_248":2367,"_391":1100,"_393":-5,"_394":-5,"_395":1101},"1842O","Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)","3c906539-bc2c-4b5f-a335-c635b317c5f0","Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented",{"_272":2384,"_248":2385},"drug:ipatasertib","ipatasertib","FINER demonstrates ipatasertib + fulvestrant improves PFS (but not OS) for both ITT and AKT pathway altered cohorts with notable AEs #ESMO26 @OncoAlert",9,"2026-10-23T22:30:58.000Z","2026-10-24T22:54:04.000Z",[2381],{"_264":2379,"_266":2373,"_267":268,"_269":2380,"_271":1774},"t1ch3i0mp5e81jlkalzfqmzeq","https://x.com/DrSGraff/status/2113887289084624919",{"_387":2382,"_19":389,"_248":2383,"_391":1100,"_393":-5,"_394":-5,"_395":1101},"LBA14","A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/","9302d91f-3089-4c1d-a39a-e4bdd19f433e","At #ESMO26 Proffered Paper 2️⃣ on #breastcancer At #ESMO26 Proffered Paper 2️⃣ on #breastcancer Results of the FINER trial Ipatasertib + ful",{"_272":2398,"_248":2399},"tag:#madrid","#MADRID","Heading to #Madrid for #ESMO26 My top 5 *abstracts* as a radiation oncologist 1. Athletico Madrid vs Deportivo (Metropolitano) 2. “El Classico” - Barcelona Vs Real Madrid (any bar in Madrid) 3. LATE BREAKING: Onco-Karaok","2026-10-22T05:58:05.000Z","2026-10-24T16:37:53.000Z",[],{"_264":2394,"_266":2395,"_267":268,"_269":2396,"_271":2397},"ewapn1w8100wokyws1fepnyyb","Heading to #Madrid for #ESMO26 My top 5 *abstracts* as a radiation oncologist 1. Athletico Madrid vs Deportivo (Metropolitano) 2. “El Classico” - Barcelona Vs Real Madrid (any bar in Madrid) 3. LATE BREAKING: Onco-Karaoke - TBA 4. SARON results - (Alicante) 5. I meant “top 4”","https://x.com/cpeedell/status/2113147864444490068","cpeedell","da55e6ed-627b-4fca-890f-5123a1344adf","Heading to #Madrid for #ESMO26 Heading to #Madrid for #ESMO26 My top 5 *abstracts* as a radiation oncologist 1",{"_272":2421,"_248":2422},"drug:bevacizumab","bevacizumab","Temab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data 👉 mOS 14.7 vs 10.2 months with FTD-TPI + Bev 👉 HR 0.62 (95% CI 0.33–1.18) Encouraging ADC signal. Simultaneous publication in Annals of Oncology! #ESMO2","2026-10-24T15:30:15.000Z",[2411,2412,2413,2414,2415],{"_264":2407,"_266":2408,"_267":268,"_269":2409,"_271":2410},"c5cqg3nhots6nvjh0tzk6wxma","Temab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data 👉 mOS 14.7 vs 10.2 months with FTD-TPI + Bev 👉 HR 0.62 (95% CI 0.33–1.18) Encouraging ADC signal. Simultaneous publication in Annals of Oncology! #ESMO26 #ESMOAmbassadors @OncoAlert","https://x.com/EvelynWongYT/status/2113986916626637146","EvelynWongYT",{"_387":1304,"_19":398,"_248":1305,"_391":1287,"_393":-5,"_394":-5,"_395":1288},{"_387":1956,"_19":398,"_248":1957,"_391":1958,"_393":-5,"_394":-5,"_395":1959},{"_387":2419,"_19":398,"_248":2420,"_391":400,"_393":-5,"_394":-5,"_395":1183},{"_387":1072,"_19":389,"_248":2418,"_391":1958,"_393":-5,"_394":-5,"_395":1959},{"_387":2416,"_19":389,"_248":2417,"_391":1287,"_393":-5,"_394":-5,"_395":1288},"LBA38","Final overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic","Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial","833P","Outcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study","1a84b238-955c-4cb3-9842-ba16ed68192d","Temab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data Temab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data 👉 mOS 1",{"_272":2444,"_248":2445},"gene:EGFR","EGFR","#PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41 🔹 ORR: 20% vs 40% 🔹 DoR: 4.2 vs. 6.9 mo 🔹 ILD: only 1.1% & al",13,"2026-10-23T10:32:17.000Z","2026-10-24T14:44:47.000Z",[2436,2437,2438],{"_264":2432,"_266":2433,"_267":268,"_269":2434,"_271":2435},"z4ofbmaj1029yuyl3nlaght7p","#PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41 🔹 ORR: 20% vs 40% 🔹 DoR: 4.2 vs. 6.9 mo 🔹 ILD: only 1.1% & all grade 1/2 #ESMO26 #ESMOAmbassadors","https://x.com/ErikaHamilton9/status/2113614882889437329","ErikaHamilton9",{"_387":1644,"_19":398,"_248":1645,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":1180,"_19":398,"_248":1181,"_391":400,"_393":-5,"_394":2443,"_395":1183},{"_387":2439,"_19":398,"_248":2440,"_391":2441,"_393":-5,"_394":2442,"_395":2440},"NCT06110663","- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","https://clinicaltrials.gov/study/NCT06110663",[2439],[1184,1184,1184],"bee61ca0-29fd-4c17-bbee-c3240d703f33","#PANKUBreast01 #PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPF",{"_272":2464,"_248":2465},"drug:osimertinib","osimertinib","#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 were ctDNA positive at 3w. mPFS 17.8m and O",12,"2026-10-15T12:00:00.000Z","2026-10-24T10:42:51.000Z",[2458,2459],{"_264":2455,"_266":2456,"_267":268,"_269":2457,"_271":1953},"s18hebg52i51uqwu7bwpz7gvr","#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 were ctDNA positive at 3w. mPFS 17.8m and OS 31.5m from start of osi - no comparator but encouraging.","https://x.com/StephenVLiu/status/2113882584367165877",{"_387":2462,"_19":398,"_248":2463,"_391":1200,"_393":-5,"_394":-5,"_395":1201},{"_387":2460,"_19":389,"_248":2461,"_391":1200,"_393":-5,"_394":-5,"_395":1201},"LBA73","PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line","2719RO","FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)","4f169784-6465-4ef4-b6d3-f08957469667","#ESMO2026 opened today in Madrid, and a big focus for EGFR+ #lungcancer is what happens when osimertinib stops working",{"_272":2483,"_248":2484},"drug:anbenitamab","anbenitamab","Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳 #ESMO26 #ESMOAmbassadors 👉 ORR: 56 vs 13% 👉 mOS: 19.6 vs 9.7 mo 👉no unexpected safety signal 🧐Supports s","2026-10-23T14:26:29.000Z","2026-10-24T17:55:33.000Z",[2477,2478],{"_264":2474,"_266":2475,"_267":268,"_269":2476,"_271":2075},"jk5a1eekxlx52lt5rrsvbaomx","Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳 #ESMO26 #ESMOAmbassadors 👉 ORR: 56 vs 13% 👉 mOS: 19.6 vs 9.7 mo 👉no unexpected safety signal 🧐Supports sequential targeting of Her2 @myESMO @ASCO","https://x.com/ArndtVogel/status/2113638192481960446",{"_387":2481,"_19":389,"_248":2482,"_391":1100,"_393":-5,"_394":-5,"_395":1101},{"_387":2479,"_19":389,"_248":2480,"_391":392,"_393":-5,"_394":-5,"_395":396},"LBA80","Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE","LBA15","Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study","d30a328a-b251-4d72-9467-509ef4da11a9","Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳 Anbenitamab plus chemotherap",{"_272":2508,"_248":2509},"drug:sacituzumab","sacituzumab","Proud of @LucaVisani2 and our Florence team presenting this poster on behalf of an international consortium - brand new data on combining sacituzumab govitecan with #radiotherapy in #breastcancer Much more to come! #ESMO",15,"2026-10-19T11:55:00.000Z","2026-10-24T16:10:37.000Z",[2498,2499,2500,2501],{"_264":2494,"_266":2495,"_267":268,"_269":2496,"_271":2497},"r8vgi0f3crjy92iccz6n5bp27","Proud of @LucaVisani2 and our Florence team presenting this poster on behalf of an international consortium - brand new data on combining sacituzumab govitecan with #radiotherapy in #breastcancer Much more to come! #ESMO26 #OncoAlert @OncoAlert @AOUCareggi @UNI_FIRENZE","https://x.com/Icro_Meattini/status/2114026787130814606","Icro_Meattini",{"_387":1300,"_19":398,"_248":1301,"_391":400,"_393":-5,"_394":2507,"_395":643},{"_387":2504,"_19":398,"_248":2505,"_391":400,"_393":-5,"_394":-5,"_395":2506},{"_387":2502,"_19":398,"_248":2503,"_391":998,"_393":-5,"_394":-5,"_395":999},{"_387":1611,"_19":398,"_248":1612,"_391":1193,"_393":-5,"_394":-5,"_395":1194},"4739RO","Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)","35P","Comparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching","Advanced breast cancer, other",[1303,1303,1303],"a5b76b50-84f3-432e-a00e-425788823503","Proud of @LucaVisani2 and our Florence team presenting this poster on behalf of an international consortium - brand new data on combining sa",{"_272":2522,"_248":2523},"code:JNJ-6143","JNJ-6143","🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC 🎤 Presented by Alice Bernard-Tessier @OncoAlert 🔬 Androgen receptor (AR) remains a central therapeutic target in mCRPC—but the field is clearly evolving beyond convent",14,"2026-10-23T14:34:20.000Z","2026-10-24T19:54:24.000Z",[],{"_264":2519,"_266":2520,"_267":268,"_269":2521,"_271":1040},"v3dhzxhkne3xf26qvfwnlpdpx","🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC 🎤 Presented by Alice Bernard-Tessier @OncoAlert 🔬 Androgen receptor (AR) remains a central therapeutic target in mCRPC—but the field is clearly evolving beyond conventional ARPIs. 📌 KEY CONCEPTS 🧬 1. AR alterations are common AR alterations are enriched in mCRPC and may be found in up to 80% of patients, including: • AR amplification • AR mutations • AR splice variants • AR rearrangements These alterations are associated with worse prognosis, although their role as fully validated predictive biomarkers of ARPI resistance remains incomplete. 💊 2. The next generation of AR targeting is expanding The session reviewed several new strategies beyond standard AR pathway inhibition: • Next-generation AR inhibitors • AR degraders • CYP11A1 inhibition • RIPTACs, a novel concept exploiting AR presence, rather than classic AR dependence 🧪 3. AR degraders are gaining momentum Emerging compounds and trials suggest that AR degradation may overcome resistance mechanisms not fully addressed by current ARPIs. Examples discussed included: • Luxdegalutamide • BMS-986460 • Other AR degraders in clinical development 🧬 4. Genotype may increasingly guide drug choice A major practical message from this talk: “Genotype picks the drug.” Different novel strategies may be better suited for different AR alterations: • AR degraders and CYP11A1 inhibition may be particularly relevant when tumors harbor AR alterations • AR activating mutations may identify biologically distinct therapeutic vulnerabilities 💥 5. RIPTACs may shift the paradigm The RIPTAC concept is especially interesting because it moves the field: ➡️ from AR dependence to AR presence This could potentially expand AR-directed therapy even in tumors where canonical AR addiction is less clear. Early phase 1 data with JNJ-6143 showed PSA responses across doses and across heterogeneous molecular backgrounds. 📌 TAKE-HOME MESSAGES 1️⃣ AR is still the target. 2️⃣ AR alterations are frequent and drive resistance to ARPIs. 3️⃣ Genotype may increasingly determine therapeutic selection. 4️⃣ RIPTACs introduce a potentially new framework for AR-directed therapy. ⭐ MY POINT OF VIEW | CLINICAL PEARL This talk reinforces that mCRPC is entering a more biologically segmented era. The future is not simply “more AR blockade,” but smarter AR targeting, choosing the right mechanism for the right resistance biology. 💡 The real shift is from one-size-fits-all AR inhibition to precision AR-directed therapy. For daily practice, this means molecular characterization will become progressively more relevant—not only for prognosis, but for selecting the next therapeutic strategy after ARPI resistance emerges. @urologysummit @gbanna74 @ravikanesvaran @Uromigos @LosUromigos @nataliagandur @brian_rini @tompowles1 @montypal @declangmurphy @salvolarosa @RenuEapen @seanmcbride @DrJaVallejo @Silke_Gillessen @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @cdanicas @AOmlin @ecancer @UrologyTimes @urotoday @wearemedsir @OpenMedicineHQ @gu_onc #ProstateCancer #mCRPC #GUOncology #AR #PrecisionOncology #ESMO","https://x.com/nataliagandur/status/2113640169928585613","820ff03f-1551-4ccb-ad7e-c1ac93b38cdd","🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC 🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC 🎤 Presented by Alice Bernard-Tessier ",{"_272":2541,"_248":2542},"drug:paclitaxel","paclitaxel","Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 ➡️prev treated #BTC wo actionable alterations ➡️ORR 17.1 v5.3%; DCR 62 v 37% ➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover ➡️OS not sig but nb crossover @myESM",18,"2026-10-09T12:00:00.000Z","2026-10-24T22:54:50.000Z",[2536,2537,2538],{"_264":2533,"_266":2534,"_267":268,"_269":2535,"_271":1321},"zb3n0qbfe1b1htjsrf7jf2rv7","Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 ➡️prev treated #BTC wo actionable alterations ➡️ORR 17.1 v5.3%; DCR 62 v 37% ➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover ➡️OS not sig but nb crossover @myESMO #ESMO26 @OncoAlert","https://x.com/graokane/status/2113910837471490108",{"_387":1857,"_19":398,"_248":1858,"_391":392,"_393":-5,"_394":-5,"_395":396},{"_387":1240,"_19":398,"_248":1241,"_391":1187,"_393":-5,"_394":-5,"_395":1188},{"_387":2539,"_19":389,"_248":2540,"_391":1287,"_393":-5,"_394":-5,"_395":1288},"LBA37","Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud","3424c2aa-8cd7-49e9-afb7-1cf54bca0386","Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 ➡️prev treated #BTC wo actionable alterations ➡️OR",{"_272":2557,"_248":2558},"code:KEYNOTE-B49","KEYNOTE-B49","Another reminder that immunotherapy is not a universal solution. KEYNOTE-B49 highlights the need for better patient selection. @myESMO @OncoAlert @OpenMedicineHQ #ESMO26",28,"2026-10-22T21:00:01.000Z","2026-10-24T19:22:31.000Z",[2554],{"_264":2552,"_266":2546,"_267":268,"_269":2553,"_271":2346},"k1cx3gx6dpsy2gbgft1jjj59m","https://x.com/DrYukselUrun/status/2113892065390002338",{"_387":2555,"_19":389,"_248":2556,"_391":1100,"_393":-5,"_394":-5,"_395":1101},"LBA51","Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)","6b80ea58-8c41-43bb-b10f-4ab4202503cc","Another reminder that immunotherapy is not a universal solution",{"_272":2572,"_248":2573},"tag:#prostatecancer","#PROSTATECANCER","Yesterday we had the pleasure of hosting @ResearchWyatt, who gave a fantastic seminar on ctDNA in #prostatecancer. Thanks Alex for visiting @VHIO ahead of #ESMO26 to strengthen collaborations!",19,30,"2026-10-22T10:00:00.000Z","2026-10-24T19:45:04.000Z",[],{"_264":2569,"_266":2562,"_267":268,"_269":2570,"_271":2571},"lxpn4i2cmzhjzuo3xsd6hhvjm","https://x.com/quimmateo/status/2113325269184639037","quimmateo","295b505c-115b-4046-9f33-cf6f61b82b95","Yesterday we had the pleasure of hosting @ResearchWyatt, who gave a fantastic seminar on ctDNA in #prostatecancer",{"_272":2589,"_248":2590},"drug:dostarlimab","dostarlimab","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Watch-and-Wait Strategy for Dostarlimab in Localized dMMR/MSI-H Gastroesophageal Adenocarcinoma: Results From the First Interim Analysis of the GERCOR-GONO DEWI Phase",20,"2026-10-19T16:22:47.000Z","2026-10-24T20:50:04.000Z",[2586],{"_264":2583,"_266":2584,"_267":268,"_269":2585,"_271":1026},"gti4rvs8yj1htu0qk1fblwiut","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Watch-and-Wait Strategy for Dostarlimab in Localized dMMR/MSI-H Gastroesophageal Adenocarcinoma: Results From the First Interim Analysis of the GERCOR-GONO DEWI Phase II Study 🔬 Phase II, first interim analysis (24 evaluable patients): dostarlimab with a watch-and-wait strategy in localized dMMR/MSI-H gastroesophageal adenocarcinoma. Primary endpoint: 1-year cCR without surgery. ➡️ 1-year cCR: 62.5% (15/24) ➡️ No relapse or death in patients with 1-year cCR (median follow-up 16.20 mo) ➡️ Grade 3–4 dostarlimab-related AEs: 21%; 9/24 underwent surgery, all R0 ✅ dostarlimab led to a 62.5% 1-year cCR at the first interim analysis, enabling organ preservation. 🎙️ Thierry André 👥 Christelle de la Fouchardière (4Sight Made from Abstracts publicly available at the ESMO website) @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, , @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,","https://x.com/OncoAlert/status/2113178581404721160",{"_387":2587,"_19":398,"_248":2588,"_391":392,"_393":-5,"_394":-5,"_395":396},"2877RO","Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study","d9125f62-20a9-4d9c-85fb-ecd5553882f0","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Watch-and-Wait Strategy for Dost",{"_272":2616,"_248":2617},"drug:durvalumab","durvalumab","POP-Durva | #ESMO26 Short-course durvalumab reshaped the immune microenvironment in early TNBC, increasing median sTILs from 10% to 22%, despite limited pCR. Does immune activation translate into clinical benefit? @OncoA",23,24,"2026-10-16T18:42:11.973Z","2026-10-24T18:42:08.000Z",[2604,2605,2606,2607,2608,2609],{"_264":2601,"_266":2602,"_267":268,"_269":2603,"_271":2032},"o03i9ljpogv56d8bb02d4qrh2","POP-Durva | #ESMO26 Short-course durvalumab reshaped the immune microenvironment in early TNBC, increasing median sTILs from 10% to 22%, despite limited pCR. Does immune activation translate into clinical benefit? @OncoAlert #BreastCancer #bcsm","https://x.com/Dr_Oncologista/status/2113905156215452130",{"_387":2614,"_19":398,"_248":2615,"_391":392,"_393":-5,"_394":-5,"_395":396},{"_387":2612,"_19":398,"_248":2613,"_391":998,"_393":-5,"_394":-5,"_395":999},{"_387":1668,"_19":389,"_248":1669,"_391":529,"_393":-5,"_394":-5,"_395":530},{"_387":1102,"_19":389,"_248":1103,"_391":1100,"_393":-5,"_394":-5,"_395":1101},{"_387":2610,"_19":389,"_248":2611,"_391":529,"_393":-5,"_394":-5,"_395":530},{"_387":2539,"_19":389,"_248":2540,"_391":1287,"_393":-5,"_394":-5,"_395":1288},"LBA3","Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial","4737RO","Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT","2879RO","Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial","26a6e52e-7a35-4396-8314-2684c69100bc","POP-Durva | #ESMO26 POP-Durva | #ESMO26 Short-course durvalumab reshaped the immune microenvironment in early TNBC, increasing median sTILs ",{"_272":2638,"_248":2639},"drug:tarlatamab","tarlatamab","Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing! ➡️ Challenge remains implementing Tarlatamab broadly + equitably so that all patients with ES-SCLC may benefit from this rev","2026-10-22T00:00:00.000Z","2026-10-24T19:47:35.000Z",[2630,2631,2632],{"_264":2626,"_266":2627,"_267":268,"_269":2628,"_271":2629},"w263tn385sfsnh5nxx163xost","Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing! ➡️ Challenge remains implementing Tarlatamab broadly + equitably so that all patients with ES-SCLC may benefit from this revolutionary therapy. @OncoAlert #ESMO26 @NEJM","https://x.com/christine_lovly/status/2114071129442963880","christine_lovly",{"_387":2636,"_19":398,"_248":2637,"_391":400,"_393":-5,"_394":-5,"_395":2635},{"_387":2633,"_19":398,"_248":2634,"_391":400,"_393":-5,"_394":-5,"_395":2635},{"_387":2610,"_19":389,"_248":2611,"_391":529,"_393":-5,"_394":-5,"_395":530},"3848P","Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis","SCLC","3821P","Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study","1c38d894-4870-47ae-8d50-4b9c804cc0a5","Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing",{"_272":2650,"_248":2651},"tag:#charisma","#CHARISMA","Excited to join this incredible list of @DanaFarber colleagues presenting at #ESMO26 Don’t miss our #CHARISMA presentation on Monday morning!","2026-10-22T13:50:02.000Z","2026-10-23T09:18:25.000Z",[],{"_264":2648,"_266":2643,"_267":268,"_269":2649,"_271":657},"a38tkpgoydmlg61o0sonfnegv","https://x.com/PTarantinoMD/status/2113266634249142450","fc6c4903-532d-4e5d-a4ed-05d1b8e7e720","Excited to join this incredible list of @DanaFarber colleagues presenting at #ESMO26 Excited to join this incredible list of @DanaFarber col",{"_272":2662,"_248":2663},"nct:NCT06120140","NCT06120140","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line (1L) Subcutaneous (SC) Amivantamab + Lazertinib: F","2026-10-24T06:49:30.000Z",[],{"_264":2659,"_266":2660,"_267":268,"_269":2661,"_271":729},"gpl6cwmrc14scik99iwmv1k8e","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line (1L) Subcutaneous (SC) Amivantamab + Lazertinib: First Results From a New COCOON Cohort 🎙️ @cbcbc1971 🔢2700RO 🎯Optimized Dermatologic Management With Zinc Supplementation 🎯Grade≥2 DAEIs by Wk 12 in 34% 🎯Scalp 5%, Paronychia 18%; Dose Reductions 11%, Discontinuations 3% ☑️NCT06120140 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters","https://x.com/HHorinouchi/status/2112891661244346767","e3ea20cd-8f33-4f3d-9253-6808491017a1","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adve",{"_272":2676,"_248":2677},"tag:#cancerdata","#CANCERDATA","@myESMO 2026: Day 1 Preview Explore #ESMO26 insights here: https://clin.larvol.com/conference/abstract/ESMO%202026 #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrial","2026-10-21T15:44:21.000Z","2026-10-24T16:13:43.000Z",[],{"_264":2672,"_266":2673,"_267":268,"_269":2674,"_271":2675},"vrtno13sqlvbn1p6it588dsdh","@myESMO 2026: Day 1 Preview Explore #ESMO26 insights here: https://clin.larvol.com/conference/abstract/ESMO%202026 #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @PTarantinoMD | @ErikaHamilton9 | @stolaney1 | @pashtoonkasi | @ArndtVogel | @Erman_Akkus | @DrChoueiri | @DrYukselUrun | @neerajaiims","https://x.com/Larvol/status/2113313616455958933","Larvol","30e78a4e-2826-4ae9-97aa-eb5e68dff3aa","@myESMO 2026: Day 1 Preview @myESMO 2026: Day 1 Preview Explore #ESMO26 insights here: https://clin",{"_272":2696,"_248":2697},"tag:#pdac","#PDAC","AMPLIFY-7P randomised ph2 ✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile ➡️curative intent & no recurrence <6mth #PDAC ✅T cell responses,primary endpt-ve ➡️benefit in ctDNA-ve& no rads? ➡️DFS @6mt","2026-10-23T13:08:20.000Z","2026-10-23T15:31:19.000Z",[2689,2690],{"_264":2686,"_266":2687,"_267":268,"_269":2688,"_271":1321},"swu8eov57ymfx5cuxqkk9vk6e","AMPLIFY-7P randomised ph2 ✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile ➡️curative intent & no recurrence <6mth #PDAC ✅T cell responses,primary endpt-ve ➡️benefit in ctDNA-ve& no rads? ➡️DFS @6mth benefit of 14% p=0.056 ✅ph3 planned @myESMO @OncoAlert #ESMO26","https://x.com/graokane/status/2113618528251314320",{"_387":1312,"_19":389,"_248":2695,"_391":2693,"_393":-5,"_394":-5,"_395":2694},{"_387":2691,"_19":389,"_248":2692,"_391":2693,"_393":-5,"_394":-5,"_395":2694},"LBA83","Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/241","Proffered paper 1: Gastrointestinal tumour, upper digestive","Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study","f533b6bd-7791-413c-9c57-f95596e78523","AMPLIFY-7P randomised ph2 AMPLIFY-7P randomised ph2 ✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile ➡️curative intent & no r",{"_272":2720,"_248":2721},"code:KRASCENDO","KRASCENDO","1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO 5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes. The question each one answers 🧵 #LCSM @Lung","2026-10-19T18:04:30.000Z","2026-10-23T02:15:25.000Z",[2710,2711,2712],{"_264":2706,"_266":2707,"_267":268,"_269":2708,"_271":2709},"e2wn2yec3xdsy4zanqqytwatk","1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO 5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes. The question each one answers 🧵 #LCSM @LungCancerRx @OncoAlert @oncodaily","https://x.com/ADesaiMD/status/2113454214810591712","ADesaiMD",{"_387":2114,"_19":398,"_248":2115,"_391":400,"_393":-5,"_394":2719,"_395":2117},{"_387":2717,"_19":389,"_248":2714,"_391":2715,"_393":-5,"_394":2718,"_395":2714},{"_387":2713,"_19":398,"_248":2714,"_391":2715,"_393":-5,"_394":2716,"_395":2714},"NCT06497556","KRASCENDO-1","https://clinicaltrials.gov/study/NCT06497556",[2713],"LBA5",[2713],[2118,2118,2118],"edad0c79-a6c9-4e49-9a11-ad865870de28","1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked",{"_272":2733,"_248":2734},"code:4736O","4736O","🧬 #ESMO26 | Abstract 4736O OncoAlert🚨 #Podium2Screen Series What did the phase III CA017-078 trial reveal about perioperative immunotherapy in muscle-invasive bladder cancer (MIBC)? 📊 Key results 🔹 Event-free surviva","2026-10-23T11:57:00.000Z","2026-10-23T14:11:00.000Z",[],{"_264":2730,"_266":2731,"_267":268,"_269":2732,"_271":1026},"jl7ri8c5sd886htct845fvhm6","🧬 #ESMO26 | Abstract 4736O OncoAlert🚨 #Podium2Screen Series What did the phase III CA017-078 trial reveal about perioperative immunotherapy in muscle-invasive bladder cancer (MIBC)? 📊 Key results 🔹 Event-free survival: No statistically significant difference between perioperative nivolumab + gemcitabine/cisplatin (GC) and GC alone (HR 0.94; P = 0.67). 🔹 Pathologic complete response: 39.1% vs 29.6%, respectively; the difference was not statistically significant. 🔹 Overall survival: Data remained immature. 🔹 Safety: Grade ≥3 treatment-related adverse events occurred in 45.9% vs 49.5%. 🎤 Abstract 4736O 👨‍⚕️ Speaker: @AndreaNecchi 🇮🇹, Milan, Italy 🕐 Presentation: 13:40–13:50 @shilpaonc, @MattGalsky Although the primary endpoints were not significantly different, these findings contribute to the ongoing discussion about optimizing perioperative treatment strategies for MIBC. 💬 How might future biomarker analyses, including ctDNA, help refine treatment selection? Pinging Our Faculty @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3","https://x.com/OncoAlert/status/2113633344088907958","0a607ed5-cca9-4e8b-bc80-2fb7b797721f","🧬 #ESMO26 | Abstract 4736O 🧬 #ESMO26 | Abstract 4736O OncoAlert🚨 #Podium2Screen Series What did the phase III CA017-078 trial reveal abou",{"_272":2745,"_248":2746},"tag:#bladdercancer","#BLADDERCANCER","Is this the end of platinum-based chemo + immunotherapy in #bladdercancer? 🤔 What should we do with NIAGARA from now on? 😬 @OncoAlert @myESMO @OncoDailyGU #ESMO26","2026-10-23T11:58:44.000Z","2026-10-23T21:15:08.000Z",[],{"_264":2743,"_266":2738,"_267":268,"_269":2744,"_271":1939},"p0lyhfcj1zmqr6ddmx8e8p8cq","https://x.com/drenriquegrande/status/2113601012510716106","38009290-5ec7-49f1-b984-59b1ff92fd76","Is this the end of platinum-based chemo + immunotherapy in #bladdercancer",{"_272":2760,"_248":2761},"code:NADINA","NADINA","I expect various sellsiders will be firefighting $MRNA today, but that's a very measured take from Evercore ISI's Cory Kasimov. Good to see! #Esmo26","2026-10-22T22:56:17.000Z","2026-10-23T14:46:19.000Z",[2758],{"_264":2755,"_266":2750,"_267":268,"_269":2756,"_271":2757},"so7jmydr371i4g9xv14eqsw6q","https://x.com/JacobPlieth/status/2113643183993450941","JacobPlieth",{"_387":2291,"_19":398,"_248":2292,"_391":400,"_393":-5,"_394":2759,"_395":2294},[2295,2295,2295],"9a772238-6a7a-4537-bfa5-38eed6dfedaa","Kicking off #ESMO26 with the best colleagues and friends at the INMC meeting",{"_272":2773,"_248":2774},"code:LITESPARK-012","LITESPARK-012","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 First-Line Pembrolizumab + Lenvatinib + Belzutifan or MK-1308A + Lenvatinib in Advanced RCC: The Randomized Open-Label Phase 3 LITESPARK-012 Study @DrChoueiri @tompow","2026-10-21T12:00:58.000Z","2026-10-22T16:06:02.000Z",[],{"_264":2770,"_266":2771,"_267":268,"_269":2772,"_271":1026},"mmg7dina7xcuig60p0dkp5vwj","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 First-Line Pembrolizumab + Lenvatinib + Belzutifan or MK-1308A + Lenvatinib in Advanced RCC: The Randomized Open-Label Phase 3 LITESPARK-012 Study @DrChoueiri @tompowles1 @MVossMD @ERPlimackMD @HowardGurney @brian_rini 🔬 Phase 3 (n=1688), untreated advanced ccRCC: pembrolizumab + lenvatinib + belzutifan (Arm A) or MK-1308A + lenvatinib (Arm B) vs pembrolizumab + lenvatinib. Dual primary: PFS by BICR and OS. ➡️ Arm A: PFS HR 1.08 (0.93–1.26); OS HR 1.04 (0.87–1.25) ➡️ Arm B: PFS HR 1.07 (0.92–1.25); OS HR 1.12 (0.94–1.35) ➡️ Discontinuation due to AEs: 51.6% (A), 51.4% (B), 36.2% (control) ✅ Neither belzutifan nor CTLA-4 blockade added to pembrolizumab + lenvatinib improved efficacy; pembrolizumab + lenvatinib remains a 1L SOC. #KidneyCancer 🎙️ Toni Choueiri 👥 Thomas Powles · Martin Voss · Elizabeth Plimack · Howard Gurney · Yue Song · Rodolfo Perini · Karla Rodriguez-Lopez · Brian Rini (4Sight Made solely from Abstracts publicly available at the ESMO website) Pinging Our Faculty @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper","https://x.com/OncoAlert/status/2112876795540148541","87f0a315-bcc4-4060-8446-e8d311061285","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 First-Line Pembrolizumab + Lenva",{"_272":2787,"_248":2788},"code:AVA6103","AVA6103","We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechanistic evidence for fibroblast recruitment, rapid and deep tumor penetration and e","2026-10-23T06:05:32.000Z","2026-10-24T11:23:52.000Z",[],{"_264":2783,"_266":2784,"_267":268,"_269":2785,"_271":2786},"f8698sec9zsqz2kfwarziepvo","We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechanistic evidence for fibroblast recruitment, rapid and deep tumor penetration and enhanced payload exposure over traditional ADC #LetsDoThis","https://x.com/coughlin582/status/2113605727269146860","coughlin582","7a95e0a1-5ff2-4c0b-a5aa-ede5eedf6e37","We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechani",{"_272":2801,"_248":2802},"code:STARBOARD","STARBOARD","My top 🥈💎 #Melanoma #ESMO26 STARBOARD - Triplet therapy in BRAF V600 melanoma: enco + bini + pembro vs pembro alone in 1L. 💥 ORR: 70% vs 32.7% || mPFS: 33.0 vs 3.4 mo ▪️G3/4 TEAEs: 70% vs 39% OS: positive trend, but i","2026-10-23T14:26:52.000Z","2026-10-23T22:28:46.000Z",[2800],{"_264":2797,"_266":2798,"_267":268,"_269":2799,"_271":613},"juqug7dowgmhcxhxdsqr388nf","My top 🥈💎 #Melanoma #ESMO26 STARBOARD - Triplet therapy in BRAF V600 melanoma: enco + bini + pembro vs pembro alone in 1L. 💥 ORR: 70% vs 32.7% || mPFS: 33.0 vs 3.4 mo ▪️G3/4 TEAEs: 70% vs 39% OS: positive trend, but immature after early trial closure. Impressive PFS! But STARBOARD has not reached the OS shore yet⚓ @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma","https://x.com/MarioBalsaMD/status/2113651822715949170",{"_387":2089,"_19":398,"_248":2090,"_391":2091,"_393":-5,"_394":-5,"_395":2092},"eabdb807-62f2-4e02-b1f4-a451e386a7f7","My top 🥈💎 #Melanoma #ESMO26 STARBOARD - Triplet therapy in BRAF V600 melanoma: enco + bini + pembro vs pembro alone in 1L",{"_272":2815,"_248":2816},"code:TROFUSE-005","TROFUSE-005","🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH! From chemotherapy-free immunotherapy to next-generation ADCs, #ESMO26 could reshape gynaecological oncology! 🔥 My Top 10, by cancer subtype: 🔴 ENDOMETRIAL CANCER Tr","2026-10-22T06:38:47.000Z","2026-10-24T11:07:28.000Z",[],{"_264":2811,"_266":2812,"_267":268,"_269":2813,"_271":2814},"ngj3p9g1jcfjmgj1odvxjw4w9","🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH! From chemotherapy-free immunotherapy to next-generation ADCs, #ESMO26 could reshape gynaecological oncology! 🔥 My Top 10, by cancer subtype: 🔴 ENDOMETRIAL CANCER TroFuse-005 (LBA11) | Sacituzumab tirumotecan vs physician’s choice in recurrent/advanced disease. KEYNOTE-C93 (LBA12) | Pembrolizumab alone vs chemotherapy in 1L dMMR disease. Can we omit chemotherapy? NRG-GY020 (1239O) | Adjuvant radiotherapy ± pembrolizumab in early-stage dMMR disease. Sacituzumab tirumotecan + pembrolizumab (1259P) | ADC + immunotherapy in post-platinum pMMR disease. 🔵 OVARIAN CANCER BEHOLD-1 (LBA41) | Mocertatug rezetecan, a B7-H4 ADC, in platinum-resistant disease. REJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab in platinum-resistant disease. REJOICE-Ovarian01 (1331P) | Updated efficacy and safety of raludotatug deruxtecan. BEHOLD-1 biomarker analysis (1248RO) | Which biomarkers predict response to B7-H4 ADC therapy? 🟣 CERVICAL CANCER CALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs chemotherapy in recurrent/metastatic disease. EMPOWER-Cervical 1 (1250O) | Cemiplimab-based strategies and long-term outcomes. ⭐ My top 3 to watch: KEYNOTE-C93 | TroFuse-005 | BEHOLD-1 Which trial has the greatest potential to change your practice? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #GynOnc #Oncology","https://x.com/DrRishabhOnco/status/2113566049102889208","DrRishabhOnco","893b0fd5-84e2-4e0e-bd5e-8962ed8e3da5","🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH",{"_272":2841,"_248":2842},"code:UNION","UNION","Floor (3530O): UNION phase 3. Locally advanced rectal cancer, n=231. SCRT → CAPOX plus camrelizumab → TME vs long-course CRT → CAPOX → TME. 3-year EFS 91.3% vs 77.4%, HR 0.33 (0.15–0.71), P=0.0029. RT schedule and IO both changed, so the readout does not isolate either one.","2026-10-18T23:00:37.000Z","2026-10-23T12:17:00.000Z",[2834,2835],{"_2830":2831,"_2832":-5},{"_264":2826,"_266":2827,"_267":268,"_269":2828,"_271":2829},"q55pt2c1ljyq3tfp457qtm58y","🚨UNION Trial🚨 Locally advanced rectal cancer N=231 🔍Randomized 🔵Chemoradiation➡️2c CAPOX➡️TME➡️6c CAPOX 🟢SCRT➡️2c CAPOX + camrelizumab ➡️TME➡️6c CAPOX+ cam 🔥SCRT + chemo-IO demonstrated a whopping difference in EFS, 91% vs. 77%!!! #ESMO26","https://x.com/KrishanJethwa/status/2113390661793677605","KrishanJethwa","paragraphs",[2820,2833],"directionLabel","Journal skeleton: UNION's earlier pCR readout is in Ann Oncol 2024. This meeting is the prespecified EFS analysis.",{"_387":2839,"_19":398,"_248":2819,"_391":2837,"_393":-5,"_394":2840,"_395":2819},{"_387":2836,"_19":398,"_248":2819,"_391":2837,"_393":-5,"_394":2838,"_395":2819},"NCT04928807","https://clinicaltrials.gov/study/NCT04928807",[2836],"3530O",[2836],"892e8d5e-1d74-4380-842f-96ffe3827f63","🚨UNION Trial🚨 🚨UNION Trial🚨 Locally advanced rectal cancer N=231 🔍Randomized 🔵Chemoradiation➡️2c CAPOX➡️TME➡️6c CAPOX 🟢SCRT➡️2c CAPOX",{"_272":2857,"_248":2858},"code:ARION","ARION","Floor (2879RO): ARION randomised phase 2. Locally advanced esophageal cancer (77% SCC), definitive CRT ± durvalumab. n=112. Centrally reviewed PFS HR 0.91 (0.55–1.49), P=0.351; OS HR 0.99 (0.59–1.68), P=0.489. Negative.","2026-10-22T21:50:53.000Z","2026-10-23T15:24:31.000Z",[2856],{"_2830":2855,"_2832":-5},{"_264":2852,"_266":2853,"_267":268,"_269":2854,"_271":2829},"g16jovcizzp286wz631jpogh0","🚨ARION PRODIGE 67🚨 Locally Advanced Esophagus Cancer (adeno or squam) n=112 Randomized CRT (50 Gy/25 Fx + FOLFOX) +/- concurrent and adjuvant durvalumab (total 12 m) No SS differences in: PFS 48% vs. 50% OS 68% vs. 75% #ESMO26","https://x.com/KrishanJethwa/status/2113387641013936310",[2846],{"_387":2614,"_19":398,"_248":2615,"_391":392,"_393":-5,"_394":-5,"_395":396},"e52b0dc5-7685-4abe-bd7c-a037d0b19341","🚨ARION PRODIGE 67🚨 🚨ARION PRODIGE 67🚨 Locally Advanced Esophagus Cancer (adeno or squam) n=112 Randomized CRT (50 Gy/25 Fx + FOLFOX) +/-",{"_272":2871,"_248":2872},"code:GY020","GY020","GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone. Leaving study counted as failure. KM RFS numerically favored pembro, but CI crossed 1. G3/4 toxicity 43% vs 15%. RT alone remains my de","2026-10-22T23:04:05.000Z","2026-10-24T20:09:05.000Z",[2870],{"_264":2867,"_266":2868,"_267":268,"_269":2869,"_271":1426},"jfe170t9t9tr86jlv5cl0pa1w","GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone. Leaving study counted as failure. KM RFS numerically favored pembro, but CI crossed 1. G3/4 toxicity 43% vs 15%. RT alone remains my default here. #ESMO26 #radonc https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/presentation/list?q=1239O","https://x.com/jryckman3/status/2113406063185658168",{"_387":1306,"_19":398,"_248":1307,"_391":1287,"_393":-5,"_394":-5,"_395":1288},"aacf0bd7-f5d5-4edb-982b-71d0aae6cd66","GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone",{"_272":2885,"_248":2886},"drug:deuderuxtecan","deuderuxtecan","APEX Breast01 TQB2102 (biapotropic ADC against HER2 with topo1 payload) Rolditamig Deuderuxtecan (TQB2102) vs TPC Chemo in HER2low MBC, no prior chemo (461 HR+, 81 TNBC) PFS HER2low: 16.4 vs 5.5 mo, HR 0.29 ILD 1.1% @Onc","2026-10-20T10:57:00.000Z","2026-10-23T18:09:01.000Z",[],{"_264":2881,"_266":2882,"_267":268,"_269":2883,"_271":2884},"ckixaekd5wjq31g3m9hh0rbvg","APEX Breast01 TQB2102 (biapotropic ADC against HER2 with topo1 payload) Rolditamig Deuderuxtecan (TQB2102) vs TPC Chemo in HER2low MBC, no prior chemo (461 HR+, 81 TNBC) PFS HER2low: 16.4 vs 5.5 mo, HR 0.29 ILD 1.1% @OncoAlert #ESMO2026","https://x.com/stolaney1/status/2113603452353798538","stolaney1","3cc428ae-905d-427b-8812-4847fba4a2ce","APEX Breast01 APEX Breast01 TQB2102 (biapotropic ADC against HER2 with topo1 payload) Rolditamig Deuderuxtecan (TQB2102) vs TPC Chemo in HER",{"_272":2902,"_248":2903},"code:KEYNOTE-365","KEYNOTE-365","Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0","2026-10-23T11:46:45.000Z","2026-10-24T13:30:07.000Z",[2898],{"_264":2895,"_266":2896,"_267":268,"_269":2897,"_271":300},"hlux2lrn8oz0jgzqstyo8vh2d","Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert","https://x.com/DrChoueiri/status/2113601390496915517",{"_387":2899,"_19":398,"_248":2900,"_391":1204,"_393":-5,"_394":2901,"_395":1206},"2217RO","Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)",[1207],"242467e2-4577-4b74-8815-198b3f1337d0","Encouraging OS results in neuroendocrine prostate cancer at #ESMO26",{"_272":2916,"_248":2917},"drug:tucatinib","tucatinib","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 BRIDGET: A Phase II Trial of Tucatinib Added to Trastuzumab/Pertuzumab or Ado-Trastuzumab Emtansine After Isolated Intracranial Progression in Patients With Advanced ","2026-10-10T00:40:00.000Z","2026-10-24T13:34:00.000Z",[2915],{"_264":2912,"_266":2913,"_267":268,"_269":2914,"_271":1026},"zge51i0wavyusj7cr0dfwvjy9","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 BRIDGET: A Phase II Trial of Tucatinib Added to Trastuzumab/Pertuzumab or Ado-Trastuzumab Emtansine After Isolated Intracranial Progression in Patients With Advanced HER2-Positive Breast Cancer @drsarahsam @DrVanSwearingen @rashmikmurthy @CareyAnders1 🔬 Single-arm phase II (47 evaluable): tucatinib added to ongoing HP or T-DM1 after SRS for isolated intracranial progression in HER2+ MBC. Primary endpoint: iPFS (RANO-BM). ➡️ Median iPFS not reached; p<0.0001 vs historical median of 5 mo ➡️ iPFS 91% at 6 mo, 64% at 12 mo, 59% at 18 mo ➡️ Grade ≥3 AEs 15%; extracranial progression 4.3% ✅ Adding tucatinib to HP after radiation met the primary endpoint, with more than half of patients free of intracranial progression at 18 months. #BreastCancer 🎙️ Sarah Sammons 👥 Amanda Van Swearingen · Laura Noteware · Nusayba Bagegni · Kelly Moulton · Stevie Threatt · Denise Jaggers · Shannon Shea · Eric Lipp · Erin Riley · Sin-Ho Jung · Gloria Broadwater · Masey Ross · Kimberly Strickland · Sasha Beyer · Alison Conlin · Aki Morikawa · Rashmi Murthy · Carey Anders (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76","https://x.com/OncoAlert/status/2113208953446232179",{"_387":1245,"_19":398,"_248":1246,"_391":1247,"_393":-5,"_394":-5,"_395":1248},"0a014b45-87c9-463e-8f9b-9fe0b54dd076","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 BRIDGET: A Phase II Trial of Tuc",{"_272":2929,"_248":2930},"code:DELLPHI-304","DELLPHI-304","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 DeLLphi-304 Trial @charlesrudin @g_mountzios @cbcbc1971 @JulienMazieres","2026-10-22T13:01:24.000Z","2026-10-24T07:07:49.000Z",[],{"_264":2926,"_266":2927,"_267":268,"_269":2928,"_271":1026},"kn869jm7og55m9pw1nnwzit8h","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 DeLLphi-304 Trial @charlesrudin @g_mountzios @cbcbc1971 @JulienMazieres @teekayowo @LuisPaz_Ares 🫁 Phase 3 (n=509): tarlatamab vs chemotherapy (topotecan, lurbinectedin or amrubicin) in SCLC after first-line platinum-based chemotherapy. Primary endpoint: OS; median follow-up 23 mo. ➡️ Median OS 13.6 vs 8.4 mo; HR 0.62 (0.51–0.76); 18-mo OS 42% vs 24% ➡️ Baseline brain metastases subgroup: OS HR 0.52 (0.38–0.70) ➡️ Grade ≥3 TRAEs 28% vs 63% ✅ Durable survival benefit with a manageable safety profile and no new safety signals, reinforcing tarlatamab as standard of care after first-line platinum-based chemotherapy. #LungCancer #SCLC 🎙️ Charles Rudin 👥 Giannis Mountzios · Longhua Sun · Byoung Chul Cho · Umut Demirci · Sofia Baka · Mahmut Gümüş · Antonio Lugini · Bo Zhu · Yan Yu · Ippokratis Korantzis · Ji-Youn Han · Tudor-Eliade Ciuleanu · Myung-Ju Ahn · Pedro Rocha · Julien Mazières · Sally Lau · Martin Schuler · Fiona Blackhall · Tatsuya Yoshida · Taofeek Owonikoko · Luis Paz-Ares · Tony Jiang · Ali Hamidi · Diana Gauto · Gonzalo Recondo (4Sight Made from Abstracts publicly available at the ESMO website) Pinging our faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers","https://x.com/OncoAlert/status/2113254395777327329","9fae653c-545c-41ad-a90c-7196984bd3cf","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Tarlatamab in Previously Treated",{"_272":2944,"_248":2945},"code:DESTINY-BREAST11","DESTINY-BREAST11","#ESMO26 | DESTINY-Breast11 MRI Analysis At cycle 4, ORR was 77.3% in the T-DXd→THP arm vs 50.8% in the ddAC→THP arm. Among patients who achieved CR, PR, or no objective response on MRI after 4 cycles of T-DXd, pCR was ac","2026-10-14T11:13:00.000Z","2026-10-24T14:12:42.000Z",[2943],{"_264":2939,"_266":2940,"_267":268,"_269":2941,"_271":2942},"zp9rors4s4jjlvz9pqzpj579q","#ESMO26 | DESTINY-Breast11 MRI Analysis At cycle 4, ORR was 77.3% in the T-DXd→THP arm vs 50.8% in the ddAC→THP arm. Among patients who achieved CR, PR, or no objective response on MRI after 4 cycles of T-DXd, pCR was achieved in 90%, 67%, and 54%, respectively, after completion of THP. These data show that early MRI response does not reliably predict pCR. Serial MRI response data from the T-DXd monotherapy arm are not included in the abstract. I hope they will be presented during the session. These data will be important for individualizing the duration of neoadjuvant treatment based on response.","https://x.com/dr_yakupergun/status/2112097446469767592","dr_yakupergun",{"_387":1240,"_19":398,"_248":1241,"_391":1187,"_393":-5,"_394":-5,"_395":1188},"071f4219-afe0-4454-a62b-15bdd235a848","#ESMO26 | DESTINY-Breast11 MRI Analysis At cycle 4, ORR was 77",{"_272":2958,"_248":2959},"code:ELI-002","ELI-002","$ELTX: One of our #ESMO2026 watchlist catalysts just reported. Phase 2 ELI-002 7P pancreatic cancer update: • Primary DFS endpoint misse already disclosed in June. • New subgroup data: DFS HR 0.51 in ctDNA-negative patie","2026-10-23T13:03:27.000Z","2026-10-24T15:25:54.000Z",[],{"_264":2954,"_266":2955,"_267":268,"_269":2956,"_271":2957},"uymukguincf71f9o3m004z125","$ELTX: One of our #ESMO2026 watchlist catalysts just reported. Phase 2 ELI-002 7P pancreatic cancer update: • Primary DFS endpoint misse already disclosed in June. • New subgroup data: DFS HR 0.51 in ctDNA-negative patients; 0.57 in ctDNA-positive patients. 📊Shares pared earlier losses to −1.5% Our pre-ESMO Prob/Mag scenarios below 👇 Next watch: Phase 3 development plans.","https://x.com/BiopharmIQ/status/2113666444835651691","BiopharmIQ","940c1779-6273-4726-bef5-2a2247971326","$ELTX: One of our #ESMO2026 watchlist catalysts just reported",{"_272":2973,"_248":2974},"drug:tavatecan","tavatecan","G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis #ESMO26 #ESMOAmbassadors 🇨🇳🇯🇵, 2600 prescreened, 430 included 👉ORR: 37 vs 7.7% 👉 mPFS: 7.1 vs 3.1 mo 👉 mOS: 10.2 vs","2026-10-23T11:39:36.000Z","2026-10-24T06:59:07.000Z",[2971],{"_264":2968,"_266":2969,"_267":268,"_269":2970,"_271":2075},"dqe0qcebhr0obgt600luxd32a","G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis #ESMO26 #ESMOAmbassadors 🇨🇳🇯🇵, 2600 prescreened, 430 included 👉ORR: 37 vs 7.7% 👉 mPFS: 7.1 vs 3.1 mo 👉 mOS: 10.2 vs 6.9 mo 🧐CLDN-2 ADC, strong signal of efficacy, acceptable safety @myESMO @ASCO","https://x.com/ArndtVogel/status/2113596197877195234",{"_387":249,"_19":389,"_248":2972,"_391":2693,"_393":-5,"_394":-5,"_395":2694},"Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G","1a98dc0d-0e15-4687-b8d2-323a92544fa2","G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis G-HOPE-001 phs-3: Arcotatug tavatecan vs T",{"_272":2988,"_248":2989},"code:DESTINY-BREAST05","DESTINY-BREAST05","DESTINY-Breast05: PROs at #ESMO26 HRQoL was largely maintained with both T-DXd and T-DM1 in high-risk HER2+ early breast cancer with residual invasive disease. @OncoAlert #BCSM #BreastCancer","2026-10-09T09:40:00.000Z","2026-10-24T17:03:29.000Z",[2985],{"_264":2983,"_266":2978,"_267":268,"_269":2984,"_271":2032},"rvfqu8i0o4201vz90ulyjqcdg","https://x.com/Dr_Oncologista/status/2113649521402015942",{"_387":2986,"_19":398,"_248":2987,"_391":1187,"_393":-5,"_394":-5,"_395":1188},"539RO","Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)","94e6e5e6-9d1c-4949-9002-1720d8ddd282","DESTINY-Breast05: PROs at #ESMO26 DESTINY-Breast05: PROs at #ESMO26 HRQoL was largely maintained with both T-DXd and T-DM1 in high-risk HER2",{"_272":3002,"_248":3003},"drug:talazoparib","talazoparib","Bienvenidos a Madrid para #ESMO26 🎥 Nueva Educational Capsule | @GuardConsortium 🇪🇸 TALAPRO-3: ¿Un nuevo paso para los PARP inhibitors en prostate cancer hormonosensible? Dr. Joaquín Mateo (@quimmateo) from @VHIO in B","2026-10-24T14:00:33.000Z",[3000],{"_264":2997,"_266":2998,"_267":268,"_269":2999,"_271":1026},"u1ls36pwnn9gqbag86m4qgwh4","Bienvenidos a Madrid para #ESMO26 🎥 Nueva Educational Capsule | @GuardConsortium 🇪🇸 TALAPRO-3: ¿Un nuevo paso para los PARP inhibitors en prostate cancer hormonosensible? Dr. Joaquín Mateo (@quimmateo) from @VHIO in Barcelona breaks down the TALAPRO-3 trial, presented at ASCO 2026 and published in the New England Journal of Medicine, alongside @AzadOncology, @neerajaiims and colleagues. 🧬 What did TALAPRO-3 show? This phase 3 trial evaluated talazoparib + enzalutamide versus placebo + enzalutamide in patients with HRR-altered metastatic hormone-sensitive prostate cancer (mHSPC). 🔹 599 patients enrolled across both treatment arms. 🔹 Radiographic progression-free survival (rPFS) at 3 years: 77% vs. 56% (HR 0.48; 95% CI 0.36–0.65; p<0.001). 🔹 Overall survival (OS): 78% vs. 72% at 3 years in the interim analysis (HR 0.77; 95% CI 0.56–1.04). OS data remain immature. 🔹 Safety matters: Grade ≥3 anemia occurred in 51% of patients receiving talazoparib. 💡 La gran pregunta: ¿Estamos ante un cambio en el papel de los PARP inhibitors, moving them earlier into the hormone-sensitive setting? Watch Dr. Mateo’s analysis and join the conversation. 👇 🔗 https://nejm.org/doi/full/10.1056/NEJMoa2604126?referrer=https%3A%2F%2Fwww.google.com%2F #GuardConsortium #TALAPRO3 #ProstateCancer #ASCO2026 GU Oncology colleagues: @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @OncBrothers @Helena_de_Palma @DrIacovelli @mjuanfi81 OncoALert faculty: @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @AndreaNecchi @scocmem","https://x.com/OncoAlert/status/2113564356210245960",{"_387":1208,"_19":398,"_248":1209,"_391":1204,"_393":-5,"_394":3001,"_395":1206},[1207],"4e1738f5-f82c-4a60-b721-6d8fdd71411e","Bienvenidos a Madrid para #ESMO26 Bienvenidos a Madrid para #ESMO26 🎥 Nueva Educational Capsule | @GuardConsortium 🇪🇸 TALAPRO-3: ¿Un nuev",{"_272":3025,"_248":3026},"code:KEYNOTE-975","KEYNOTE-975","Floor (2875O): KEYNOTE-975 IA2. Unresectable locally advanced esophageal/GEJ cancer, pembrolizumab added to definitive CRT. EFS in CPS≥10: 15.2 vs 14.7 months, HR 0.97 (0.77–1.23), P=0.3994, negative. Hierarchy stopped; OS not formally tested. n=703.","2026-10-18T22:36:10.000Z","2026-10-24T22:55:20.000Z",[3017,3018],{"_2830":3016,"_2832":-5},{"_264":3013,"_266":3014,"_267":268,"_269":3015,"_271":2075},"uysa97zwjqp7jasxwqgbk7ivi","KEYNOTE-975 phs-3 study: Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in E/GEJ cancer #ESMO26 #ESMOAmbassadors 👉 mEFS: 15.2 vs 14.7 mo 👉 mOS: 32 vs 35 mo 🧐disappointing, no benefit in all & CPS>10 pts @myESMO @ASCO","https://x.com/ArndtVogel/status/2113600912883146920",[3007],{"_387":3023,"_19":398,"_248":3024,"_391":2693,"_393":-5,"_394":-5,"_395":2694},{"_387":3019,"_19":398,"_248":3020,"_391":3021,"_393":-5,"_394":3022,"_395":3020},"NCT04210115","- **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","https://clinicaltrials.gov/study/NCT04210115",[3019],"2875O","Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: The phase 3 randomized KEYNOTE-975 study","ce5373e3-ce15-480e-a89a-0ed4c42937b8","KEYNOTE-975 phs-3 study: Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in E/GEJ cancer KEYNOTE-975 phs-3 study: Pemb",{"_272":3044,"_248":3045},"code:KEYNOTE-905","KEYNOTE-905","Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph.III ad hoc analysis of cis-ineligible MIBC. 2-yr EFS: 75.8% EV/Pembro vs 55.8% Pembro vs 41.0% surgery alone. EFS HR 0.40 vs 0.71 (each vs control). ","2026-10-22T16:04:17.000Z","2026-10-23T21:13:56.000Z",[3038,3039],{"_264":3035,"_266":3036,"_267":268,"_269":3037,"_271":300},"i089ge7cftiubrk05p458u235","Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph.III ad hoc analysis of cis-ineligible MIBC. 2-yr EFS: 75.8% EV/Pembro vs 55.8% Pembro vs 41.0% surgery alone. EFS HR 0.40 vs 0.71 (each vs control). pCR 58.8% vs 25.3% vs 10.3%. #ESMO26 #BladderCancer @myESMO @OncoAlert","https://x.com/DrChoueiri/status/2113611550653022558",{"_387":1681,"_19":398,"_248":1682,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":3040,"_19":398,"_248":3041,"_391":3042,"_393":-5,"_394":3043,"_395":3041},"NCT03924895","- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","https://clinicaltrials.gov/study/NCT03924895",[3040],"cffe56eb-7123-4c1e-8ee6-aaddbee6d033","Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph",{"_272":3059,"_248":3060},"tag:#lcsm","#LCSM","Getting ready for @myesmo #ESMO26? Here are the top ten #LCSM presentations by @oncoalert @SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert ",26,"2026-10-21T11:08:49.000Z","2026-10-24T15:53:33.000Z",[],{"_264":3055,"_266":3056,"_267":268,"_269":3057,"_271":3058},"zsf69sjmia098gcvejfoeww4f","Getting ready for @myesmo #ESMO26? Here are the top ten #LCSM presentations by @oncoalert @SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen","https://x.com/GlopesMd/status/2112863672980619411","GlopesMd","5511de82-01d8-4fc0-bdb8-05408eb8f1ab","Getting ready for @myesmo #ESMO26",{"_272":3079,"_248":3080},"code:MASTERPLAN","MASTERPLAN","Floor: MASTERPLAN phase 2. High-risk operable / borderline / locally advanced pancreas, chemo ± pancreatic SBRT 40 Gy/5 fx. n=74. 12-month locoregional recurrence 52.0% vs 20.2% (P=0.022); mPFS 6.3 vs 11.9 months (P=0.002); OS 14 vs 22 months (P=0.006). HRs not reported. Secondary signals, not definitive OS evidence.",11,"2026-10-22T21:55:49.000Z","2026-10-24T10:59:20.000Z",[3076],{"_2830":3075,"_2832":-5},{"_264":3071,"_266":3072,"_267":268,"_269":3073,"_271":3074},"m8fbwsgyc023y4fitddnoyzew","🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - https://www.thelancet.com/journals/lanonc/article/S1470-2045(26)00532-2/fulltext","https://x.com/_ShankarSiva/status/2113653564354539854","_ShankarSiva",[3064],{"_387":3077,"_19":398,"_248":3078,"_391":392,"_393":-5,"_394":-5,"_395":396},"3136RO","Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial","e4cf20d6-7d15-46c3-804c-7769ce5c4021","🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️",{"_272":3093,"_248":3094},"code:HERIZON-GEA","HERIZON-GEA","🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 1) Arcotatug tavatecan improved PFS in CLDN18.2+ G/GEJA in the 3L+ setting 2) SANO trial, OS at 5 years similar between active surveillance and surgery in patients ","2026-10-23T03:16:15.000Z",[3092],{"_264":3088,"_266":3089,"_267":268,"_269":3090,"_271":3091},"j8lest4uk0olbn6sct2soaein","🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 1) Arcotatug tavatecan improved PFS in CLDN18.2+ G/GEJA in the 3L+ setting 2) SANO trial, OS at 5 years similar between active surveillance and surgery in patients with oesophageal cancer and a complete clinical response after nCR, despite more distant metastasis 3) Adding pembrolizumab to dCRT did not improve EFS in untreated unresectable esophageal or GEJ cancer with PD-L1 CPS ≥10 4) Daraxonrasib demonstrated consistent OS benefit in different RAS mutatin subgroups in RASolute-302 5) mKRAS-specific lymph node targeted amphiphile immunotherapy in PDAC did not met primary DFS endpoint. 6) Zani + CT +/- tisle keep OS benefit in at IA2 of HERIZON-GEA-01 7) Anbenitamab plus ChT improved OS in patients with HER2-positive GC/GEJC adenoca after previous trastuzumab 8) TQB2102 (HER2 bispecific antibody-drug conjugate) plus bemotrizumab and capecitabine demonstrates promising antitumor activity in 1L of advanced GC/GEJC 9) Dostarlimab in Pts with localized dMMR/MSI-H GEA led to a 62.5% 1y-cCR at the first interim analysis, enabling organ preservation. 10) FOLFIRI and Ram vs paclitaxel in taxan-pretreated GEA imporved PFS but no OS 11) Stage II–IIIB gastric cancer after D2 resection, four months of adjuvant XELOX was noninferior to six months for 3-year DFS 12) Adding durvalumab to dCRT in locally advanced esophagus carcinoma did not improve PFS 13) Adding SBRT to MFOLFIRINOX in high risk, borderline resectable or locally advanced pancreatic cancer mproved LRR and PFS 14) FGFR2b expressing GC/GEJ with co-existing FGFR2 amp may define a biologically distinct subset with potential sensitivity to bemarituzumab #cancer #oncology #MedX #GI #gastrointestinal @OncoAlert","https://x.com/Erman_Akkus/status/2113505152879546834","Erman_Akkus",{"_387":388,"_19":389,"_248":390,"_391":392,"_393":-5,"_394":-5,"_395":396},"693d12ff-5290-4d92-816d-c45fe2da647f","🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 1) Arcotatug tavatecan impro",{"_272":3113,"_248":3114},"gene:MET","MET","Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26 ! 👏 Ph3, n=653 cis-eligible MIBC: neoadj GC + nivo → adj nivo vs GC alone. Median f/u 54.5 mo. 🔹 pCR 39.1% vs 29.6%: not dig 🔹 EFS HR 0","2026-10-22T13:46:00.000Z","2026-10-24T15:32:43.000Z",[3107,3108],{"_264":3103,"_266":3104,"_267":268,"_269":3105,"_271":3106},"y2bjwcxrnyfuu1eteicr9v6ol","Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26 ! 👏 Ph3, n=653 cis-eligible MIBC: neoadj GC + nivo → adj nivo vs GC alone. Median f/u 54.5 mo. 🔹 pCR 39.1% vs 29.6%: not dig 🔹 EFS HR 0.94: co-primaries not met 🔹 OS HR 0.88 👉Negative trial, but the ctDNA data are a key message: detectable ctDNA at baseline and after NAC strongly prognostic for worse EFS & OS. Selecting patients by ctDNA, rather than adding IO for all, is where the field is heading! Great to see this build on our Ph2 BLASST-1. Despite the negative result, it's very practice-informing. Proud to be a part of this effort! @CleClinicMD @caseccc @CleClinicUro @sonpavde @MattGalsky @MichvdHeijden @Uromigos @Annals_Oncology @tompowles1","https://x.com/shilpaonc/status/2113611608068874349","shilpaonc",{"_387":3110,"_19":398,"_248":3111,"_391":400,"_393":-5,"_394":-5,"_395":3112},{"_387":2439,"_19":398,"_248":2440,"_391":2441,"_393":-5,"_394":3109,"_395":2440},[2439],"1017P","Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","Developmental therapeutics","0c236e06-f08f-4e9b-bed3-4d1ddc39e2f2","Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26",{"_272":3136,"_248":3137},"gene:BRAF","BRAF","#ESMO26 Abstracts Are Out! In our meta-analysis with the @OncBrothers (Rohit and Rahul), we compared first-line BRAF/MEK inhibitors with ICI-based regimens in BRAF V600E-mutant aNSCLC. Among 589 patients, BRAF/MEKis achi","2026-10-18T22:59:41.000Z","2026-10-24T19:01:40.000Z",[3126,3127,3128,3129,3130,3131],{"_264":3123,"_266":3124,"_267":268,"_269":3125,"_271":2942},"ytqloaoageyk7v3r8jsb6ywg8","#ESMO26 Abstracts Are Out! In our meta-analysis with the @OncBrothers (Rohit and Rahul), we compared first-line BRAF/MEK inhibitors with ICI-based regimens in BRAF V600E-mutant aNSCLC. Among 589 patients, BRAF/MEKis achieved higher response rates (61% vs 48%), with no differences in PFS or OS👇","https://x.com/dr_yakupergun/status/2111955405093872029",{"_387":2089,"_19":398,"_248":2090,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":2291,"_19":398,"_248":2292,"_391":400,"_393":-5,"_394":3135,"_395":2294},{"_387":1741,"_19":398,"_248":2088,"_391":1958,"_393":-5,"_394":-5,"_395":1959},{"_387":1180,"_19":398,"_248":1181,"_391":400,"_393":-5,"_394":3134,"_395":1183},{"_387":2084,"_19":398,"_248":2085,"_391":2086,"_393":-5,"_394":3133,"_395":2085},{"_387":2080,"_19":398,"_248":2081,"_391":2082,"_393":-5,"_394":3132,"_395":2081},[2080],[2084],[1184,1184,1184],[2295,2295,2295],"49d62ca0-d986-4026-9c3c-17f432799aac","#ESMO26 Abstracts Are Out",{"_272":3157,"_248":3158},"gene:KRAS","KRAS","A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers. MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #ESMO26. The v","2026-10-21T13:48:56.000Z","2026-10-24T21:19:29.000Z",[3149,3150,3151],{"_264":3146,"_266":3147,"_267":268,"_269":3148,"_271":2278},"apsmt9u4axjmbblq0cvyfhb4b","A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers. MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #ESMO26. The vaccine targets KRAS mutations, which are found in more than 90% of pancreatic cancers. 99% of patients receiving the vaccine developed cancer-fighting immune T cells. Patients with the strongest immune responses had the lowest recurrence rates. “Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” says Dr. O’Reilly. “This gives hope for people with pancreatic cancer who have been out of effective treatments when their disease returns.” Learn more: https://bit.ly/3VSsO3h","https://x.com/MSKCancerCenter/status/2113699507502281212",{"_387":3153,"_19":398,"_248":3154,"_391":400,"_393":-5,"_394":3155,"_395":3112},{"_387":2114,"_19":398,"_248":2115,"_391":400,"_393":-5,"_394":3152,"_395":2117},{"_387":1494,"_19":398,"_248":1495,"_391":400,"_393":-5,"_394":-5,"_395":621},[2118,2118,2118],"1039P","Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study",[3156,3156,3156],"NCT05067283","39cfb6e5-9810-44ad-86b0-5235b829a9e4","#ESMO26 Our trial of the #KRAS vaccine 💉presented today alongside concurrent publication in @NatureMedicine",{"_272":3170,"_248":3171},"tag:#breastcancer","#BREASTCANCER","NSABP B-42 (15-year data): #ESMO26 Extended letrozole reduces distant recurrence, but without a significant OS benefit. 🔹 Node-positive: 4.4% absolute benefit 🔹 Node-negative: 1.6% (not statistically significant) @Onco","2026-10-21T09:00:31.000Z","2026-10-24T08:35:39.000Z",[],{"_264":3167,"_266":3168,"_267":268,"_269":3169,"_271":2032},"x3bevzk62e3yyop0796fw9fbq","NSABP B-42 (15-year data): #ESMO26 Extended letrozole reduces distant recurrence, but without a significant OS benefit. 🔹 Node-positive: 4.4% absolute benefit 🔹 Node-negative: 1.6% (not statistically significant) @OncoAlert #BreastCancer #bcsm","https://x.com/Dr_Oncologista/status/2113618945060073853","a55ef582-e9d7-4c6f-a932-9125a06b6ff5","NSABP B-42 (15-year data): #ESMO26 NSABP B-42 (15-year data): #ESMO26 Extended letrozole reduces distant recurrence, but without a significa",{"_272":3185,"_248":3186},"code:APEX-BREAST01","APEX-BREAST01","APEX-Breast01: #ESMO26 TQB2102 Delivers a Substantial PFS Benefit in HER2-Low Metastatic Breast Cancer, With OS and Long-Term Safety Still to Mature @OncoAlert #BreastCancer #Bcsm","2026-10-20T12:40:00.000Z","2026-10-24T09:34:00.000Z",[3182],{"_264":3180,"_266":3175,"_267":268,"_269":3181,"_271":2032},"v11l76obv4xc8of0rszf3a2p9","https://x.com/Dr_Oncologista/status/2113607208344727916",{"_387":3183,"_19":389,"_248":3184,"_391":702,"_393":-5,"_394":-5,"_395":703},"LBA27","APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study","57906bb7-3f25-41f7-bb0c-bc8c03a249dd","APEX-Breast01: #ESMO26 APEX-Breast01: #ESMO26 TQB2102 Delivers a Substantial PFS Benefit in HER2-Low Metastatic Breast Cancer, With OS and L",{"_272":3202,"_248":3203},"code:SANO","SANO","🚨SANO 5y: surveillance vs surgery after cCR OS 50% vs 54% (NS) Distant mets 46% vs 29% (P<.01) Reminder: only 41.4 Gy/23 fx, a pre-op, arguably non-definitive dose, especially with/ ~75% adenocarcinoma. Nonsignificant O",16,"2026-10-22T22:42:42.000Z","2026-10-24T17:14:02.000Z",[3199],{"_264":3196,"_266":3197,"_267":268,"_269":3198,"_271":1426},"ilyta7tipxm6cng879fi8mtwv","🚨SANO 5y: surveillance vs surgery after cCR OS 50% vs 54% (NS) Distant mets 46% vs 29% (P<.01) Reminder: only 41.4 Gy/23 fx, a pre-op, arguably non-definitive dose, especially with/ ~75% adenocarcinoma. Nonsignificant OS doesn't establish noninferiority. #ESMO26 #RadOnc #OncTwitter","https://x.com/jryckman3/status/2113400682065891547",{"_387":3200,"_19":389,"_248":3201,"_391":2693,"_393":-5,"_394":-5,"_395":2694},"LBA78","Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: Long-term results of a cluster-randomised controlled trial (SANO)","e067b758-4d3d-49c5-b626-bb6a7f204d1c","🚨SANO 5y: surveillance vs surgery after cCR 🚨SANO 5y: surveillance vs surgery after cCR OS 50% vs 54% (NS) Distant mets 46% vs 29% (P<",{"_272":3223,"_248":3224},"drug:docetaxel","docetaxel","ABBV-969 dual-targeting ADC #ESMO26 MOA = PSMA/STEAP1— TOPO1 Deep responses in metastatic castration-resistant prostate cancer Surely this one can beat Docetaxel?","2026-10-22T11:00:33.000Z","2026-10-24T20:19:45.000Z",[3215,3216,3217],{"_264":3212,"_266":3207,"_267":268,"_269":3213,"_271":3214},"wm7w1bm9epny83cslvjvj7r4x","https://x.com/tompowles1/status/2113682217134080012","tompowles1",{"_387":1350,"_19":398,"_248":1351,"_391":400,"_393":-5,"_394":3222,"_395":496},{"_387":2481,"_19":389,"_248":2482,"_391":1100,"_393":-5,"_394":-5,"_395":1101},{"_387":3218,"_19":398,"_248":3219,"_391":3220,"_393":-5,"_394":3221,"_395":3219},"NCT04884282","- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","https://clinicaltrials.gov/study/NCT04884282",[3218],[1353,1353,1353],"8129e33d-8f84-44ed-b5f7-1959e20f76bd","ABBV-969 dual-targeting ADC #ESMO26 ABBV-969 dual-targeting ADC #ESMO26 MOA = PSMA/STEAP1— TOPO1 Deep responses in metastatic castration-res",{"_272":3239,"_248":3240},"code:HORIZON-BREAST06","HORIZON-BREAST06","HORIZON-Breast06: Trastuzumab Rezetecan in HER2-Low Metastatic #BreastCancer — A Major PFS Benefit, With OS and Long-Term Safety Requiring Further Follow-Up @OncoAlert #ESMO26 @myESMO #Bcsm",17,"2026-10-23T06:06:56.000Z","2026-10-24T08:40:00.000Z",[3236],{"_264":3234,"_266":3228,"_267":268,"_269":3235,"_271":2032},"yzwgwq4y4uxuwkw2y19vp0so6","https://x.com/Dr_Oncologista/status/2113603145678888996",{"_387":3237,"_19":389,"_248":3238,"_391":702,"_393":-5,"_394":-5,"_395":703},"LBA13","Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)","7a641e6b-afd6-47e2-b1bb-c773bf4a33aa","HORIZON-Breast06: HORIZON-Breast06: Trastuzumab Rezetecan in HER2-Low Metastatic #BreastCancer — A Major PFS Benefit, With OS and Long-Term ",{"_272":3258,"_248":3259},"code:KEYNOTE-B15","KEYNOTE-B15","ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC. ctDNA clearance 82.1% vs 66.7%. Post-surgery ctDNA+ 4.8% vs 13.5%. EFS benefit with EV/Pembro across base","2026-10-22T12:25:02.000Z","2026-10-24T22:56:08.000Z",[3252,3253],{"_264":3249,"_266":3250,"_267":268,"_269":3251,"_271":300},"n3362ftkwg37bq2lph383j4gy","ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC. ctDNA clearance 82.1% vs 66.7%. Post-surgery ctDNA+ 4.8% vs 13.5%. EFS benefit with EV/Pembro across baseline ctDNA strata, exploratory ctDNA+ HR 0.54. #ESMO26 #BladderCancer @myESMO @OncoAlert","https://x.com/DrChoueiri/status/2113615213631058231",{"_387":1191,"_19":398,"_248":1192,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":3254,"_19":398,"_248":3255,"_391":3256,"_393":-5,"_394":3257,"_395":3255},"NCT04700124","- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","https://clinicaltrials.gov/study/NCT04700124",[3254],"366a571b-8033-4300-8f8c-abbcc746ff22","ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC",{"_272":3274,"_248":3275},"code:DASL-HICAP","DASL-HICAP","Floor (LBA4): DASL-HiCaP. Very-high-risk localized prostate cancer, darolutamide plus ADT with radiotherapy. Interim readout. NCT04136353. Wait for the slide numbers; the background does not yet have a full endpoint table.",22,"2026-10-17T21:42:01.000Z","2026-10-24T23:03:14.000Z",[],{"_2830":3273,"_2832":-5},{"_264":3270,"_266":3271,"_267":268,"_269":3272,"_271":2814},"cedyqubqvllu2kg5s7foli1mo","🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH! From perioperative immunotherapy and AR pathway intensification to HIF-2α inhibition and long-term survival updates, GU oncology is set for some major presentations at #ESMO26. Here are my Top 10, grouped by subspecialty. 👇 🔵 PROSTATE CANCER 1️⃣ DASL-HiCaP (LBA4) Can adding darolutamide to ADT + radiotherapy improve outcomes in very high-risk localized prostate cancer? 2️⃣ PROTEUS (LBA53) Perioperative apalutamide + ADT in high-risk localized prostate cancer. Important additional data from the PROTEUS programme. 3️⃣ CAPItello-281 (LBA56) Updated overall survival with capivasertib + abiraterone in PTEN-deficient mHSPC. Could AKT inhibition redefine biomarker-driven treatment? 4️⃣ PEACE-1 (2215O) Long-term survival outcomes with abiraterone-based treatment intensification in de novo metastatic castration-sensitive prostate cancer. 🟢 BLADDER / UROTHELIAL CANCER 5️⃣ VOLGA (LBA2) One of the biggest presentations at ESMO 2026! Can perioperative durvalumab ± tremelimumab with neoadjuvant enfortumab vedotin improve outcomes in cisplatin-ineligible muscle-invasive bladder cancer? 6️⃣ KEYNOTE-866 (4735O) Perioperative pembrolizumab + gemcitabine/cisplatin in cisplatin-eligible MIBC. Will the detailed results clarify the role of adding immunotherapy to conventional perioperative chemotherapy? 7️⃣ ENERGIZE / CA017-078 (4736O) Does adding perioperative nivolumab to cisplatin-based chemotherapy improve outcomes in MIBC? 🟠 RENAL CELL CARCINOMA 8️⃣ LITESPARK-011 (3587O) Belzutifan + lenvatinib versus cabozantinib following prior PD-(L)1 therapy in advanced RCC. Can a HIF-2α inhibitor combination improve treatment outcomes? 9️⃣ LITESPARK-012 (3586O) Belzutifan- or quavonlimab-containing regimens with pembrolizumab + lenvatinib in first-line advanced RCC. Important efficacy and safety data for next-generation combinations. 🔟 KEYNOTE-564 (3589RO) Final prespecified analysis of adjuvant pembrolizumab in clear-cell RCC. How durable is the benefit with extended follow-up? 🔬 ALSO ON MY RADAR • PE-PE: Perioperative immunotherapy in oligometastatic RCC • KEYNOTE-B15: ctDNA analysis in MIBC • TALAPRO-3: Molecular and patient-reported outcomes • NIAGARA: Molecular subtype analysis • SWOG S2200: Papillary RCC 🔥 THREE BIG QUESTIONS FOR ESMO 2026 🔹 Will perioperative treatment strategies redefine management of MIBC? 🔹 Can treatment intensification and biomarker selection improve prostate cancer outcomes? 🔹 Will HIF-2α combinations reshape advanced RCC treatment sequencing? 📌 Pre-congress watchlist. Not all trials are expected to report positive results. Which GU trial has the greatest potential to change your clinical practice? 👇 @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #GUOncology #ClinicalTrials #Oncology","https://x.com/DrRishabhOnco/status/2112521101825986695",[3263],"eaab3b14-d205-4901-a120-6f2390f26e44","🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH",{"_272":3292,"_248":3293},"code:PANKU-BREAST01","PANKU-BREAST01","Floor (LBA50, breast proffered paper 1, 23 Oct 14:35): PANKU-Breast01. Previously treated unresectable LA/M HR+/HER2− breast cancer, iza-bren (EGFR/HER3 bispecific ADC) vs physician's-choice chemo. mPFS 8.18 vs 4.01 months, HR 0.41 (0.33–0.53; P<0.0001); ORR 40.5% vs 20.2%; mDoR 6.93 vs 4.21 months; ILD 1.1% (grade 1–2 only); OS immature.","2026-10-20T10:12:54.000Z","2026-10-24T16:00:11.000Z",[3289],{"_2830":3288,"_2832":-5},{"_264":3285,"_266":3286,"_267":268,"_269":3287,"_271":1026},"nx9y5onuy5q7g57femtq54b9z","🚨 #ESMO26 Breast Cancer: Top Ten by @OncoAlert 🎗️ The abstracts our faculty flagged as must-know from MADRID🇪🇸 👇 1️⃣ PANKU-Breast01 (LBA50): iza-bren in HR+/HER2− mBC 2️⃣ FOURLIGHT-1 (1842O): atirmociclib + fulvestrant post-CDK4/6i 3️⃣ NATALEE (LBA25): 6-year OS for adjuvant ribociclib 4️⃣ APEX-Breast01 (LBA27): TQB2102 in HER2-low 5️⃣ KEYNOTE-B49 (LBA51): pembro + chemo in HR+/HER2− 6️⃣ HORIZON-Breast06 (LBA13): SHR-A1811 in HER2-low 7️⃣ POP-DURVA (LBA26): preop durvalumab in stage I TNBC 8️⃣ SWITCH (4RO): ADC target switching after prior ADC 9️⃣ postMONARCH (1RO): OS for abemaciclib + fulvestrant 🔟 DESTINY-Breast09 (LBA49): T-DXD + P with baseline brain mets #BreastCancer @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @double_whammied @maryam_lustberg @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @SirohiBhawna @jamecancerdoc @nataliagandur @acampsmalea @FernandoOnco @realbowtiedoc @Lucarecco @AmandaNizamMD @scocmem @MarioBalsaMD @Dr_Oncologista","https://x.com/OncoAlert/status/2112487214869295477",[3279],{"_387":3290,"_19":389,"_248":3291,"_391":702,"_393":-5,"_394":-5,"_395":703},"LBA50","PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)","40bceb8e-4726-4a32-8fdf-4c5af8f6cb96","🚨 #ESMO26 Breast Cancer: Top Ten by @OncoAlert 🎗️ The abstracts our faculty flagged as must-know from MADRID🇪🇸 👇 1️⃣ PANKU-Breast01 (LB",{"_272":3306,"_248":3307},"code:POSTMONARCH","POSTMONARCH","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 1RO: Final Overall Survival Analysis of postMONARCH: Abemaciclib Plus Fulvestrant After Progression on Prior CDK4/6 Inhibitor in HR+, HER2– Advanced Breast Cancer @Ka","2026-10-21T11:00:32.000Z","2026-10-24T21:39:36.000Z",[3305],{"_264":3302,"_266":3303,"_267":268,"_269":3304,"_271":1026},"cdpg9l08rfng9kntkvsoiokph","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 1RO: Final Overall Survival Analysis of postMONARCH: Abemaciclib Plus Fulvestrant After Progression on Prior CDK4/6 Inhibitor in HR+, HER2– Advanced Breast Cancer @KalinskyKevin @BianchiniGP @ErikaHamilton9 @DrSGraff @drsarahsam @MuozMateu 🔬 Phase 3, double-blind trial (n=368): abemaciclib or placebo plus fulvestrant in HR+, HER2– ABC after progression on prior CDK4/6i + ET. Final OS analysis. ➡️ Median OS 32.1 vs 24.6 mo; HR 0.80 (0.60–1.06); p=0.1145, statistical significance not reached ➡️ Updated PFS HR 0.78 (0.62–0.99); nominal p=0.0390 ➡️ Safety consistent with the established abemaciclib profile; no new signals ✅ Numerically longer median OS, not statistically significant. While absolute PFS benefit was modest, overall evidence supports considering abemaciclib-based treatment after disease progression on prior CDK4/6i + ET. #BreastCancer 🎙️ Kevin Kalinsky 👥 Giampaolo Bianchini · Erika Hamilton · Stephanie Graff · Kyong Hwa Park · Rinath Jeselsohn · Umut Demirci · Miguel Martin · Rachel Layman · Sara Hurvitz · Sarah Sammons · Peter Kaufman · Montserrat Muñoz · Jiun-I Lai · Holly Knoderer · Cynthia Sandoval · Aarti Chawla · Bastien Nguyen · Yanhong Zhou · Elizabeth Ravenberg · Lacey Litchfield · Lillian Smyth · Seth Wander (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista","https://x.com/OncoAlert/status/2112861589820891194",{"_387":1781,"_19":398,"_248":1782,"_391":1247,"_393":-5,"_394":-5,"_395":1248},"0fbd2577-0c77-4437-9ef1-b24ca091945f","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 1RO: Final Overall Survival Anal",{"_272":3332,"_248":3333},"drug:trastuzumab","trastuzumab","🧵 Presented at #ESMO26: Among patients with low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs physician’s choice of chemotherapy. Benefit was obs",27,"2026-10-24T07:12:02.000Z",[3320,3321,3322,3323,3324,3325,3326,3327],{"_264":3316,"_266":3317,"_267":268,"_269":3318,"_271":3319},"ruzdtlwzx9wx3r916a2fsk0ed","🧵 Presented at #ESMO26: Among patients with low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs physician’s choice of chemotherapy. Benefit was observed in both chemotherapy-naive patients and the overall population, supporting trastuzumab rezetecan as a potential treatment option in this setting. https://ja.ma/3Ub9qxU @myESMO","https://x.com/JAMA_current/status/2113631529142235384","JAMA_current",{"_387":1245,"_19":398,"_248":1246,"_391":1247,"_393":-5,"_394":-5,"_395":1248},{"_387":1242,"_19":398,"_248":1243,"_391":400,"_393":-5,"_394":-5,"_395":1244},{"_387":3330,"_19":398,"_248":3331,"_391":400,"_393":-5,"_394":-5,"_395":1244},{"_387":2504,"_19":398,"_248":2505,"_391":400,"_393":-5,"_394":-5,"_395":2506},{"_387":2986,"_19":398,"_248":2987,"_391":1187,"_393":-5,"_394":-5,"_395":1188},{"_387":1240,"_19":398,"_248":1241,"_391":1187,"_393":-5,"_394":-5,"_395":1188},{"_387":3237,"_19":389,"_248":3238,"_391":702,"_393":-5,"_394":-5,"_395":703},{"_387":3328,"_19":389,"_248":3329,"_391":1247,"_393":-5,"_394":-5,"_395":1248},"LBA17","HER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trial","1795TIP","A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide","a68accf4-c263-4977-9157-59cf9e4dfa7a","China keeps delivering new assets and studies, now in HER2+ gastric 🇨🇳 China keeps delivering new assets and studies, now in HER2+ gastric",{"_272":3350,"_248":3351},"code:FOURLIGHT-1","FOURLIGHT-1","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Efficacy and Safety of Atirmociclib + Fulvestrant in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer Who Progressed on Prior CDK4/6 Inhibitor in a Randomize","2026-10-21T14:01:40.000Z","2026-10-24T22:51:48.000Z",[3345,3346],{"_264":3342,"_266":3343,"_267":268,"_269":3344,"_271":1026},"wjms5nz0nsmlpl6l7ajh6vxcu","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Efficacy and Safety of Atirmociclib + Fulvestrant in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer Who Progressed on Prior CDK4/6 Inhibitor in a Randomized Phase 2 Study (FOURLIGHT-1) @antgiorda 🔬 Randomized phase 2 (n=263): atirmociclib + fulvestrant vs investigator’s choice (fulvestrant or everolimus + exemestane) in HR+/HER2– mBC after prior CDK4/6i. Primary: investigator-assessed PFS. ➡️ Median PFS 9.4 vs 6.6 mo; HR 0.60 (0.440–0.825); 1-sided p=0.0007 ➡️ ORR in patients with measurable disease: 19.3% vs 11.3%; CBR: 61.9% vs 46.0% ➡️ Atirmociclib discontinuation due to TRAEs: 4.0%; most common TRAE neutropenia (46.4%) ✅ First next-generation CDKi to show significant and clinically meaningful PFS improvement after prior CDK4/6i, with a manageable safety profile. #BreastCancer 🎙️ Antonio Giordano (4Sight Made from Abstracts publicly available at the ESMO website) @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76","https://x.com/OncoAlert/status/2112907173822972062",{"_387":2366,"_19":398,"_248":2367,"_391":1100,"_393":-5,"_394":-5,"_395":1101},{"_387":3347,"_19":398,"_248":3336,"_391":3348,"_393":-5,"_394":3349,"_395":3336},"NCT06105632","https://clinicaltrials.gov/study/NCT06105632",[3347],"9f61581b-d428-44c0-bbd1-f78a22ccba7b","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Efficacy and Safety of Atirmocic",{"_272":3366,"_248":3367},"code:KEYNOTE-866","KEYNOTE-866","KEYNOTE-866 did not show EFS not OS. Great presentation 👏🏼by Prof Jens Bedke #ESMO26 @OncoAlert @Uromigos @urotoday @Uroweb @DGUrologie @high5md","2026-10-21T15:01:30.000Z","2026-10-24T19:11:53.000Z",[3363],{"_264":3360,"_266":3355,"_267":268,"_269":3361,"_271":3362},"n5gnol8m1igwfd8oik82erqln","https://x.com/amerseburger/status/2113598642334691643","amerseburger",{"_387":3364,"_19":398,"_248":3365,"_391":1193,"_393":-5,"_394":-5,"_395":1194},"4735O","Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study","479512a1-1eab-4c58-bbe8-57e74617006f","KEYNOTE-866 did not show EFS not OS",{"_272":3382,"_248":3383},"drug:daraxonrasib","daraxonrasib","Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vo",31,34,"2026-10-24T11:38:59.000Z",[3381],{"_264":3377,"_266":3378,"_267":268,"_269":3379,"_271":3380},"mdw1gkd38xyfvcs4may7gq6x6","Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/ Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.","https://x.com/Aiims1742/status/2113594963795836982","Aiims1742",{"_387":1312,"_19":389,"_248":2695,"_391":2693,"_393":-5,"_394":-5,"_395":2694},"8a4a3564-0004-4148-bb6f-c97626ab30b0","Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 T",{"_272":3405,"_248":3406},"drug:nivolumab","nivolumab","So many hot drops leading up to #ESMO26. Not to be outdone by AZUR-1, CheckMate 8HW, or any of the other incredible IO breakthroughs, Chalabi comes out with the long-term NICHE-2 follow-up. In a word? Perfect. 111 patien",37,"2026-10-13T17:40:14.000Z","2026-10-24T17:21:49.000Z",[3397,3398,3399,3400,3401],{"_264":3393,"_266":3394,"_267":268,"_269":3395,"_271":3396},"zbv2671mqbvn3uj5tn11krzzs","So many hot drops leading up to #ESMO26. Not to be outdone by AZUR-1, CheckMate 8HW, or any of the other incredible IO breakthroughs, Chalabi comes out with the long-term NICHE-2 follow-up. In a word? Perfect. 111 patients with locally advanced dMMR colon cancer. Just 6 weeks of neoadjuvant nivolumab/ipilimumab followed by surgery. Zero recurrences. 100% overall survival at 5 years. And remember, these weren’t all low-risk tumors. Many had high-risk stage III disease. We’re curing patients with just weeks of immunotherapy. Now, can we avoid the surgery altogether? What a time to be treating GI cancers. @TheGutOncLab @OncoAlert @Onco_Nexus https://www.sciencedirect.com/science/article/pii/S0140673626016028","https://x.com/GIMedOnc/status/2113153087284097401","GIMedOnc",{"_387":2296,"_19":398,"_248":2297,"_391":400,"_393":-5,"_394":3404,"_395":2294},{"_387":2724,"_19":398,"_248":3403,"_391":1193,"_393":-5,"_394":-5,"_395":1194},{"_387":1887,"_19":398,"_248":1888,"_391":998,"_393":-5,"_394":-5,"_395":999},{"_387":2289,"_19":389,"_248":2290,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":3218,"_19":398,"_248":3219,"_391":3220,"_393":-5,"_394":3402,"_395":3219},[3218],"Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)",[2295,2295,2295],"ec738536-313b-47bb-9f6d-230df6c62dfa","So many hot drops leading up to #ESMO26",{"_272":3422,"_248":3423},"code:TALENT","TALENT","#ESMO26 | TALENT Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer: - T-DXd: 7% - T-DXd + anastrozole: 3% - T-DXd → chemotherapy: 9% We should remember that pCR is a limited surrogate endpoi",33,36,"2026-10-24T15:45:29.000Z",[3419],{"_264":3416,"_266":3417,"_267":268,"_269":3418,"_271":2942},"l8cmilenf6mhdm9kqkn9m855b","#ESMO26 | TALENT Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer: - T-DXd: 7% - T-DXd + anastrozole: 3% - T-DXd → chemotherapy: 9% We should remember that pCR is a limited surrogate endpoint in HR+ disease. However, these results do not support T-DXd as an alternative to standard neoadjuvant chemotherapy. Moreover, given the heterogeneity of HER2-low disease, I find it unsurprising that the success of T-DXd in the metastatic setting does not translate into similar outcomes in early-stage disease, despite the lower tumor burden.","https://x.com/dr_yakupergun/status/2113491790409990418",{"_387":3420,"_19":389,"_248":3421,"_391":702,"_393":-5,"_394":-5,"_395":703},"LBA23","Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer","3be53e72-4395-46d6-b9c7-4834f5d6f67f","#ESMO26 | TALENT #ESMO26 | TALENT Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer: - T-DXd: 7% - T-DXd + ana",{"_272":3442,"_248":3443},"code:NATALEE","NATALEE","NATALEE is adjuvant treatment after surgery: hormone receptor-positive, HER2-negative early breast cancer, CDK4/6 inhibitor ribociclib (blocking G1→S) added to endocrine therapy versus endocrine therapy alone. The population is broader than monarchE and includes some node-negative patients. This meeting’s LBA25 is six-year overall survival, not the NEJM invasive disease-free survival.",42,51,"2026-10-18T19:20:11.000Z","2026-10-24T16:15:46.000Z",[3441],{"_2830":3438,"_2832":-5},{"_264":3435,"_266":3436,"_267":268,"_269":3437,"_271":2942},"omgibiwl7fcyzhlc06gaz9req","Today at #ESMO26, the 6-year results of NATALEE will be presented. Ahead of the presentation, my personal view on the survival gains with adjuvant CDK4/6 inhibitors… The 6-year OS rates in NATALEE were 91.86% vs 89.73%: an absolute gain of 2.1 percentage points (HR 0.809; 95% CI 0.661–0.989; nominal one-sided p=0.019). The absolute 7-year OS gain in monarchE was 1.8 percentage points (HR 0.842; p=0.027). I do not think these gains should be dismissed as “only 2%.” In the EBCTCG analysis, adding taxanes to anthracycline-based chemotherapy—an approach we have accepted as standard for years—provided an absolute 5-year OS gain of approximately 1.9 percentage points. The populations and follow-up periods differ, so we cannot directly compare treatment efficacy. However, the standards we use to judge a few percentage points of survival benefit should be consistent. Moreover, 95.4% of patients in monarchE had already received chemotherapy. This survival gain represents an additional benefit on top of chemotherapy and endocrine therapy. Patient selection, toxicity, treatment duration, and cost certainly deserve discussion. However, the survival benefit of adjuvant CDK4/6 inhibitors in appropriately selected patients should not be underestimated.","https://x.com/dr_yakupergun/status/2113551328672616726",[3427,3439,3440],"A floor post gives six-year OS 91.86% vs 89.73%, an absolute 2.1 percentage points (hazard ratio 0.809; 95% CI 0.661–0.989; nominal one-sided P=0.019). Full slides and strata wait on the oral.","Journal skeleton (OS immature at the time): NEJM 2024 (PMID 38507751); Annals of Oncology final analysis iDFS hazard ratio 0.749, 3-year rates 90.7% vs 87.6% (PMID 39442617). Keep the meeting OS separate from the papers’ iDFS; do not write 2024 disease-free survival as this six-year OS.",{"_387":1627,"_19":389,"_248":1628,"_391":702,"_393":-5,"_394":-5,"_395":703},"39a7bb41-f12c-442c-9945-2d6ae302ba7a","Today at #ESMO26, the 6-year results of NATALEE will be presented",{"_272":3467,"_248":3468},"gene:HER2","HER2","POV: novel HER2 ADCs keep raising the bar in HER2-low breast cancer. @FraSchettMDPhD #ESMO26",69,"2026-10-18T23:04:52.000Z","2026-10-24T22:52:59.000Z",[3455,3456,3457,3458,3459,3460,3461,3462],{"_264":3453,"_266":3447,"_267":268,"_269":3454,"_271":657},"qbdjx868blq4nt3a4dfq9h2ec","https://x.com/PTarantinoMD/status/2113604009848144365",{"_387":3463,"_19":398,"_248":3464,"_391":400,"_393":-5,"_394":3465,"_395":3112},{"_387":1245,"_19":398,"_248":1246,"_391":1247,"_393":-5,"_394":-5,"_395":1248},{"_387":1242,"_19":398,"_248":1243,"_391":400,"_393":-5,"_394":-5,"_395":1244},{"_387":3330,"_19":398,"_248":3331,"_391":400,"_393":-5,"_394":-5,"_395":1244},{"_387":2366,"_19":398,"_248":2367,"_391":1100,"_393":-5,"_394":-5,"_395":1101},{"_387":1289,"_19":398,"_248":1290,"_391":400,"_393":-5,"_394":-5,"_395":1291},{"_387":1781,"_19":398,"_248":1782,"_391":1247,"_393":-5,"_394":-5,"_395":1248},{"_387":1385,"_19":398,"_248":1386,"_391":392,"_393":-5,"_394":-5,"_395":396},"1067P","Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors",[3466,3466,3466],"NCT06806982","04533835-3dda-47d8-8c2c-6158a5db3e07","POV: novel HER2 ADCs keep raising the bar in HER2-low breast cancer",{"_272":3492,"_248":3493},"drug:pembrolizumab","pembrolizumab","#ESMO26 | PERSEE – Phase III In advanced NSCLC with PD-L1 ≥50%, adding chemotherapy to pembrolizumab improved median PFS from 6.9 to 16.1 months (HR 0.56). The numerical OS difference was notable (50.2 vs 29.9 months; HR",48,52,"2026-10-08T12:00:00.000Z","2026-10-24T18:01:33.000Z",[3482,3483,3484,3485,3486,3487,3488,3489],{"_264":3479,"_266":3480,"_267":268,"_269":3481,"_271":2942},"gy0ecvm5o94appijh43b5bspz","#ESMO26 | PERSEE – Phase III In advanced NSCLC with PD-L1 ≥50%, adding chemotherapy to pembrolizumab improved median PFS from 6.9 to 16.1 months (HR 0.56). The numerical OS difference was notable (50.2 vs 29.9 months; HR 0.77), but not statistically significant. However, we should remember that OS was not the primary endpoint! Grade ≥3 toxicity: 53.8% vs 19.3%. I think adding chemotherapy provides benefit, but at the cost of increased toxicity. We need to better identify the patients for whom this toxicity is worth it.","https://x.com/dr_yakupergun/status/2112439291502559300",{"_387":1306,"_19":398,"_248":1307,"_391":1287,"_393":-5,"_394":-5,"_395":1288},{"_387":1300,"_19":398,"_248":1301,"_391":400,"_393":-5,"_394":3491,"_395":643},{"_387":2089,"_19":398,"_248":2090,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":2301,"_19":398,"_248":2302,"_391":2091,"_393":-5,"_394":-5,"_395":2092},{"_387":2899,"_19":398,"_248":2900,"_391":1204,"_393":-5,"_394":3490,"_395":1206},{"_387":1494,"_19":398,"_248":1495,"_391":400,"_393":-5,"_394":-5,"_395":621},{"_387":3023,"_19":398,"_248":3024,"_391":2693,"_393":-5,"_394":-5,"_395":2694},{"_387":397,"_19":398,"_248":399,"_391":400,"_393":-5,"_394":-5,"_395":401},[1207],[1303,1303,1303],"43b94cf9-789c-4bf4-9b19-8a3b0930bc53","Final Phase 2, lifileucel + pembrolizumab, data explore earlier use of #TILtherapy in frontline melanoma at #ESMO26",{"_272":3513,"_248":3514},"code:VOLGA","VOLGA","Floor preview (LBA2, Presidential I, 24 Oct): VOLGA, MIBC, perioperative durvalumab plus tremelimumab plus neoadjuvant enfortumab vedotin. EFS/OS positive at interim; FDA priority review. NCT04960709. Treat slide numbers as the meeting readout when they land.",73,"2026-10-15T00:02:52.000Z","2026-10-25T00:08:03.000Z",[3508,3509],{"_2830":3507,"_2832":-5},{"_264":3504,"_266":3505,"_267":268,"_269":3506,"_271":1026},"un6lx8e3yjoealrnspczy15l5","🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯 #BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 #ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS #KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819 Our Participating Faculty @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista","https://x.com/OncoAlert/status/2112114051333439580",[3497],{"_387":1668,"_19":389,"_248":1669,"_391":529,"_393":-5,"_394":-5,"_395":530},{"_387":3510,"_19":398,"_248":3496,"_391":3511,"_393":-5,"_394":3512,"_395":3496},"NCT04960709","https://clinicaltrials.gov/study/NCT04960709",[3510],"a9576461-5a68-47a9-aa0b-3abe00e5fba7","🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯 #BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 #ProstateCancer: DASL-HiCaP, C",{"_272":3535,"_248":3536},"code:INTERPATH-001","INTERPATH-001","Floor / embargo lifted (LBA1, Presidential I, 24 Oct): INTerpath-001, resected stage IIB–IV melanoma, n=1137. Intismeran autogene plus pembrolizumab vs pembrolizumab. RFS HR 0.58; 2-year RFS 82.2% vs 70.0%. DMFS also met; OS immature. No new safety signals. NCT05933577.",54,72,"2026-10-15T09:26:07.000Z","2026-10-24T21:03:47.000Z",[3532,3533],{"_2830":3530,"_2832":-5},{"_264":3526,"_266":3527,"_267":268,"_269":3528,"_271":3529},"pgim7zf5vle5v6ouzsvt7mx58","#ESMO26 embargo lifted following breach. Detailed data confirm Moderna $MRNA and Merck $MRK cancer vaccine met key endpoints in melanoma trial Personalized mRNA therapy reduced disease recurrence by 42% compared to standard treatment https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/","https://x.com/adamfeuerstein/status/2113346013167489222","adamfeuerstein",[3518,3531],"Journal skeleton (not this meeting's readout): predecessor KEYNOTE-942, Lancet 2024, PMID 38246194. Keep floor numbers separate from the paper.",{"_387":527,"_19":389,"_248":528,"_391":529,"_393":-5,"_394":-5,"_395":530},{"_387":789,"_19":398,"_248":799,"_391":800,"_393":-5,"_394":3534,"_395":799},[789],"4b0f0283-5d60-4c1b-ab0c-fc4e142afcce","#ESMO26 embargo lifted following breach",{"_272":3554,"_248":3555},"code:DELLPHI-305","DELLPHI-305","Floor preview (LBA3, Presidential): DeLLphi-305, first-line maintenance in extensive-stage SCLC, tarlatamab plus durvalumab vs durvalumab. Preview says OS positive at interim. Hallway KM projections are not the official readout.",65,88,"2026-10-15T21:07:08.000Z","2026-10-24T23:36:13.000Z",[3553],{"_2830":3551,"_2832":-5},{"_264":3548,"_266":3549,"_267":268,"_269":3550,"_271":2814},"oc4xhm97bknoxf14djn70osjm","ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH! From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26. 🔥 My Top 10 Trials 1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC 2.SAFFRON | Osimertinib + savolitinib | MET-altered EGFR+ NSCLC 3.Krascendo 1 | Divarasib vs approved KRAS G12C inhibitors 4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC 5.OptiTROP-Lung04 | TROP2 ADC after EGFR-TKI progression 6.SigVie-002 | Integrin αvβ6 ADC vs docetaxel 7.SARON | Consolidation RT in oligometastatic NSCLC 8.PERSEE | Pembrolizumab ± chemotherapy | PD-L1 ≥50% 9.DeLLphi-304 | Long-term survival with tarlatamab 10.ASTRIDE | Serplulimab vs atezolizumab + chemotherapy | ES-SCLC Three Presidential presentations deserve special attention: DeLLphi-305, SAFFRON and Krascendo 1. Which trial could have the biggest impact on lung cancer treatment? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #LungCancer #Oncology","https://x.com/DrRishabhOnco/status/2112902318580752451",[3540,3552],"Journal / completed skeleton: DeLLphi-301 and DeLLphi-304 are the published DLL3 bispecific readouts, for contrast, not a substitute for 305.",{"_387":2610,"_19":389,"_248":2611,"_391":529,"_393":-5,"_394":-5,"_395":530},"dd4a3a39-59af-42c1-a3ba-78db92a07714","ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH",{"_272":3558,"_248":3557},"#CCTG","",0,[],"2026-10-23","2026-10-24","2026-10-25","2026-10-26","2026-10-27",{"_3570":3582,"_3572":3583,"_3574":3584},{"_3570":3579,"_3572":3580,"_3574":3581},{"_3570":3576,"_3572":3577,"_3574":3578},{"_3570":3571,"_3572":3573,"_3574":3575},"key","day3","label","Day 3 · Oct 25","count",565,"day2","Day 2 · Oct 24",1230,"day1","Day 1 · Oct 23",1003,"prelude","Prelude",348,"slug","esmo-2026","name","ESMO Congress 2026","startsOn","endsOn","venue","Madrid","blurb","Madrid floor. One post is one item; several people on the same trial or drug become a heat probe.","itemCount",3146,"ok",true,"changelogVersion","2026-10-24T20:30","enEditionEnabled"]